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EtIology of blooD loss aftEr carDIac surgEry
Excessive blood loss after cardiac surgery is a relatively common complication, 
occurring in approximately 20% of the patients (2-4). The normal or generally ac-
cepted amount of blood loss after cardiac surgery varies between 300-1500 ml dur-
ing the first 12 h. In 5% of the operated patients’ blood loss requires re-operation 
(5,6).
The most important predictive indicators for bleeding and consecutive re-
operation following cardiac surgery, include: age, obesity, renal insufficiency, heart 
failure, anti-platelet medication usage, operation- and cardiopulmonary bypass 
(CPB) time, temperature, number of arterial grafts and intracardiac repair (2,7,8). 
Postoperative bleeding requiring transfusions and surgical re-exploration is associ-
ated with mortality, morbidity (such as increased sternal wound infection, risk of 
transfusion-related complications) and higher costs (9,10). Consequently, preven-
tion of blood loss and reduction of blood transfusion requirements is a major target 
in cardiac surgery.
A surgical cause of bleeding (such as due to an unrecognized bleeding vessel, 
anastomosis or other suture line) is found in approximately half of the patients 
undergoing re-operation (7). In the remainder of the patients a failure in the path-
ways involved in hemostasis, due to a pre-existing coagulation factor deficiency 
or platelet defect, an iatrogenic drug-induced compromised hemostasis or an 
acquired, operation and CPB related hemostatic defect contributes to bleeding 
(2,11-13).
PrE-ExIstIng coagulatIon factor DEfIcIEncIEs anD 
PlatElEt DEfEcts
Pre-existing coagulation factor deficiencies and platelet function defects may be 
either inherited or acquired. There are two distinct groups in genetic coagulation 
problems leading to blood loss: coagulation factor deficiencies and polymorphic 
variants in coagulation and fibrinolysis genes. The inherited coagulation factor 
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deficiencies are relatively rare and severe and, usually, diagnosed before cardiac 
surgery. Hemophilia’s A (factor VIII deficiency) and B (factor IX deficiency) are 
X-linked recessive diseases. Hemophilia C (factor XI deficiency) is inherited in an 
autosomal pattern and far less prone to spontaneous bleeding than hemophilia’s 
A and B, however, there is an increased risk for perioperative bleeding (14). Von 
Willebrand disease is the most common inherited bleeding disorder, occurring in 
approximately 1% of the population, and is transmitted via autosomal dominant 
(type 1 and 2) and recessive (type 3) inheritance. There are several other even 
more rare factor deficiencies, such as factor XIII (fibrin stabilizing factor) and dys- or 
hypofibrinogenemia’s (15). Polymorphic variants cause much less severe changes 
in coagulation or fibrinolysis, and therefore, often are unrecognized before cardiac 
surgery (14). Their clinical impact varies and in combination with acquired hemo-
static problems they might contribute to excessive blood loss.
Acquired pre-existent coagulation factor deficiencies as result of e.g. cirrhosis, 
chronic active hepatitis, acute liver failure and biliary tract obstruction should be 
suspected in patients with unexplained prolongation of routine coagulation tests. 
Most of these factors can be replaced with factor concentrates to obtain normal 
preoperative and post-CPB levels in cardiac surgery (16).
Inherited platelet function defects, such as storage pool disease or Glanzmann 
thrombasthenia, are usually diagnosed prior to cardiac surgery. However, platelet 
function defects may also be acquired in case of renal or liver failure. Identifying 
acquired platelet function defects prior to surgery is important to prevent unneces-
sary bleeding.
Drug-InDucED coMProMIsED hEMostasIs
There are several groups of medication, frequently used preoperatively, that might 
contribute to bleeding complications after cardiac surgery.
Antiplatelet medications (such as Aspirin, Carbasalate calcium, Clopidogrel, 
Prasugrel, Ticagrelor), often prescribed for acute coronary syndromes or for the 
prevention of stent thrombosis after percutaneous coronary intervention (PCI), 
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inhibit platelet activation and aggregation. Aspirin (acetylsalicylic acid) and car-
basalate calcium (a derivative of acetylsalicylic acid) are salicylate drugs, that have 
analgesic, antipyretic, anti-inflammatory and anti-platelet effects. The inhibition 
of platelet aggregation is mediated by inhibition of the production of thrombox-
ane A2 (17,18). Clopidogrel and Prasugrel block the P2Y12 subtype of adenosine 
diphosphate (ADP)-receptor on platelet cell membranes irreversibly and Ticagrelor 
reversibly (19). After cessation of the irreversible drugs it takes about 7 days to 
restore normal platelet function, the time needed to produce new platelets. The 
recovery time of Ticagrelor is shorter. So, when discontinued timely, no extra 
bleeding risk is expected. Vitamin K antagonists (such as Warfarin, Phenprocou-
mon, Acenocoumarol) reduce blood clotting by inhibiting the recycling of vitamin 
K epoxide into to the active reduced form of vitamin K (20). When taken timely, 
vitamin K can effectively reverse the effects of vitamin K antagonists. In acute situ-
ations the effect of vitamin K antagonists can be reversed immediately by infusion 
of prothrombin complex concentrate or plasma.
Low molecular weight heparin (such as enoxaparin, dalteparin, tinzaparin, na-
droparin) is frequently used to stabilize acute coronary syndromes and to prevent 
deep vein thrombosis and pulmonary emboli during operation and perioperative 
immobilization, by binding to the enzyme inhibitor antithrombin, thereby, inacti-
vating thrombin and factor Xa (21,22). Unfractionated heparin is also used in high 
doses during cardiac surgery and will be discussed below.
Finally, the more recently developed Argatroban, Dabigatran and Lepirudin, are 
direct thrombin inhibitors, preventing the conversion of fibrinogen to fibrin. Apixa-
ban and Rivaroxaban are selective, direct factor Xa inhibitors, prescribed to prevent 
thrombosis and embolism (23). These medications do not possess an antagonizing 
agent, which can be given prior to cardiac surgery, potentially, increasing the risk 
of excessive blood loss when not stopped in time.
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oPEratIon anD cPb rElatED hEMostatIc DEfEcts
Suggested mechanisms for the acquired hemostatic defects in cardiac surgery 
include the use of high doses of heparin, hemodilution, hypothermia, activation of 
the coagulation cascade resulting in disseminated intravascular coagulation (DIC), 
tissue trauma, platelet dysfunction, coagulation factor loss and dysfunction and 
excessive fibrinolysis (2,3,11,12). The extent of the contribution of each of those 
factors remains unresolved.
Heparin
During CPB heparin is required to prevent blood clotting within the circuit. Plasma 
proteins, including fibrinogen and albumin, are absorbed by the extracorporeal 
surfaces, creating a pro-thrombotic environment (13). Heparin effectively inhibits 
systemic thrombin but is not able to impede surface-bound thrombin adhering to 
both fibrinogen and fibrin deposited onto the CPB circuitry. Thrombin activates 
platelets, which also adhere to specific binding sites on the fibrin- and fibrinogen-
coated surfaces, and allows more prothrombin to thrombin activation via pro-
thrombinase complexes on the phospholipid membrane surface of activated plate-
lets (2,24). As a result high-dose heparin is required to prevent the formation of a 
fibrin-rich thrombus during CPB. Protamine sulfate is the most common agent used 
to reverse heparin-induced anticoagulation at the end of CPB. However, protamine 
has a shorter effective half-life than heparin, and after appropriate neutralization 
of heparin, rebound heparin activity occurs and has shown to be a cause of postop-
erative bleeding (7). Moreover, heparin inhibits platelet aggregation, an effect not 
reversed by protamine sulfate, contributing to platelet dysfunction (2).
Hemodilution
Hemodilution during cardiac surgery results from the colloids and crystalloids 
used for CPB priming and cardioplegia, volume supplementation during cardiac 
surgery and extensive use of cell saver devices returning red blood cells without 
platelets and coagulation factors. Hemodilution due to the use of CPB and volume 
supplementation decreases red blood cell, platelet and coagulation factor con-
1
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centrations, predisposing patients to bleeding. Coagulation factor concentrations 
are reduced, parallel with hematocrit concentrations, to approximately 25-50% of 
baseline (25-27). The minimum levels of coagulation factors adequate to support 
hemostasis often are not surpassed and the reductions in coagulation factor levels 
that develop during CPB, therefore, generally do not result in excessive bleeding 
(28-30). However, in combination with a compromised hemostasis hemodilution 
should not be neglected.
Hypothermia
Hypothermia (defined as a systemic temperature below 35 °C) can cause reduced 
coagulation factor activity (significant below 33 °C) (31), platelet dysfunction and 
induction of fibrinolysis (32) and is associated with an increased risk of uncontrolled 
bleeding. Both coagulation factor activity and platelet function can be restored by 
normalization of body temperature (33). While hypothermia is sometime unavoid-
able to protect the body or heart from ischemia in special circumstances, in most 
cases it should be avoided and treated aggressively at the end of the operation.
Activation of the coagulation cascade
Blood contact with the extensive non-endothelial surface of the CPB circuit and 
direct blood-air contact lead to the activation of the contact or intrinsic coagula-
tion pathway, via kallikrein activation of factor XII when it binds to the negatively 
charged surface (13). Factor XII activates factor XI of the intrinsic pathway that 
finally leads to thrombin formation (2).
The tissue factor (TF) or extrinsic pathway is triggered by exposure to high 
shear stress and oscillating shear on circulating blood cells in the CPB circuit and by 
surgical trauma due to e.g. cannulation, coronary arteriotomy, aortic cross clamp-
ing and incision of blood vessels (13). Factor VIIa complexes with TF expressed 
on monocytes, macrophages, fibroblasts and platelets exposed on atherosclerotic 
plaques or subendothelial constituents within the vessel wall (13). Surgical trauma 
is considered a greater stimulus for extrinsic pathway activation than the CPB cir-
cuit (34). Since TF and factor VII are rapidly generated during operation and bypass, 
they reach high concentrations, especially in the pericardial sac (due to aortic cross 
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clamping). TF levels in the pericardial blood can increase to fi vefold above systemic 
levels (35). Recirculati on of sucti oned blood from the surgical fi eld, therefore, can 
aggravate the acti vati on coagulati on (and fi brinolyti c) systems.
The contact acti vati on and ti ssue factor coagulati on pathways converge 
resulti ng in acti vati on of factor X which, in combinati on with factor Va (forming 
the prothrombinase complex), and calcium, leads to the generati on of thrombin 
(12,13). Since this thrombin is not generated as a physiological reacti on to establish 
clotti  ng, it is called a ‘non-hemostati c thrombin generati on’ and represents dys-
regulati on of the normal hemostati c process. There are two major bursts of ‘non-
hemostati c thrombin generati on’. The fi rst, immediately aft er going onto CPB when 
blood fi rst contacts the oxygenator pump circuit, and the second, immediately 
aft er reperfusion of the ischemic heart at the end of CPB. Aorti c cross clamping, to 
prevent refl ux blood stream to the heart during CPB, further aggravates thrombin 
generati on by mechanical ti ssue injury (13). The acti vated thrombin mediates the 
figure 1. coagulati on and cPb.
The interface of blood with non-endothelial surfaces of the CPB, direct blood-air interface, 
high shear stresses, cannulati on and incision of blood vessels and re-transfusion of blood pro-
cured from the surgical fi eld are all triggers for acti vati on of both contact and TF-initi ated 
pathways of coagulati on (3).
1
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conversion of fibrinogen to fibrin monomers, activates factors V, VIII, XIII, platelets 
and the inflammatory cascade, specifically complement.
Activation of the coagulation cascade can ultimately lead to consumption of co-
agulation factors and platelets (i.e. a disseminated intravascular coagulation (DIC) 
state), mediated by thrombin and plasmin, and might result in increased blood 
loss (12). This consumptive process is further enhanced via leukocyte elastase pro-
duction (36-38). CD11b-expressing monocytes on the surface of oxygenator fibers 
in the CPB directly activate factor X (39) and complement (40,41). The activated 
thrombin and generated inflammation factors act synergistic maintaining a vicious 
circle stimulating each other.
Platelet activation and dysfunction
Platelet counts immediately decrease by approximately 25-60% during CPB 
(42-45). This decline is larger than expected based on hemodilution alone (46). 
Furthermore, the absence of a correlation between platelet number and the ag-
gregatory response suggests that factors other than dilution might contribute to 
thrombocytopenia and platelet dysfunction. During CPB platelets are subjected to 
two insults. The first is caused by blood contact with surface-absorbed fibrinogen 
and thrombin on the CPB circuit, activating platelets (11), and the second, is evoked 
by the oxidizing stress brought about by blood oxygenation and pump-induced 
hemolysis, causing platelet activation and injury. Increased levels of P-selectin in 
plasma indicate that the impaired platelet aggregation, as confirmed by Cheung 
(47) after ECMO (comparable to CPB), is the result of platelet activation, causing 
a platelet agonist refractory state (7). Platelet activation by e.g. the CPB circuit, 
surgical trauma and inflammation, can ultimately lead to DIC and platelet exhaus-
tion (47), creating decreased platelet numbers and function. Platelet dysfunction 
can be further aggravated by hypothermia when temperature is not adequately 
controlled.
Coagulation factors
Adequate concentrations of coagulation factors are essential to ensure normal 
coagulation. During surgery (functional) coagulation factor levels decrease due 
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to blood loss, consumption, acidosis, hypothermia, hypocalcemia and hemodilu-
tion (Table 1). Blood loss, consumption and fibrinolysis lead to an actual loss of 
coagulation factors, whereas acidosis, hypothermia (31) and hypocalcemia cause 
dysfunction. Hemodilution results in a relative decrease.
table 1. Effects of intra-operative conditions on coagulation factors.
















Activation of fibrinolysis occurs simultaneously with coagulation (48). Thrombin 
down-regulates hemostasis by stimulating release of tissue factor pathway inhibi-
tor, which inhibits the tissue factor pathway, and by stimulating the release of tis-
sue plasminogen activator (t-PA). t-PA is rapidly released by endothelial cells in 
response to venous occlusion, exercise, endotoxin and arterial ischemia (49). The 
distribution of t-PA is further promoted by hypothermia, traumatized endothelial 
cells and return of suctioned pericardial blood (12). t-PA, like urokinase plasmino-
gen activator (u-PA), activates fibrinolysis by cleaving plasminogen to plasmin. Due 
to the low levels of u-PA compared with t-PA in blood during CPB, most plasmino-
gen activation during CPB occurs on the fibrin surface by t-PA (50). Fibrinolysis via 
accelerated plasminogen activation is also stimulated by the fibrin absorbed to the 
large surface of the pump oxygenator, which is not blocked by heparinisation (50). 
Activation of fibrinolysis at the onset of CPB is mainly due to this blood contact 
with the foreign CPB surface and then further becomes extrinsically activated by 
the release of t-PA from the vascular walls throughout CPB (2).
1
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Plasmin cleaves both fibrinogen and fibrin into fragments, called fibrinogen- 
and fibrin degradation products, without clotting ability. One of these fragments, 
D-dimer, is used as a specific marker of fibrin degradation. However, the measured 
D-dimer levels during and after operation are difficult to interpret, because an 
increase does not distinguish between amplification of coagulation or primary 
fibrinolysis. The differentiation can only be made by additional coagulation tests 
like, prothrombin fragment 1 + 2, plasmin generation and thrombin generation. 
During early surgery (including sternotomy) prior to the start of CPB, plasmin and 
D-dimer generation levels do not change from baseline levels (50). This would im-
ply that even relatively large surgical wounds, including sternotomy, by itself do not 
result in fibrinolysis. However, immediately after starting CPB the t-PA, D-dimer, 
t-PA-inhibitor complex and plasmin-antiplasmin complex concentrations increase 
(50,51), suggesting an important role for CPB in inducing fibrinolysis. Valve surgery 
and longer aortic cross-clamp times are associated with enhanced activation of 
t-PA and consequently fibrinolysis during CPB (2). Elevated active t-PA during and 
immediately after CPB is associated with excessive bleeding (49,51).
Plasminogen activator inhibitor (PAI-I) is released by vascular endothelial cells, 
smooth muscle cells, platelets and hepatocytes after t-PA and u-PA release as 
a natural endogenous inhibitor of fibrinolysis (2;49). PAI-I is produced by these 
cells in response to sepsis, exposure to various cytokines, operation and trauma. 
Normally, PAI-I increases in parallel with t-PA. In cardiac surgery the increase in 
PAI-I is usually delayed relative to that of t-PA. PAI-I shows a classic acute-phase like 
response with a slow rise in secretion starting several hours after the beginning of 
surgery and peaking in the postoperative period (49,51).
Alternative pathways of fibrinolysis may also contribute to hyperfibrinolysis 
during CPB. These include fibrinolysis secondary to DIC, neutrophil elastase-
mediated fibrin digestion and platelet or their excreted microparticles mediated 
plasmin generation or propagation (11,13).
The relative contributions of heparinisation (and reversal with protamine), 
hemodilution, hypothermia, surgical trauma, CPB, coagulation factor consumption, 
decrease in platelet number and function, and fibrinolysis to the development of 
(excessive) blood loss are yet to be fully established.
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outlInE of thIs thEsIs
The aim of this thesis is to improve our understanding of the development of 
(excessive) blood loss due to ineff ecti ve hemostasis aft er coronary artery bypass 
graft  (CABG) surgery, in order to support the decision making process concerning 
medicati on and blood product substi tuti on and to explore several therapeuti c op-
ti ons to reduce the risk of bleeding.
In Part I (chapters 2-4) the eti ological mechanisms for blood loss aft er CABG 
procedures are investi gated. Management opti ons to prevent and treat bleeding 
pati ents are described in Part II (chapters 5-7).
figure 2. Eff ects of cPb and surgical trauma on hemostasis.




Part I EtIology anD DIagnosIs of blooD loss aftEr cabg 
surgEry
Fibrinogen plays an essential dual role in coagulation, at one hand enhancing 
platelet aggregation via binding to the GPIIb/IIIa receptors on platelets and on the 
other hand by its conversion to fibrin to form an insoluble clot. It is suggested that 
pre- and postoperative fibrinogen levels are associated with (excessive) blood loss 
(52-54). To evaluate the role of decreased fibrinogen levels in the development of 
(excessive) blood loss after cardiac surgery we have performed a systematic review 
and meta-analysis, as described in Chapter 2.
Cardiac surgery can result in a significant reduction of (functional) fibrinogen 
due to operation trauma and CPB usage. In Chapter 3 the relative contributions of 
hemodilution, consumption and degradation are described. Fibrin and fibrinogen 
concentrations, combined with their degradation products were evaluated in 10 
patients before and after isolated CABG.
The laboratory values seen after cardiac surgery resemble both a post-fibrino-
lytic and a pro-thrombotic state (34,37,51). In Chapter 4 we evaluate coagulation 
and fibrinolytic markers at various time intervals during and up to 5 days after 
CABG procedures, with or without CPB usage, and combined with aortic valve 
replacement (AVR), to gain more insight in the hemostatic disorders that develop 
during cardiac surgery.
Part II ManagEMEnt anD PrEvEntIon of blooD loss 
aftEr cabg surgEry
Beside etiological consideration of blood loss after CABG surgery, management and 
prevention are studied in the following chapters.
Antiplatelet medications, such as acetylsalicylic acid and clopidogrel, routinely 
prescribed to reduce early stent failure after percutaneous transluminal coronary 
angioplasty (PTCA), improve outcomes after acute coronary syndromes, and 
decrease cardiovascular morbidity and mortality (55-58). Consequently, these 
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medications are used regularly by patients prior to CABG surgery (59,60). However, 
several studies state that administration of clopidogrel prior to cardiac surgery, es-
pecially in combination with acetylsalicylic acid, increases the risk of postoperative 
bleeding (61,62). In Chapter 5 the optimal stop day, defined as the last day before 
surgery on which antiplatelet medication was used, for acetylsalicylic acid only or 
acetylsalicylic acid combined with clopidogrel in relation to the lowest amount of 
blood loss in the first 48 h after CABG surgery is evaluated.
Locally applied fibrin sealants as an adjunct to hemostasis, wound healing and 
tissue adhesion have proved to be efficient in reducing blood loss and the need 
for blood transfusions in many surgical fields, including cardiac surgery (63,64). 
Nearly all of the commercially available fibrin sealants use either bovine thrombin 
or human thrombin derived from pooled plasma, raising concerns regarding the 
antigenicity and antibody formation (65). Recently, CryoSeal was developed, a 
fibrin sealant produced from allogeneic single donor plasma, without the addition 
of fibrinolysis inhibitors or bovine proteins. Chapter 6 describes a randomized, 
multicentre study in which the safety and cost-effectiveness of CryoSeal in patients 
undergoing elective isolated CABG surgery was evaluated.
Accumulated blood in the pericardium contains elevated levels of pro- and anti-
coagulant proteins due to surgical trauma and CPB contact. Blood contact between 
pericardial and systemic blood represents a significant trigger for activation of the 
coagulation system, that might result in a DIC state and activation of fibrinolysis, 
both contributing to excessive blood loss (12,34,49). During re-exploration for 
postoperative bleeding, removal of accumulated blood and clots by solely irrigat-
ing the pericardial space with a warm saline solution often is enough to stop the 
bleeding instantly in a significant number of cases. In Chapter 7 a pilot study is 
described which evaluates the safety, feasibility and effect on blood loss of continu-
ous postoperative pericardial flushing (CPPF) after cardiac.
In Chapter 8 , the consequences of patient management of the studies de-




 1. Hall RI. Protamine dosing--the quandary continues. Can J Anaesth 1998;45:1-5.
 2. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary 
bypass: a review. Intensive Care Med 2004;30:1873-81.
 3. Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The in-
fluence of perioperative coagulation status on postoperative blood loss in complex 
cardiac surgery: a prospective observational study. Anesth Analg 2010;110:1533-40.
 4. Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk 
for excessive blood loss during coronary artery bypass surgery: thromboelastography 
versus coagulation screen. Anesth Analg 1993;76:694-700.
 5. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 
2007;356:2301-11.
 6. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardio-
vasc Surg 2011;142:662-7.
 7. Whitlock R, Crowther MA, Ng HJ. Bleeding in cardiac surgery: its prevention and 
treatment--an evidence-based review. Crit Care Clin 2005;21:589-610.
 8. Despotis G, Avidan M, Eby C. Prediction and management of bleeding in cardiac 
surgery. J Thromb Haemost 2009;7 Suppl 1:111-7.
 9. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions 
during coronary artery bypass graft surgery are associated with serious adverse 
outcomes. Transfusion 2004;44:1143-8.
 10. Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004;44:4S-14S.
 11. Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 
1999;104:208-19.
 12. Despotis GJ, Avidan MS, Hogue CW, Jr. Mechanisms and attenuation of hemostatic 
activation during extracorporeal circulation. Ann Thorac Surg 2001;72:S1821-S1831.
 13. Yavari M, Becker RC. Coagulation and fibrinolytic protein kinetics in cardiopulmonary 
bypass. J Thromb Thrombolysis 2009;27:95-104.
 14. Morozowich ST, Donahue BS, Welsby IJ. Genetics of coagulation: considerations for 
cardiac surgery. Semin Cardiothorac Vasc Anesth 2006;10:297-313.
 15. Welsby IJ, Podgoreanu MV, Phillips-Bute B, Mathew JP, Smith PK, Newman MF, et 
al. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 
2005;3:1206-12.
 16. MacKinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in 
patients with haemophilia. Haemophilia 2000;6:84-8.
 17. Lewis HD, Jr., Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, III, et 
al. Protective effects of aspirin against acute myocardial infarction and death in men 
with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl 
J Med 1983;309:396-403.
 18. Mathieu P, Villemot JP, Stoltz JF, Scheck F, Garnier LF. [Antiaggregant effect and toler-
ance of calcium carbasalate administrated immediately after aorto-coronary bypass. 
Results of a double-blind versus placebo study]. Pathol Biol (Paris) 1996;44:571-80.
24 CHAPTER 1
 19. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, et al. 
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and parti-
tions them out of lipid rafts. Proc Natl Acad Sci U S A 2006;103:11069-74.
 20. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 
2008;100:530-47.
 21. Chuang YJ, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of 
antithrombin for thrombin and factor Xa independent of the reactive center loop 
sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-
activated antithrombin. J Biol Chem 2001;276:14961-71.
 22. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Bio-
chem 1982;48:161-82.
 23. Berman JP, Halperin JL. Novel oral anticoagulants for stroke prevention in patients 
with atrial fibrillation. Hosp Pract (Minneap ) 2013;41:37-48.
 24. Edmunds LH, Jr., Colman RW. Bleeding that won’t stop. Ann Thorac Surg 2008;85:1153-
4.
 25. Ucar HI, Oc M, Tok M, Dogan OF, Oc B, Aydin A, et al. Preoperative fibrinogen levels as 
a predictor of postoperative bleeding after open heart surgery. Heart Surgery Forum 
2007;10:284-8.
 26. Marengo-Rowe AJ, Lambert CJ, Leveson JE, Thiele JP, Geisler GF, Adam M, et al. The 
evaluation of hemorrhage in cardiac patients who have undergone extracorporeal 
circulation. Transfusion 1979;19:426-33.
 27. Ternstrom L, Radulovic V, Karlsson M, Baghaei F, Hyllner M, Bylock A, et al. Plasma 
activity of individual coagulation factors, hemodilution and blood loss after cardiac 
surgery: a prospective observational study. Thromb Res 2010;126:e128-e133.
 28. Gelb AB, Roth RI, Levin J, London MJ, Noall RA, Hauck WW, et al. Changes in blood 
coagulation during and following cardiopulmonary bypass: lack of correlation with 
clinical bleeding. Am J Clin Pathol 1996;106:87-99.
 29. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelas-
tography to bleeding time and standard coagulation tests in patients after cardiopul-
monary bypass. J Cardiothorac Vasc Anesth 1993;7:410-5.
 30. Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, et al. He-
mostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 
1985;11:281-92.
 31. Wolberg AS, Meng ZH, Monroe DM, III, Hoffman M. A systematic evaluation of the 
effect of temperature on coagulation enzyme activity and platelet function. J Trauma 
2004;56:1221-8.
 32. Yoshihara H, Yamamoto T, Mihara H. Changes in coagulation and fibrinolysis occurring 
in dogs during hypothermia. Thromb Res 1985;37:503-12.
 33. Johansson PI, Solbeck S, Genet G, Stensballe J, Ostrowski SR. Coagulopathy and he-
mostatic monitoring in cardiac surgery: an update. Scand Cardiovasc J 2012;46:194-
202.
 34. Vallely MP, Bannon PG, Bayfield MS, Hughes CF, Kritharides L. Quantitative and tem-
poral differences in coagulation, fibrinolysis and platelet activation after on-pump 
and off-pump coronary artery bypass surgery. Heart Lung Circ 2009;18:123-30.
1
General Introduction 25
 35. Philippou H, Adami A, Davidson SJ, Pepper JR, Burman JF, Lane DA. Tissue factor is 
rapidly elevated in plasma collected from the pericardial cavity during cardiopulmo-
nary bypass. Thromb Haemost 2000;84:124-8.
 36. Despotis GJ, Levine V, Goodnough LT. Relationship between leukocyte count and pa-
tient risk for excessive blood loss after cardiac surgery. Crit Care Med 1997;25:1338-
46.
 37. Paulitsch FS, Schneider D, Sobel BE, Rached R, Ramires J, Jatene F, et al. Hemostatic 
changes and clinical sequelae after on-pump compared with off-pump coronary artery 
bypass surgery: a prospective randomized study. Coron Artery Dis 2009;20:100-5.
 38. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary 
bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-5.
 39. Parratt R, Hunt BJ. Direct activation of factor X by monocytes occurs during cardiopul-
monary bypass. Br J Haematol 1998;101:40-6.
 40. Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch J, Li L, et al. Selective blockade 
of membrane attack complex formation during simulated extracorporeal circulation 
inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg 1999;118:460-
6.
 41. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, et al. Pharmacology and 
biological efficacy of a recombinant, humanized, single-chain antibody C5 comple-
ment inhibitor in patients undergoing coronary artery bypass graft surgery with 
cardiopulmonary bypass. Circulation 1999;100:2499-506.
 42. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal 
bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet 
dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.
 43. McKenna R, Bachmann F, Whittaker B, Gilson JR, Weinberg M. The hemostatic mecha-
nism after open-heart surgery. II. Frequency of abnormal platelet functions during 
and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
 44. SALZMAN EW. BLOOD PLATELETS AND EXTRACORPOREAL CIRCULATION. Transfusion 
1963;3:274-7.
 45. Czer LS, Bateman TM, Gray RJ, Raymond M, Stewart ME, Lee S, et al. Treatment of 
severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduc-
tion in blood product usage with desmopressin. J Am Coll Cardiol 1987;9:1139-47.
 46. Wolk LA, Wilson RF, Burdick M, Selik N, Brown J, Starricco A, et al. Changes in anti-
thrombin, antiplasmin, and plasminogen during and after cardiopulmonary bypass. 
Am Surg 1985;51:309-13.
 47. Cheung PY, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms 
of platelet dysfunction during extracorporeal membrane oxygenation in critically ill 
neonates. Crit Care Med 2000;28:2584-90.
 48. Umlas J. Fibrinolysis and disseminated intravascular coagulation in open heart 
sergery. Transfusion 1976;16:460-3.
 49. Illig KA, Green RM, Ouriel K, Riggs PN, Bartos S, Whorf R, et al. Primary fibrinolysis 
during supraceliac aortic clamping. J Vasc Surg 1997;25:244-51.
 50. Chandler WL, Velan T. Plasmin generation and D-dimer formation during cardiopul-
monary bypass. Blood Coagul Fibrinolysis 2004;15:583-91.
 51. Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen 
activator inhibitor 1 during cardiopulmonary bypass. Thromb Res 2003;112:185-92.
26 CHAPTER 1
 52. Bolliger D, Gonsahn M, Levy JH, Williams WH, Tanaka KA. Is preoperative fibrinogen 
predictive for postoperative bleeding after coronary artery bypass grafting surgery? 
Transfusion 2009;49:2006-7.
 53. Ozolina A, Strike E, Vanags I. Plasma fibrinogen level and postoperative bleeding 
after on-pump cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 
2011;Conference:S45-S46.
 54. Liu G, McNicol PL, McCall PR, Bellomo R, Connellan J, McInnes F, et al. Prediction 
of the mediastinal drainage after coronary artery bypass surgery. Anaesth Intensive 
Care 2000;28:420-6.
 55. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events 
(CURE) trial programme; rationale, design and baseline characteristics including 
a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 
2000;21:2033-41.
 56. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in 
addition to aspirin in patients with acute coronary syndromes without ST-segment 
elevation. N Engl J Med 2001;345:494-502.
 57. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of 
clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Inves-
tigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 
1999;21:325-35.
 58. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, et al. Early and 
sustained dual oral antiplatelet therapy following percutaneous coronary interven-
tion: a randomized controlled trial. JAMA 2002;288:2411-20.
 59. Kang W, Theman TE, Reed JF, III, Stoltzfus J, Weger N. The effect of preoperative clopi-
dogrel on bleeding after coronary artery bypass surgery. J Surg Educ 2007;64:88-92.
 60. Hijazi E. Aspirin does not increase bleeding and allogeneic blood transfusion in coro-
nary artery surgery. Thorac Cardiovasc Surg 2011;59:421-4.
 61. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin 
when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.
 62. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass 
surgery. Crit Care Med 2001;29:2271-5.
 63. Goerler H, Oppelt P, Abel U, Haverich A. Safety of the use of Tissucol Duo S in cardio-
vascular surgery: retrospective analysis of 2149 patients after coronary artery bypass 
grafting. Eur J Cardiothorac Surg 2007;32:560-6.
 64. Lamm P, Adelhard K, Juchem G, Weitkunat R, Milz S, Kilger E, et al. Fibrin glue in 
coronary artery bypass grafting operations: casting out the Devil with Beelzebub? Eur 
J Cardiothorac Surg 2007;32:567-72.
 65. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. 
N Engl J Med 2006;354:353-65.


 Part I 
Eti ology and Diagnosis

CHAPTER 2
The effects of pre- and postoperative fibrinogen 
levels on blood loss after cardiac surgery: 
A systematic review and meta-analysis
Chantal Gielen, Olaf Dekkers, Theo Stijnen, Jan Schoones, Anneke Brand, 
Robert Klautz and Jeroen Eikenboom




Fibrinogen concentrate is increasingly used in cardiac surgery when bleeding is 
anticipated or ongoing. As randomized clinical studies to support this are lacking, it 
is relevant to know whether lower fibrinogen levels are associated with excessive 
bleeding. We performed a systematic review and meta-analysis to define the as-
sociation between fibrinogen levels and blood loss after cardiac surgery.
Methods
A database search (January 2013) was performed on publications assessing the as-
sociation between pre- and postoperative fibrinogen levels and postoperative blood 
loss in adult patients undergoing cardiac surgery. Cohort studies and case-control 
studies were eligible for inclusion. The main outcome was the pooled correlation 
coefficient, calculated via the Fisher’s Z transformation scale, in a random effects 
meta-analysis model stratified for time point at which fibrinogen was measured.
Results
A total of 20 studies were included. The pooled correlation coefficient of studies 
(n=9) concerning preoperative fibrinogen levels and postoperative blood loss was 
-0.40 (95% confidence interval: -0.58, -0.18), pointing towards more blood loss in 
patients with lower preoperative fibrinogen levels. Among articles (n=16) reporting 
on postoperative fibrinogen levels and postoperative blood loss, the pooled cor-
relation coefficient was -0.23 (95% confidence interval: -0.29, -0.16).
Conclusions
Our meta-analysis indicated a significant but weak to moderate correlation be-
tween pre- and postoperative fibrinogen levels and postoperative blood loss in 
cardiac surgery. This moderate association calls for appropriate clinical studies, 
whether fibrinogen supplementation will decrease postoperative blood loss.
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IntroDuctIon
Excessive blood loss is a frequent complication after cardiac surgery (1,2) requiring 
reoperation in about 5-10% of patients. Postoperative bleeding obligating transfu-
sions and surgical re-exploration is associated with mortality, morbidity (such as 
increased sternal wound infection, risk of transfusion-related complications) and 
higher costs (3-5).
Multiple factors are associated with excessive bleeding after cardiac surgery, 
but causal pathways have not been elucidated in full detail (5). A surgical cause is 
only found in approximately half of the patients undergoing reoperation for bleed-
ing. In the remainder of patients an acquired coagulopathy contributes to bleeding. 
The latter can either be caused by a pre-existing coagulation factor deficiency, a 
drug-induced platelet inhibition or by an acquired, operation related hemostatic 
defect (3,6). Suggested mechanisms for the acquired defects include the use of 
high doses insufficiently neutralized heparin, hemodilution, activation of the he-
mostatic system resulting in disseminated intravascular coagulation, tissue trauma, 
platelet dysfunction and excessive fibrinolysis (7,8). Identification of patients at risk 
for excessive blood loss would offer possibilities to initiate preventive measures. 
However, diagnostic efficiency of the hemostasis screening tests to identify such 
indicators is often low.
A suggested predictor of excessive blood loss is fibrinogen, a protein which plays 
an essential role in coagulation. It has a dual role as it enhances platelet aggregation 
via binding to the GPIIb/IIIa receptors on platelets and it is converted into fibrin to 
form an insoluble clot. Cardiac surgery, however, can result in a significant reduc-
tion of fibrinogen concentration and function, due to blood loss, hemodilution, 
platelet activation by cardiopulmonary bypass (CPB), a large wound area for clot 
formation, hypothermia and acidosis (9,10). The threshold of fibrinogen at which 
bleeding complications are provoked is difficult to define, as it depends on the 
status of hematocrit, thrombin formation, platelet number and function, clotting 
enzyme activities (9), underlying clinical conditions (e.g. hematological malignancy 
and liver insufficiency (10)) and age. Several reports suggest that a fibrinogen level 
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of >2 g/l would be sufficient to ensure adequate coagulation even in the presence 
of moderate thrombocytopenia (10-12).
An inverse association between pre- and postoperative fibrinogen levels, and 
bleeding risk, even for levels within the normal reference range (1.5-4.0 g/l) was 
often reported (11). It is suggested that fibrinogen supplementation might decrease 
blood loss after cardiac surgery (10). Although clinical trials are lacking (1,13), 
fibrinogen supplementation is increasingly used, also in cardiac surgery. To support 
such policy a role of pre- and postoperative fibrinogen levels in the development of 
(excessive) blood loss after cardiac surgery should be unequivocal. We performed a 
systematic review and meta-analysis to define the association between fibrinogen 
levels and blood loss after cardiac surgery.
MEthoDs
Information sources and search
We searched PubMed, Embase, Web of Science, COCHRANE, CINAHL, Academic 
Search Premier and ScienceDirect using predefined search terms (Supplemental 
data, Appendix A). The search was performed in January 2013. We used both 
MeSH terms and free text words. Language restrictions for Dutch, English, French 
and German articles were set in advance. Full-text articles and meeting abstracts 
published since 1957 (the year in which the Clauss method to measure fibrinogen 
was first described) were eligible for evaluation (14).
Study selection and endpoint definitions
To be included in the analysis, studies had to assess the association between pre- 
and postoperative fibrinogen levels and postoperative blood loss or transfusions 
in adult patients undergoing cardiac surgery. The study should report either the 
amount of blood loss or transfusions stratified by levels of fibrinogen or the risk for 
blood loss (risk ratio or odds ratio (OR)) when comparing fibrinogen levels. Because 
most articles presented information about the association between fibrinogen 
level and blood loss we focused on the correlation with bleeding. Only two studies 
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included in the meta-analysis presented a correlation with blood transfusions. Co-
hort and case-control studies were considered. Intervention studies with fibrinogen 
supplementation were excluded.
The definition of (excessive) postoperative blood loss varied between the 
included articles. Excessive bleeding was defined by the authors of the included 
articles as total postoperative drain volume of  >400 ml in 1 hour, >200 ml for 2 
consecutive hours, or >100 ml for 4 consecutive hours, as >200 ml per hour, >150 
ml for 2 consecutive hours, or >100 ml for 3 consecutive hours postoperative or 
as >1500 ml within the first 24 h after surgery. Patients with excessive blood loss 
(PEBL) were characterised as patients with postoperative blood loss of >1000 ml 
in the first 24 h after operation, mean blood loss of 1650 ml ± 280 ml, median 
blood loss of 949 ml, blood loss >1000 ml in the first 16 h after operation, bleeding 
>600 ml in the first 8 h postoperative, postoperative blood loss >200 ml per hour 
within the first 4 h after operation with median of 787 ml, requiring re-exploration 
for bleeding ≥200 ml per hour for over 4 h or experiencing a sudden increase in 
bleeding after 2 h postoperative, postoperative blood loss >500 ml in the first 24 h 
after operation or patients in the higher tertile of blood loss with median 1050 ml 
(700-2550 ml). All definitions for blood loss were accepted and PEBL stated in the 
article were handled as PEBL for analysis (Table 1).
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Data extraction and risk of bias assessment
Selection, data extraction and risk of bias assessment was done by 2 reviewers 
independently (J.E and C.L.I.G) using a predefined extraction sheet. Concerning 
our research questions, we collected the following variables: study population, 
time point at which fibrinogen was measured, level of fibrinogen, amount of peri-
operative blood loss and transfusions. To assess the risk of bias, we evaluated the 
study design, measurement of exposure, blinding for fibrinogen level, definition 
and measurement of outcomes, completeness of follow-up and adjustment for 
confounders. These variables were used to explore sources of heterogeneity. No 
summary score for the risk of bias assessment was used for analytical purposes.
Summary measures and synthesis of results
For all studies the main effect-measure was extracted (odds ratio, mean-difference, 
correlation coefficient, P-value) with accompanying measure of uncertainty (95% 
confidence interval, standard error or P-value). We stratified studies based on the 
time point at which fibrinogen was measured (pre- vs postoperatively).
For analytical purposes, we transformed all effect-measures to correlation 
coefficients (r). P-values were transformed with Fisher’s Z transformation scale and 
via the inverse Fisher’s Z transformation to correlation coefficients. Odds ratios 
were transformed to a correlation scale using the tetrachoric correlation. When 
the association between fibrinogen and blood loss was characterized by a regres-
sion coefficient, the correlation was calculated from the regression coefficient 
and the standard deviation of the independent variable in the regression. These 
transformed correlation coefficients were pooled in a random effects model as for 
instance described by Borenstein  (15). Finally, results were transformed back to 
the correlation scale by the inverse Fisher’s Z-transformation. All analyses were 
performed with STATA release 10 (StataCorp, Texas, USA).
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rEsults
Study selection and characteristics
Our search strategy provided 959 articles of which 77 were retrieved for more 
detailed assessment. The search strategy’s flow-chart is shown in Figure 1. A total 
of 20 articles were included, which incorporated 5972 patients. In Table 1 details 
of included studies are provided. Nine articles were classified as cohort studies in 
which fibrinogen was measured before or after operation and the presence of a 
correlation with blood loss was evaluated. The other 11 studies were nested case-
control studies, where cases were defined as PEBL and controls as patients without 
figure 1. flow chart of study selection.
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excessive blood loss (non-PEBL). The definition to classify blood loss (and therefore 
also case-control status) differed between the articles. Fibrinogen was measured 
by the Clauss method in 6 papers, 7 papers used an automated, Clauss like, coagu-
lation method and 7 articles did not report the method used. Effect estimates were 
reported as correlations in 13 studies, as P-values in 5 studies, Prohaska  reported 
an odds ratio and the article of Fassin  reported mean differences.
Risk of bias
All studies included assessed the association between pre- and postoperative 
fibrinogen levels and postoperative blood loss or transfusions in adult patients 
undergoing cardiac surgery. Four articles reported to have performed fibrinogen 
measurement before patients received any coagulation factors or FFPs. In the 
majority of articles this form of bias was not reported, 2 stated that they could 
not exclude it. Furthermore, factors that also might have influenced postoperative 
figure 2. Meta-analysis of the correlation between preoperative fibrinogen and postopera-
tive blood loss.
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blood loss are drug-induced platelet dysfunction, postoperative administration of 
low molecular weight heparins, or impairment of von Willebrand factor and factor 
VIII by hydroxyethyl starch solutions. Most articles do not report how these poten-
tial confounding factors were dealt with. None of the articles reported included 
patients lost in follow up.
Synthesis of results
Nine studies contributed to the meta-analysis on the association between preop-
erative fibrinogen level and blood loss. Calculated correlations were all below -0.10 
(Figure 2). In a random effects model, the pooled correlation for the association be-
tween preoperative fibrinogen levels and postoperative blood loss was -0.40 (95% 
CI, -0.58, -0.18). Clear heterogeneity was shown: I2 = 95.7%, x2 = 187.58, P<0.0001.
figure 3. Meta-analysis of the correlation postoperative fibrinogen and postoperative blood 
loss.
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Sixteen studies contributed to the meta-analysis on the association between 
postoperative fibrinogen level and blood loss. Calculated correlations were all 
below -0.07 (Figure 3). In a random effects model, the pooled correlation for the 
association between postoperative fibrinogen levels and blood loss was -0.23 (95% 
CI, -0.29, -0.16). Tests for heterogeneity showed the following results:  I2 = 54.5%, 
x2 = 32.97, P = 0.005).
DIscussIon
The present meta-analysis revealed a significant pooled correlation between pre-
operative (r = -0.40, 95% CI, -0.58, -0.18) or postoperative (r = -0.23, 95% CI, -0.29, 
-0.16) fibrinogen levels on the one hand and blood loss after cardiac surgery on 
the other hand. This confirms the important role of fibrinogen in the coagulation 
process. However, as the correlation is not very strong, it is likely that other factors 
like hematocrit, thrombin formation, platelet number and function and clotting 
enzyme activities are at least as important in the origination of excessive blood 
loss.
Despite the presence of statistical heterogeneity among studies, likely reflect-
ing methodological differences between studies, all included studies showed a 
negative correlation between fibrinogen level and postoperative blood loss. Be-
cause of this absence of qualitative heterogeneity, we decided to pool correlation 
coefficients in a random-effects model, which partly accounts for heterogeneity.
It is important to state that the primary aim of this study was to evaluate the 
correlation an association between the pre- and postoperative fibrinogen levels 
and blood loss after cardiac surgery. This may be is most validly represented by 
the preoperative measurement. Due to operation influences e.g. CPB usage, 
hemodilution, platelet dysfunction etc. (5,16), the postoperative fibrinogen levels 
are probably more biased, and therefore, less accurate for this evaluation, even 
when no FFP or fibrinogen administration is reported in the original article. These 
surgery related hemostatic defects may have had more impact causing bleeding 
than those existing prior to the operation (17). Still, the preoperative correlation 
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found is stronger than the postoperative one, suggesting that surgical procedures 
also might have a negative, downsizing effect on the correlation. Ternström  (18) 
demonstrated a correlation between pre- and postoperative fibrinogen level (r = 
0.80, P<0.001), suggesting that the time point at which fibrinogen is measured 
might be less important.
Hemodilution due to the use of CPB and volume supplementation reduces 
coagulation factor levels to approximately 25-50% of baseline, parallel with the de-
crease of the hematocrit level (1,18,19). Each coagulation factor has to be present 
at a minimum level adequate to support hemostasis, often well below the normal 
range. Simultaneous reductions in multiple coagulation factor levels that develop 
during CPB, therefore, generally do not result in bleeding complications (16). How-
ever, patients with a lower baseline value are more prone to develop a fibrinogen 
level insufficient to ensure adequate coagulation. Moreover, if a low fibrinogen 
level occurs in combination with other factors impairing the strength of clot forma-
tion the risk of bleeding may increase. In this context Fenger-Erikson  (20) demon-
strated that a dilutional coagulopathy due to administration of hydroxyethyl starch 
(HES) products resulted in less stable clotting assessed by thromboelastometry. 
Also, patients undergoing urgent surgery while using (dual) antiplatelet therapy 
may need higher fibrinogen levels to avoid excessive bleeding. Unfortunately, only 
a few studies in our review included urgent surgery patients and no correlation 
between fibrinogen levels and bleeding in this population was possible. The lowest 
average of fibrinogen levels reported in the assessed articles for this meta-analysis 
is 2.6 ± 0.79 g/l pre- and 1.6 ± 1.18 g/l postoperative, normal reference range is 
1.5-4.0 g/l.
Other laboratory parameters, e.g. activated partial thromboplastin time (APTT), 
prothrombin time (PT), platelet count have also been studied in this context 
(2,5,7,13), but all these tests, including fibrinogen, have (as single parameter) 
limited utility for diagnosis of postoperative coagulopathy because their results 
are only weakly associated with parameters of clinical bleeding or because they 
are not rapidly available (7,21). Collective assessment of several laboratory values 
using thromboelastography (TEG) or whole blood hemostatometry may provide 
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more applicable diagnostic information (5,21), but their association with blood loss 
remains low.
Although, the correlation between fibrinogen levels and blood loss is not very 
strong, fibrinogen concentration administration in patients with ongoing bleeding 
could be considered as a possible treatment option. Indeed, several investigators 
advocate that fibrinogen can act as first-line therapy to correct postoperative 
bleeding and reduce the use of allogeneic blood products without evidence of 
thrombotic complications (10). A recent meta-analysis on the effect of fibrinogen 
concentrate in patients with various bleeding conditions reported no outcome 
differences for bleeding, mortality, length of stay at the intensive care unit or side 
effects. Patients treated with fibrinogen concentrate used significantly less other 
blood products. The authors concluded that the six included RCTs were of low 
quality and comprised altogether only 248 patients, not all eligible for evaluation 
for all outcome effects (22). In this context, it is important to note that fibrinogen 
is an acute-phase protein which level increases gradually after surgical procedures 
(1,10,18). Therefore, the use of fibrinogen concentrate, in combination with this 
physiologic increase postoperative, might enlarge the risk of thrombosis.
Many studies concluding that there is no statistically significant correlation 
between fibrinogen and postoperative blood loss did not give information about 
the strength of the correlation or exact P-value, and could therefore not be in-
cluded. This reporting bias could have been further influenced by unpublished 
studies failing to demonstrate significant correlations. Therefore, the association 
between fibrinogen and postoperative blood loss that we calculated could be over-
estimated. Other important limitations of this meta-analysis are the low power and 
quality of the included studies, the substantial heterogeneity among studies and 
the variability in the definition of the endpoint blood loss. Systematic reviews on 
the effect of intervention with fibrinogen concentrate reveal similar lack of quality 
of the studies (22, 23). However, fibrinogen supplementation is currently solely 
substantiated on this questionable information. The different assays used among 
studies, should not be of influence on the analysis of the association with bleeding, 
while the comparison between PEBL and non-PEBL within the article is performed 
by the same assay. Also, although the definition of blood loss or a bleeding patient 
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appeared to be highly divergent among studies, overall, blood loss of  >200 ml per 
hour or > 1 liter in the postoperative period was considered as excessive bleeding. 
Furthermore, in some of the evaluated studies there is a lack of differentiation 
between patients who bleed from surgical causes and those that apparently have a 
severe coagulopathy without a specific surgical source of bleeding (24). Moreover, 
it is not always clear whether fibrinogen supplementation, transfusions of FFPs or 
platelets took place before sampling, influencing the results, or after the postop-
erative fibrinogen measurements. Finally, the usage of other methods to measure 
fibrinogen, like PT-derived method, or the presence of HES products may lead to an 
overestimation of the fibrinogen amount (25).
In conclusion, although the results of our meta-analysis support the association 
between lower fibrinogen levels and a higher bleeding risk after cardiac surgery, 
the correlation is weak to moderate, the studies evaluated contain substantial het-
erogeneity, and are of low power and quality. However, this cumbersome available 
information forms the current base to substantiate fibrinogen supplementation. 
Fibrinogen supplementation for patients with a lower preoperative fibrinogen level 
or concomitant factors impairing coagulation such as the use of antiplatelet drugs 
might have a beneficial effect in reducing the risk of excessive blood loss, but stud-
ies of better quality, preferentially randomized, are required before any specific 
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aPPEnDIx a
Predefined search terms for electronic databases
PubMed
((”cardiac surgery” OR ”heart surgery” OR ”cardiac surgical” OR ”heart surgi-
cal” OR ”Cardiac Surgical Procedures”[mesh:noexp] OR Cardiomyoplasty OR 
”Heart Bypass, Right”[mesh] OR ”heart bypass” OR ”Heart Valve Prosthesis 
Implantation”[mesh] OR ”Heart Valve Prosthesis Implantation” OR ”Myocar-
dial Revascularization”[mesh:noexp] OR ”Myocardial Revascularization”[tw] OR 
”Atherectomy, Coronary”[mesh] OR ”Coronary Atherectomy” OR ”Coronary Artery 
Bypass”[mesh] OR ”Coronary Artery Bypass” OR cabg OR ”Internal Mammary-
Coronary Artery Anastomosis”[mesh] OR ”Internal Mammary-Coronary Artery 
Anastomosis” OR ”Heart Diseases/surgery”[Mesh] OR ”Cardiovascular Diseases/
surgery”[Mesh]) AND (fibrinogen OR fibrinogens OR ”Coagulation Factor I” OR 
”Factor I”) AND (”blood loss” OR Hemorrhage OR Haemorrhage OR Hemorrhages 
OR Haemorrhages OR Hemorrhagic OR Haemorrhagic OR hematoma OR haema-
toma OR hematomas OR haematomas)) NOT (child NOT adult) AND (English[lang] 
OR French[lang] OR German[lang] OR Dutch[lang])
Embase
((heart surgery/ or cardiomyoplasty/ or coronary artery surgery/ or heart valve 
surgery/ or heart ventricle remodeling/ or minimally invasive cardiac surgery/ or 
mustard operation/ or norwood procedure/ or open heart surgery/ OR (”cardiac 
surgery” OR ”heart surgery” OR ”cardiac surgical” OR ”heart surgical” OR Cardio-
myoplasty OR ”Heart Bypass*” OR ”Heart Valve Prosthe*” OR ”Myocardial Revas-
cularization” OR ”Coronary Atherectom*” OR ”Coronary Artery Bypass*” OR cabg 
OR ”Internal Mammary-Coronary Artery Anastomosis”).mp OR exp heart disease/
su) AND (fibrinogen/ OR fibrinogen*.mp OR ”Coagulation Factor I”.mp OR ”Factor 
I”.mp) AND (exp bleeding/ OR (”blood loss” OR Hemorrhag* OR Haemorrhag* 
OR hematoma* OR haematoma*).mp)) AND (adult/ or aged/ or middle aged/ OR 
adult*.mp) limit 10 to (dutch or english or french or german)
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Web of science
TS=((“cardiac surgery” OR “heart surgery” OR “cardiac surgical” OR “heart surgical” 
OR Cardiomyoplast* OR “Heart Bypass*” OR “Heart Valve Prosthe*” OR “Myocar-
dial Revascularization” OR “Coronary Atherectom*” OR “Coronary Artery Bypass*” 
OR cabg OR “Internal Mammary-Coronary Artery Anastomosis”) AND (fibrinogen* 
OR “Coagulation Factor I” OR “Factor I”) AND (bleeding OR “blood loss” OR Hemor-
rhag* OR Haemorrhag* OR hematoma* OR haematoma*)) NOT TS=((child* OR 
infant*) NOT (adult* OR aged*))
Refined by: Languages=( ENGLISH OR GERMAN OR FRENCH OR DUTCH)
Cochrane
ID Search
#1 MeSH descriptor Cardiac Surgical Procedures, this term only
#2 MeSH descriptor Cardiomyoplasty explode all trees
#3 MeSH descriptor Heart Bypass, Right explode all trees
#4 MeSH descriptor Heart Valve Prosthesis Implantation explode all trees
#5 MeSH descriptor Myocardial Revascularization, this term only
#6 (“cardiac surgery” OR “heart surgery” OR “cardiac surgical” OR “heart surgi-
cal” OR Cardiomyoplasty OR “heart bypass” OR “Heart Valve Prosthesis Im-
plantation” OR “Myocardial Revascularization” OR “Coronary Atherectomy” 
OR “Coronary Artery Bypass” OR cabg OR “Internal Mammary-Coronary 
Artery Anastomosis”) 
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Fibrinogen explode all trees
#9  (fibrinogen OR fibrinogens OR “Coagulation Factor I” OR “Factor I”) 
#10 (#8 OR #9)
#11 MeSH descriptor Hemorrhage explode all trees
#12 (“blood loss” OR Hemorrhage OR Haemorrhage OR Hemorrhages OR Haem-
orrhages OR Hemorrhagic OR Haemorrhagic OR hematoma OR haematoma 
OR hematomas OR haematomas)
#13 (#11 OR #12)
#14 (#7 AND #10 AND #13)
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#15 ((child* OR infant*) NOT (adult* OR aged*))
#16 #14 AND #15
#17 (#14 AND #15)
#18 (#14 AND NOT #15)
cInahl
((“cardiac surgery” OR “heart surgery” OR “cardiac surgical” OR “heart surgical” OR 
Cardiomyoplast* OR “Heart Bypass*” OR “Heart Valve Prosthe*” OR “Myocardial 
Revascularization” OR “Coronary Atherectom*” OR “Coronary Artery Bypass*” OR 
cabg OR “Internal Mammary-Coronary Artery Anastomosis”) AND (fibrinogen* OR 
“Coagulation Factor I” OR “Factor I”) AND (bleeding OR “blood loss” OR Hemor-
rhag* OR Haemorrhag* OR hematoma* OR haematoma*)) NOT ((child* OR infant*) 
NOT (adult* OR aged*)))
Academic Search Premier
((“cardiac surgery” OR “heart surgery” OR “cardiac surgical” OR “heart surgical” OR 
Cardiomyoplast* OR “Heart Bypass*” OR “Heart Valve Prosthe*” OR “Myocardial 
Revascularization” OR “Coronary Atherectom*” OR “Coronary Artery Bypass*” OR 
cabg OR “Internal Mammary-Coronary Artery Anastomosis”) AND (fibrinogen* OR 
“Coagulation Factor I” OR “Factor I”) AND (bleeding OR “blood loss” OR Hemor-
rhag* OR Haemorrhag* OR hematoma* OR haematoma*)) NOT ((child* OR infant*) 
NOT (adult* OR aged*)))
scienceDirect
((“cardiac surgery” OR “heart surgery” OR “cardiac surgical” OR “heart surgical” OR 
Cardiomyoplast* OR “Heart Bypass*” OR “Heart Valve Prosthe*” OR “Myocardial 
Revascularization” OR “Coronary Atherectom*” OR “Coronary Artery Bypass*” OR 
cabg OR “Internal Mammary-Coronary Artery Anastomosis”) AND (fibrinogen* OR 
“Coagulation Factor I” OR “Factor I”) AND (bleeding OR “blood loss” OR Hemorrhag* 
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Fibrinogen as precursor of fibrin, plays an essential role in clot formation. There are 
three main mechanisms associated with a reduction in fibrinogen concentration 
during cardiac surgery; hemodilution, consumption, and degradation. Moreover, 
early fibrinogen degradation products (FgDPs) can interfere with normal fibrin 
formation of intact fibrinogen.
Objectives
The aim of this study was to determine the relative contributions of hemodilution, 
consumption and degradation to fibrinogen loss in cardiac surgery and to evaluate 
the effects fibrinogen degradation products on blood clot formation in vitro.
Methods
First, fibrin and fibrinogen concentrations, their degradation products, hematocrit, 
and albumin concentrations were compared in 10 patients before and after iso-
lated coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass. 
Second, ex vivo fibrinogen supplementation experiments were performed. Finally, 
the effects of purified FgDPs on clotting time and clot firmness were established in 
vitro in whole blood by ROTEMTM.
Results
Fibrinogen plasma concentration decreased 30% during surgery. This drop appears 
to be mainly caused by hemodilution, since both hematocrit and albumin levels 
decreased and no relevant increase in D-dimer levels and FgDPs was observed. 
Furthermore, the coagulation profile normalized after addition of purified fibrino-
gen. Early FgDPs demonstrated a significant impact on in vitro whole blood clotting.
Conclusions
Although early FgDPs have a pronounced effect on blood clot formation in vitro 
and therefore may induce or enhance in vivo coagulopathy, the drop of fibrinogen 
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Fibrinogen, as precursor of fibrin, plays an essential role in clot formation. In 
contrast with most other coagulation factors that have enzymatic activity and can 
activate multiple downstream target molecules, fibrinogen is a structural protein 
that at the final stage of the coagulation cascade has a dual role as it enhances 
platelet aggregation and is converted into an insoluble fibrin clot. Modest changes 
in plasma concentration were not considered to be important for the hemostatic 
capacity of blood. However, recent reports have demonstrated that a decrease in 
fibrinogen plasma concentration of 25-50%, which resembles a decrease of 1-2 g/l, 
affects blood clot formation (1,2).
There are several mechanisms via which fibrinogen concentrations or function-
ality in blood can be decreased during cardiac surgery. Cardiopulmonary bypass 
(CPB) priming, volume replacement with crystalloids and colloids, and blood trans-
fusions containing low levels of fibrinogen and other coagulation factors (3), can 
result in hemodilution, and consequently, a significant reduction of fibrinogen (4), 
hematocrit (Ht), and albumin (Alb) concentrations. Second, excessive activation of 
the hemostatic system, owing to, for example, blood contact with the surface of 
the CPB circuit and operation trauma, occasionally instigate a disseminated intra-
vascular coagulation process with consumption of platelets, fibrinogen, and other 
coagulation factors. This process can be demonstrated by evaluation of the fibrin 
degradation product D-dimer (FbDP), which also reflects fibrinogen consumption. 
A third mechanism leading to fibrinogen loss during surgery is fibrinogenolysis or 
fibrinogen degradation, caused by e.g. plasmin mediated proteolysis after activa-
tion of plasminogen through tissue plasminogen activator (t-PA) (5). This mecha-
nism warrants special attention because it can not only reduce the concentrations 
of normal functional fibrinogen but it can also result in formation of various stages 
of fibrinogen degradation products (FgDPs) that can interfere with normal fibrin 
formation of intact fibrinogen. It is unknown to which extent these different 
mechanisms contribute to the decrease in fibrinogen concentration during cardiac 
surgery.
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Degradation of fibrinogen and FgDPs has direct effects on thrombus formation 
(6,7). Degradation of fibrinogen starts at the carboxyl terminus of the Aα-chain, 
a domain that is very sensitive to enzymatic proteolysis (8). Further degradation 
of fibrinogen takes place at specific sites on the Bβ- and γ-chains and results in 
the early FgDP designated fragments X and Y. Late stage degradation products are 
fragment E and fragment D1. FgDPs are considered an important risk factor for 
bleeding after thrombolysis therapy (9) and have been detected in high levels after 
coronary artery bypass graft (CABG) surgery performed in the absence of aprotinin 
(10). However, it is not known what effects various fibrinogen degradation frag-
ments have on rotation thromboelastometry  (ROTEMTM) analysis of coagulation.
The present study evaluates the contribution of hemodilution, fibrin(ogen) 
consumption, and degradation to fibrinogen concentration reduction after isolated 
CABG surgery with the use of tranexamic acid (i.e. standard procedure in most 
hospitals in the Netherlands). Furthermore, ex vivo fibrinogen supplementation is 
performed to confirm our findings and finally, the impact of FgDPs on in vitro whole 
blood clotting is studied.
MEthoDs
Patients
Ten adult patients undergoing elective, isolated CABG with usage of CPB and a 
preoperative fibrinogen concentration of less than 3.8 g/l (11) were included in this 
prospective, observational study. Patients that needed emergency surgery, with 
heart failure (defined as an echocardiographically estimated ejection fraction bi-
plane below 35%), a history of bleeding diathesis, or coagulopathy were excluded. 
Patient characteristics are shown in Table 1. The study protocol was approved by 
the Medical Ethical commission (MEC number P10.154) of the Leiden University 
Medical Centre (LUMC, Leiden, The Netherlands) and written informed consent 
was obtained from each patient.
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table 1. baseline and clinical characteristics.
age (years) 68.5 (54-80)
female 1 (10%)
logistic EuroscorE 2.37 (0.88-8.15)
carbasalate calcium continued before 
operation
9 (90%)
clopidogrel continued before operation 3 (30%)
operation time (min) 297 (215-385)
cPb* time (min) 127 (102-194)
aorta cross clamp time (min) 102 (79-140)
Minimal ph during surgery 7.35 (7.28-7.44)
Minimal rectal temperature (°c) 34.5 (32.6-35.5)
tranexamic acid used (mg) 3923 (2000-4927)
Postoperative blood loss witdin 24 h (ml) 780 (200-1240)
Preoperative laboratory values (t0)
hemoglobin (mmol/l) 8.7 (7.3-9.0)
hematocrit (l/l) 0.41 (0.36-0.46)
fibrinogen clauss (g/l) 3.2 (2.4-3.7)
fIbtEM Mcf† (mm) 14 (10-18)
aPtt (s) 29.7 (25.9-32.4)
Pt (s) 15.3 (13.7-16.3)
Platelet count (x109/l) 159 (116-276)
* Cardiopulmonary bypass; † ROTEMTM analysis of the maximum clot firmness (MCF) with 
FIBTEM for the assessment of fibrinogen under platelet inhibition by cytochalasine D. Data are 
presented as number (percentage) or median (range).
Clinical management
CABG surgery was performed according to local standardized protocol. All surgical 
procedures were executed via a midline sternotomy under normothermic CPB ma-
chine (Jostra Maquet, Marquet, Hirrlingen, Germany) with intermittent antegrade 
warm-blood cardioplegia and prevention of acidosis. Heparin was injected as single 
bolus (300 U/kg in both groups) and the degree of anticoagulation was monitored 
using the activated clotting time (ACT, Hemochron Signature Elite; ITC; Pleasanton, 
CA, USA). Additional heparin (5000 U) was given if the ACT fell below 400 s. After 
surgery heparin was neutralized with protamine sulphate (1000 IE heparin with 10 
mg protamine sulphate). Patients were followed until discharge from the hospital. 
None of the patients received fresh frozen plasma or fibrinogen concentrate trans-
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fusion prior to blood sampling. Three patients received cell saver with a median of 
474 ml (150-750). Tranexamic acid was used in all patients with a median of 3923 
mg (2000-4927).
Coagulation measurements
Of each patient citrated whole blood aliquots with 0.105 mol/l buffered trisodium 
citrate solution (BD Vacutainer, Plymouth, UK) were sampled preoperative (T0) and 
directly after sternum closure (T1). All samples were drawn from the central venous 
line (v. jugularis). Standard blood tests were performed at the hospital laboratory. 
Within 10 min after obtaining the sample ROTEMTM (Pentapharm, Munich, Ger-
many), analysis was performed and the remaining aliquots were centrifuged at 
2700 g for 10 min at 18 ºC to obtain platelet-poor plasma. Plasma was aliquotted 
and stored at -80 ºC until batch analysis. Albumin concentrations were measured 
using the ALB plus assay (Cobas, Roche Diagnostics, Mannheim, Germany), to dif-
ferentiate between a general dilution of the blood or a specific fibrinogen loss (by 
other cause).
Functional fibrinogen concentrations in plasma were determined according 
to the method by Clauss (12), using STA fibrinogen reagent (Roche Diagnostics, 
Almere, The Netherlands). ROTEMTM analysis was performed in two channels, 
with EXTEM as extrinsic test and FIBTEM for fibrinogen assessment under platelet 
inhibition by cytochalasine D. For both EXTEM and FIBTEM clotting time (CT), clot 
formation time (CFT), and maximum clot firmness (MCF) were determined. Total 
fibrinogen antigen, reflecting all fibrinogen species in plasma, was measured using 
the Polyclonal Rabbit Anti-Human Fibrinogen ELISA (Dako, Glostrup, Denmark), 
reacting with all fibrinogen species in plasma. The level of intact fibrinogen, repre-
senting only fibrinogen species that contain intact Aα chain, was measured using 
an ELISA based on two monoclonal antibodies (Mab) that react with the carboxyl 
terminus (G-8) and amino terminus (Y-18) of the fibrinogen Aa chain (13). Fibrin 
degradation products, that is, D-dimers (FbDPs), which reflect fibrinogen consump-
tion, were determined using STA Liatest D-dimer (Roche Diagnostics, Almere, The 
Netherlands). Furthermore, a quantitative evaluation of plasmin-induced fibrino-
gen degradation was performed by determination of  FgDPs using an ELISA based 
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on 2 Mabs; the Y-18 and the FDP-14. The latter Mab is specifically designated for 
plasmin degradation products. Qualitative assessment of fibrinogen degradation 
was performed using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) (Invitrogen, Carlsbad, CA, USA). To exclude degradation of fibrinogen 
by proteolytic enzymes other than plasmin, qualitative assessment of fibrinogen 
degradation using Western blot analysis was performed with Mab Y-18. In this 
analysis, the gradation profile of the carboxyl terminal region of the fibrinogen 
Aa chain was used as an indicator for fibrinogen degradation. Fibrinolysis activa-
tion was analyzed via t-PA measurement using TECHNOZYM® t-PA Antigen ELISA 
(Technoclone GmbH, Vienna, Austria). All samples were analysed without any 
knowledge of any clinical data or patient outcomes.
Fibrinogen supplementation
To determine if indeed the reduction in fibrinogen concentration is causally related 
to the observed prolonged CT and reduced MCF, and not the dilution of other 
coagulation factors, we performed an ex vivo supplementation study were puri-
fied fibrinogen (Haemocomplettan, CSL) was added to blood of the CABG patients 
sampled after sternum closure (n=10).
The purified plasma fibrinogen was dissolved in phosphate-buffered saline to 
a concentration of 10mg/ml (A280,1% = 15.0). Than 0.18ml of fibrinogen solution 
or PBS was added to 1.2ml of whole blood.  ROTEMTM analysis in the EXTEM mode 
was performed as described by the manufacturer and the effect of adding purified 
fibrinogen on CT and MCF was recorded.
Effects of fibrinogen degradation products (FgDPs) on coagulation
Early and late-stage FgDPs were prepared and purified as described by Nieuwenhui-
zen  (6) and kindly provided by M. Voskuilen. To determine the purity and estimate 
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their molecular weights, the FgDPs were analysed using non-reducing SDS-PAGE 
(Life Technologies, The Netherlands). Citrated whole blood was diluted 1:1 using 
ringer lactate that contained various concentrations of the different FgDPs.
The influence of early (fragment X and Y) and late-stage (fragment D1) FgDPs on CT, 
CFT, and clot firmness (A 25) of the diluted whole blood of healthy volunteers was 
determined using ROTEMTM analysis in the EXTEM mode.
Statistical analysis
Data is mainly reported as median (range). Differences between pre and postop-
erative fibrinogen and fibrin concentrations and their degradation products, he-
moglobin, hematocrit, albumin concentrations, and platelet count were calculated 




The functional Clauss assay revealed a median plasma fibrinogen concentration of 
3.2 g/l (2.4-3.7) preoperative and 2.0 g/l (1.5-2.7) after sternum closure, indicating 
a 34% decrease during cardiac surgery (P=0.005, Supplementary Table 1). MCF de-
creased significantly in both in EXTEM (10%, P=0.007) and FIBTEM (43%, P=0.005) 
analysis (Table 2).
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table 2. Pre- and postoperative laboratory values.
Preoperative (t0) after sternum 
closure (t1)
Median ∆ (%) p
total fibrinogen (mg/ml) 2.7 (2.0-3.7) 1.9 (1.5-2.7) -28 0.005
Intact fibrinogen (mg/ml) 2.7 (2.0-3.5) 1.9 (1.7-2.3) -29 0.005
fibrinogen clauss (g/l) 3.2 (2.4-3.7) 2.0 (1.6-2.7) -34 0.005
ExtEM
ct (s) 52 (44-88) 65 (35-94) 23 0.201
cft (s) 102 (69-130) 152 (126-219) 52 0.005
Mcf (mm) 63 (54-67) 55 (50-60) -10 0.007
Ml (%) 5 (1-13) 0 (0-0) -100 0.027
fIBTEM
ct (s) 57 (41-101) 64 (46-84) 9 0.283
cft (s) NA NA NA NA
Mcf (mm) 14 (10-18) 7 (6-14) -43 0.005
fbDPs (ng fEu/ml) 338 (209-1209) 838 (209-1532) 114 0.059
fgDPs (ng fEu/ml) 157 (70-260) 170 (105-272 14 0.241
t-Pa (ng/ml) 0.9 (0.2-1.8) 2.5 (0.5-4.3) 157 0.013
hemoglobin (g/l) 8.7 (7.3-9) 6.4 (4.7-7.7) -25 0.005
hematocrit (%Pcv) 0.41 (0.36-0.46) 0.31 (0.23-0.38) -25 0.005
albumin (g/l) 36.6 (29.9-38.5) 23.8 (20.6-27.0) -30 0.005
Platelet count (×109/l) 159 (116-276) 120 (70-194) -29 0.005
Fibrinogen levels (total and intact ELISA, Clauss); thromboelastometry (EXTEM) assessment of 
clotting time (CT); clot formation time (CFT); and maximum clot firmness (MCF); not available 
(NA); maximum lysis (ML); fibrin (FbDP) and fibrinogen (FgDP); degradation products, tissue 
plasminogen activator (t-PA); hemoglobin, hematocrit, and platelet count immediately before 
surgery (T0); and directly after sternum closure (T1). Data are median (range).
Total fibrinogen antigen concentrations demonstrated a median preoperative level 
of 2.7 g/l (2.0-3.7) as compared to 1.9 g/l (1.5-2.7) after sternum closure, indicating 
a reduction in total fibrinogen antigen of 28% (P=0.005).
Intact fibrinogen antigen concentrations demonstrated similar results with a 
median level of 2.7 g/l (2.0-3.5) preoperative and 1.9 g/l (1.7-2.3) after sternum 
closure, representing a 29% reduction in intact fibrinogen antigen levels (P=0.005).
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Hemodilution
The hematocrit level demonstrated a significant reduction of 25% (P=0.005) and 
was decreased to a median of 0.31 (0.23-0.38) after sternum closure compared 
to 0.41 (0.36-0.46) preoperative (Table 2, Figure 1). Hemoglobin and albumin con-
centrations in plasma confirmed this finding with a corresponding 25% (P=0.005) 
and 30% (P=0.005) decline, respectively. During reperfusion, after releasing the 
aortic clamp, patients presented the lowest hematocrit levels with a median of 
0.29 (0.23-0.32).
figure 1. Median postoperative percentage of functional, intact and total fibrinogen (fgn) 
loss, as compared to the hematocrit (ht) and albumin (alb) levels. Error bar (SD).
Consumption
D-dimer (FbDP) concentrations demonstrated a median rise of 338 ng Fibrinogen 
Equivalent Units (FEU)/ml (209-1209) in preoperative samples to 838 ng FEU/ml 
(209-1532) after sternum closure, which was not significant (P=0.059, Supple-
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mentary Table 2). Five patients revealed an increase ranging from 173 to 343% 
(P=0.043), while other patients demonstrated lower increases or even decreasing 
FbDPs.
Degradation
Small differences, both increases and decreases, in fibrinogen degradation prod-
ucts (FgDP) concentrations were observed. The median FgDP concentration in 
preoperative samples was 157 ng FEU/ml (70-260) which remained quite stable 
after sternum closure (Supplementary Table 2).
Western blot analysis, as presented in Figure 2, did not reveal any differences 
in the Aa chain profile between preoperative samples and samples after sternum 
closure, indicating that no detectable proteolytic degradation of fibrinogen has 
taken place during the surgery. As the detection antibody used , Y-18, specifi-
cally detects fibrinogen, and not fibrin, the second band observed in most of the 
samples suggests the presence of very early degradation products of the Aα-chain 
of fibrinogen.
t-PA concentrations increased approximately 3 times after sternum closure 
(P=0.013), but there was no clear correlation between t-PA concentrations and 
FgDP or FbDP products. Two patients revealed almost a tenfold increase in t-PA 
levels after sternum closure, without (equally) elevated FgDPs and FbDPs relative 
to the other patients.
Fibrinogen supplementation study
The average CT after sternum closure increased to 65 s (35-94), whereas preopera-
tive samples showed an average CT of 52 s (44-88). The average MCF after sternum 
closure was decreased to 55 mm (50-60), whereas the preoperative measurement 
showed an average MCF of 63 mm (54-67). Addition of purified fibrinogen to the 
samples taken after sternum closure resulted in a shortening of the CT and an 
increase of the clot firmness (A25, Figure 3). Taking into account the effect of the 
approximately 10% dilution introduced by adding fibrinogen or PBS solution to 
whole blood samples, both the CT and clot firmness returned to levels similar to 
that measured in undiluted preoperative whole blood samples.
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figure 2. reduced western blot analysis.
Patient 1 till 10, preoperative (A) and after sternum closure (B), with a positive control (CSL).
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figure 3. fibrinogen (fgn) supplementation study.
Effects of fibrinogen degradation products on coagulation
The purified FgDPs (Figure 4) showed the progressive degradation of fibrinogen 
with a MW of approximately 340 kDa into fragment X (MW approximately 260 kDa), 
fragment Y (MW approximately 160 kDa), and fragment D1 (Mw approximately 90 
kDa). Estimated purity of the fragments used was >95%.
Figure 5A showed that the early FgDPs fragments X and Y prolonged the CT 
at concentrations of 0.2-4 µmol/l, reflecting fibrinogen to FgDP ratios in the test 
samples ranging from approximately 1:0.06 to approximately 1:1. Fragment D1 did 
not show a significant influence on the CT up to a concentration of 3.6 µmol/l re-
flecting a fibrinogen to fragment D1 ratio of approximately 1:1. Similar results were 
obtained when recording the CFT in the same samples. Figure 5B demonstrates 
the effect of the different FgDPs on the clot firmness, which is represented by the 
amplitude recorded at 25 min (A25).
3
Fibrinogen reduction and coagulation in cardiac surgery 67
figure 4. non reduced sDs-PagE analysis of fibrinogen degradation products (fgDPs).
Lane 1 HiMark (Life Technologies), Lane 2 HMW Fibrinogen (ERL FIB3) ˜ 340 kD, Lane 3 Fibrino-
gen degradation fragment X  ˜ 260 kD, Lane 4 Fibrinogen degradation fragment Y  ˜ 160 kD, 
Lane 5 Fibrinogen degradation fragment D1  ˜ 90 kD.
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figure 5. Effects of fibrinogen degradation products (fgDPs) in rotEMTM ExtEM analysis.
A on clotting time (CT)
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DIscussIon
The 30% decrease  in plasma fibrinogen concentration seen during CABG surgery 
appears to be mainly caused by hemodilution. No relevant consumption or deg-
radation was observed under the condition that tranexamic acid was present. 
Furthermore, normalization of the clot firmness during ROTEMTM analysis after 
ex vivo addition of purified fibrinogen confirmed that the reduction in fibrinogen 
concentration is causally related to the observed prolonged CT and reduced MCF, 
and not the dilution of other coagulation factors. Finally, the early FgDPs had a 
pronounced effect on blood clot formation in vitro.
There seems to be little evidence that fibrinogen consumption plays an impor-
tant role in the fibrinogen decrease during cardiac surgery, as D-dimer (FbDP) con-
centrations did not increase. The rise of more than 100% in FbDP concentrations 
seen in 5 individuals after sternum closure is comparable to an increase of 1 µg/ml 
in plasma concentration, and therefore, could only account for a decrease of less 
than 0.1% in fibrinogen concentrations.
FgDPs did not reveal a significant increase after sternum closure, indicating that 
the contribution of fibrinogen degradation to the decline in fibrinogen concentra-
tions after operation also is limited. Fibrinogen degradation might have occurred 
by proteases other than plasmin, since the FgDP ELISA uses a monoclonal antibody 
that is specific for plasmin FgDPs. However, the absence of any alteration in the 
degradation profile of the Aa chain in Western blot analysis excludes this option. 
Another explanation may be the administration of tranexamic acid during surgery in 
order to prevent fibrinolysis via plasminogen activation. Takada  (14) demonstrated 
that tranexamic acid inhibited fibrinolysis as measured by the generation of FbDPs, 
but that it inhibited fibrinogenolysis only partly. The concentrations of tranexamic 
acid reported to prevent FgDP generation in vitro (15) are 10-fold higher than those 
applied in clinical settings (5.5 mg/ml relative to 0.2-0.5 mg/ml). Nevertheless, no 
FgDPs were observed in the plasma of patients, indicating that in vivo the relatively 
low tranexamic acid levels were sufficient to prevent fibrinogenolysis. The rise in 
t-PA concentration seen after sternum closure possibly resulted as a reaction to 
surgical manipulation, damaging the endothelial cells and inducing ischemia by 
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arterial or venous occlusion (16), hypothermia, and blood return from pericardial 
suction (17), without clinical evidence of fibrinolysis.
As we observed a median drop of 25% in hematocrit level and a correspond-
ing decrease of 30% in albumin concentration between pre- and postoperative 
measurements, we believe that hemodilution, causing dilutional coagulopathy, is 
the most important mechanism reducing fibrinogen concentration during CABG 
procedures with the usage of CPB and tranexamic acid. The parallel decrease in 
hematocrit and fibrinogen concentration during cardiac surgery with usage of CPB 
is confirmed by several studies (18,19).
To determine if indeed the reduction in fibrinogen concentration is causally 
related to the observed coagulopathy as measured by ROTEM (with prolonged CT 
and reduced MCF), and not the dilution of other coagulation factors, we performed 
an ex vivo supplementation study were purified fibrinogen (Haemocomplettan, CSL) 
was added to the postoperative blood of the CABG patients. This study showed that 
both the CT and MCF values measured with ROTEMTM normalized to preoperative 
values after addition of only purified plasma fibrinogen. This demonstrates that 
dilution of other blood components like platelets and other coagulation factors 
have little effect on whole blood clotting, and therefore, that fibrinogen concentra-
tion is the rate limiting factor.
FgDPs have been reported to interfere with fibrin formation in plasma through 
inhibition of fibrin polymer formation. This is first described by Nieuwenhuizen   in 
1982 (6) who found that fragments Y exhibit twice as much anticlotting activity as 
fragments X. Using the very same fragments we demonstrated that in vitro early 
FgDP fragment Y and X not only have a significant impact on the CT of whole blood 
of healthy volunteers, but also on the clot firmness (MA), both measured here for 
the first time using ROTEMTM analysis and as such created significant coagulopathy 
in whole blood. Late FgDP fragments D1 showed very little influence on these 
parameters, suggesting that the effect of FgDPs could be transient and that it can 
vary with the stage of degradation. These findings suggest that in vivo only limited 
degradation of fibrinogen, resulting in the presence of fragments Y and X, may have 
a strong effect on coagulation. First by reduction of the fibrinogen concentrations 
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directly, and secondly, and more importantly, via the generation of the inhibitory 
fragments Y and X.
There are several limitations to this study. First, it is important to note that all 
patients in this study received tranexamic acid (according to standard protocol in 
most hospitals in the Netherlands), a lysine analogue that reduces plasminogen 
activation by preventing the binding of plasminogen to fibrin and thereby reduc-
ing plasmin-mediated degradation of fibrin. Without the use of tranexamic acid, 
probably, the role of degradation in fibrinogen concentration reduction is more 
pronounced and the level of FgDPs increased. Second, almost all patients used 
antiplatelet medication before CABG surgery, possibly influencing ROTEMTM results 
for functional fibrinogen and fibrinogen supplementation testing. However, Lang 
(20) demonstrated that acetylsalicylic acid and clopidogrel did not have any influ-
ence on ROTEM measurements. While healthy volunteers were used to determine 
the effects of FgDPs on clot firmness in ROTEMTM analysis, these results were cer-
tainly not affected by antiplatelet usage. Furthermore, fibrinogen is an acute phase 
protein, which is very fast regenerated. This mirrors the chance that the balance of 
fibrinogen metabolism between consumption and synthesis is towards synthesis. 
Finally, the study consists of only a few patients, but contains a large amount of 
measurements.
In conclusion, hemodilution appears to be the primary cause of the 30% plasma 
fibrinogen concentration drop seen in this investigational study in patients under-
going CABG surgery using tranexamic acid. Normalization of the coagulation profile 
after ex vivo addition of purified fibrinogen confirmed that fibrinogen is the first 
clotting factor to drop below a critical level and a major contributor to the onset of 
dilutional coagulopathy. Supplementation of fibrinogen after cardiac surgery could 
therefore contribute to the treatment of dilutional coagulopathy as suggested 
by Rahe-Meyer  (21,22) and Levy  (2). Furthermore, early fibrinogen degradation 
products (FgDPs) have a pronounced effect on blood clot formation in vitro and 
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Hemostatic alterations during 
coronary artery bypass grafting
Chantal L.I. Gielen, Anneke Brand, Waander L. van Heerde, Theo Stijnen, Robert 
J.M. Klautz and Jeroen Eikenboom




The origination of blood loss after cardiac surgery is not fully explained, but is 
related to operation trauma and use of cardiopulmonary bypass (CPB). However, 
the extent of their contribution is incompletely known and might differ between 
distinct operation procedures.
Materials and Methods
Three groups of CABG procedures were studied: 1) off-pump coronary artery by-
pass surgery (OPCAB, n=11) without CPB, 2) CABG with use of CPB (CABG, n=11) 
and 3) CABG with use of CPB combined with aortic valve replacement (AVR, n=11). 
Activation of coagulation and fibrinolysis was measured at various time points by 
flow cytometry, platelet aggregometry, thrombelastography, the Nijmegen Hemo-
stasis Assay, prothrombin fragment 1+2 and tissue plasminogen activator.
Results and Conclusions
The use of CPB during cardiac surgery decreased platelet counts, clot strength, 
fibrinogen, hematocrit and albumin concentrations during the procedure. No peri-
operative platelet activation was observed and functional (collagen induced) plate-
let aggregation was transiently impaired, but recovered after surgery in all groups. 
Patients operated with use of CPB showed increased tissue plasminogen activator 
concentrations after reperfusion followed by minor and transient fibrinolysis. After 
all types of surgery coagulation parameters and platelet aggregation showed a 
rebound above preoperative levels. To conclude, no evident platelet activation, 
dysfunction or consumption was demonstrated. In patients using tranexamic acid 
the most prominent factor impairing hemostasis after CABG surgery was hemodilu-
tion associated with CPB.
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IntroDuctIon
Bleeding necessitating blood transfusions or requiring exploration by reoperation 
is a common complication after cardiac surgery (1,2). A bleeding of surgical origin 
is found in half of the patients undergoing reoperation (3). In the remainder of 
patients there is diffuse bleeding. An unambiguous explanation for the origination 
of bleeding tendency has not yet been established. Ineffective hemostasis can 
be due to pre-existing coagulation factor deficiencies, drug-induced inhibition of 
hemostasis or surgery related acquired hemostatic defects (2,4). Suggested causes 
of acquired hemostatic defects in cardiac surgery include usage of heparin, he-
modilution due to priming fluids of the cardiopulmonary bypass (CPB) circuit (5), 
activation of clotting by the non-endothelial CPB surface,  hypothermia, acidosis, 
tissue trauma, platelet dysfunction and excessive fibrinolysis (4,5-8).
The extent of the contribution of each of those factors remains unresolved.
To gain more insight in the hemostatic disorders that develop during cardiac 
surgery, while using tranexamic acid, we have measured activation of coagulation 
and fibrinolysis by the release of prothrombin fragment 1+2 and tissue plas-
minogen activator at several time points during and up to 5 days after surgery in 
patients undergoing elective coronary artery bypass grafting (CABG). Furthermore, 
flow cytometry, platelet aggregometry, thrombelastography (TEG) (5,6) and the 
Nijmegen Hemostasis Assay (NHA), for simultaneous measurement of coagulation, 
fibrinolysis and the interplay of both (7), were performed.
MEthoDs
Patient population
This observational study included a total of 33 adult patients undergoing elective 
CABG surgery, equally divided into three groups; 1) off-pump coronary artery by-
pass surgery (OPCAB) without CPB, 2) CABG with use of CPB (CABG) and 3) CABG 
with use of CPB combined with aortic valve replacement (AVR). These three groups 
were chosen to compare the hemostatic effects of the surgery and tissue damage 
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itself (OPCAB group),  with the effects of the use of CPB (CABG group) and the ad-
ditional contribution of longer CPB times (AVR group). Patients needing emergency 
surgery, with heart failure (left ventricular ejection fraction <35%) or a history of 
bleeding diathesis or coagulopathy were excluded.
The study  was performed in accordance with the Declaration of Helsinki and 
relevant Dutch laws, and was approved by the hospitals’ ethics committee. All 
patients provided written informed consent.
Clinical and surgical management
All CPB procedures were executed normothermic (CPB machine (Jostra Maquet, 
Marquet, Hirrlingen, Germany), with intermittent antegrade warm-blood cardio-
plegia and prevention of acidosis. Heparin was injected as single bolus (300 U/kg 
in both groups) and monitored using the activated clotting time (ACT, Hemochron 
Signature Elite; ITC; Pleasanton, CA, USA). Additional heparin (5000 U) was given 
if ACT fell below 400 s. Tranexamic acid was used during surgery in 32 patients, 
using a bolus of 15 mg/kg prior to surgery and a continuous infusion of 5 mg/
kg during operation. Pump flow rates were settled between 2-2.5 l index with a 
systemic mean arterial pressure target of 50-70 mmHg and systemic vasodilators or 
vasoconstrictors were used to maintain pressure between the ranges. After surgery 
heparin was neutralized with protamine sulphate (1000 IE heparin:10 mg protamine 
sulphate). All blood from the operative field was filtered, stored in a separate cell 
saver system (Electa; Sorin Group; Mirandola, Italy) and retransfused according to 
local standards at the end of the procedure. Blood transfusion practice was based 
on the transfusion guidelines of the American Society of Anesthesiologists and the 
Dutch Institute for Healthcare Improvement (CBO). It recommends RBC transfu-
sion when the hemoglobin (Hb) level is <7 g/dl and advices against the use when 
the Hb is >9 g/dl. In case of the Hb is >7 g/dl and <9 g/dl, the transfusion trigger 
is determined by blood loss, cardiopulmonary reserve, age, comorbidity, and at 
the discretion of the anesthesiologist or intensivist. Patients were extubated when 
hemodynamically stable, rewarmed, awake, without surgical bleeding and with op-
timal blood gases. Antiplatelet medication and low-molecular-weight heparin were 
4
Hemostatic alterations during coronary artery bypass grafting 81
both (re)started on the first postoperative day. If indicated, vitamin K antagonists 
were started five days after operation.
Blood loss was determined by drainage from the pleural and mediastinal tubes 
immediately after surgery until 48 h postoperative. Chest tubes were removed 
when drainage was less than 20 ml per hour or 200 ml per 24 h.
Blood sample collection
Blood was sampled in citrate (0.105 mol/l buffered trisodium citrate solution, BD 
Vacutainer, Plymouth, UK), EDTA (BD Vacutainer) and CTAD (containing theoph-
ylline, adenosine and dipyridamol, BD Vacutainer) tubes at various time points: 
preoperative (T0), before CPB or 30 min after start of operation (T1), 30 min into 
CPB or 30 min after heparinisation administration (T2), 5 min after reperfusion 
(removal of aortic cross-clamp) or 5 min after completion of the last anastomosis 
(T3), 1 h after protamine administration (T4), postoperative days 1 (T5) and 5 (T6). 
Baseline (T0) and T6 samples were obtained via venous puncture. At all other time 
points blood was drawn from the central venous line.
Standard blood tests hematocrit (Ht), complete blood count, albumin, fibrino-
gen (Clauss, Roche Diagnostics, Almere, The Netherlands), D-dimer (Roche Diag-
nostics),  activated partial thromboplastin time (aPTT) and prothrombin time (PT) 
were performed at the hospital laboratory. Citrated whole blood was centrifuged 
at 2700 g for 10 min at 18 ºC and the CTAD tubes were centrifuged at 4200 g for 15 
min at 4 ºC , aliquotted and stored at -80 ºC until batch analysis. All samples were 
analyzed blinded for clinical data or patient outcomes.
Hemostasis parameters
Platelet tests Immediately after collection, P-selectin expression, spontaneous and 
induced by adenosine diphosphate (ADP, 10-4 mol/l) and Collagen Related Peptide 
( 10 μg/ml) ,were determined by whole blood flow cytometry (6) (Beckman Coulter 
FC500 MPL, Beckman Coulter, USA), at all time points.
Light transmission aggregometry (Chrono-Log 490 aggregometer, Chrono-Log 
Corporation Havertown, PA) with ADP (4 µmol/l), collagen (2.0 µg/ml) and arachi-
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donic acid (1.6 mmol/l) as activators was performed at T0, 2, 5 and 6 in platelet 
rich plasma.
Thrombelastography Within 10 min after sampling whole blood thrombelastog-
raphy (TEGR 5000 Thrombelastograph® Hemostasis Analyzer System, Hemonetics 
Corporation, USA) analysis was performed at all time points using kaolin as ac-
tivator. TEG parameters included the r value (intrinsic coagulation cascade activ-
ity), the α angle (speed of solid clot formation) and the maximal amplitude (clot 
strength, MA). The MA measurement was also separately performed for functional 
fibrinogen (FF MA), blocking GPIIb/IIIa receptors on platelets.
Coagulation and fibrinolysis prothrombin fragment 1+2 were measured at T0, 
3, 5 and 6 by   ELISA (Antibodies-Online, Aachen, Germany).
The Nijmegen Hemostasis Assay (NHA) was performed for simultaneous mea-
surement of coagulation and fibrinolysis at T0, 3, 5 and 6 (7). The NHA measures 
thrombin generation lag time (time between initiation and the start of thrombin 
generation, TGlt), time to peak thrombin generation (time at which the thrombin 
generation reached its maximal rate, TTP), thrombin peak height (maximal velocity 
of thrombin production, TPH) and area under the curve (thrombin generation ca-
pacity, AUC) for coagulation and the fibrin lysis time (FLT) and plasmin peak height 
(height of plasmin generation, PPH) for fibrinolysis.
Tissue plasminogen activator (t-PA) levels in CTAD plasma were determined at 
T0, 3, 5 and 6, using the Human tPA activity assay (Kordia, The Netherlands) which 
is not sensitive to tranexamic acid administration.
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Statistical analysis
For descriptive purposes we used medians and ranges. Statistical significance was 
defined as  P<0.05. For comparison of several outcome variables between the 3 
treatment groups at each time point and between time points, we used a linear 
mixed model with time and group and their interaction as categorical covariates 
and with compound symmetry as covariance model. All analyses were corrected 
for the following covariates: blood transfusions (i.e. red blood cells, fresh frozen 
plasma (FFP), platelet rich plasma and cell saver blood), preoperative acetylsali-
cylic acid and clopidogrel usage, dilution with colloids and crystalloids, and current 
value of hematocrit. The statistical analyses were performed using SPSS Statistics 
20.0 software (IBM Corporation, Armonk, NY).
rEsults
Patient characteristics
Patient groups significantly differed on 2 baseline characteristics: logistic EuroS-
CORE and extracardiac arteriopathy, defined as any one or more of the following: 
claudication, carotid occlusion or >50% stenosis, previous or planned intervention 
on the abdominal aorta, limb arteries or carotids (Table 1). All other baseline vari-
ables, including laboratory, were comparable among groups.
As expected patients in the AVR group had the longest operation, CPB and aortic 
clamping time, the lowest minimum temperature and received the highest amount 
of tranexamic acid and heparin during operation (Table 2). Patients operated on 
CPB (CABG and AVR) received more colloids during operation, while the amount of 
crystalloids was similar in the 3 groups.
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Male 8(73) 8(73) 7(64) 0.866
age (years) 74(55-88) 66(46-84) 78(53-86) 0.254
Diabetes mellitus 4(36) 4(36) 4(36) 1.000
Systemic hypertension 6(55) 6(55) 7(64) 0.883
unstable angina 0 2(18) 0 0.207
Previous cardiac surgery 0 2(18) 1(9) 0.333
Previous PTCA 1(9) 4(36) 1(9) 0.160
MI within 3 months before 
CABG
1(9) 1(9) 0 0.478
left ventricular ejection 
fraction
0.543
30-50% 3(27) 1(9) 2(18)
Extracardiac arteriopathy 4(36) 1(9) 0 0.047
renal insufficiency 1(9) 0 0 0.357
coPD 1(9) 2(18) 2(18) 0.790
logistic EuroscorE 4.02(1.22-11.51) 2.05(0.88-13.07) 4.92(1.51-17.05) 0.031
acetylsalicylic acid continued 5(45) 6(55) 7(64) 0.537
clopidogrel continued 4(36) 1(9) 1(9) 0.236
laboratory values (t0)
hemoglobin (mmol/l) 7.8(5.9-9.0) 8.5(6.5-9.1) 7.7(6.7-8.7) 0.155
hematocrit (l/l) 0.38(0.27-0.45) 0.42(0.34-0.44) 0.37(0.34-0.43) 0.326
albumin (g/l) 38(33-40) 40(30-48) 39(36-49) 0.301
fibrinogen clauss (g/l) 3.7(2.7-4.6) 3.2(2.1-3.7) 3.1(2.4-5.6) 0.087
functional fibrinogen Ma 
(mm)
66.5(55.7-73.4) 61.2(51.7-68.2) 65.0(51.3-77.8) 0.057
D-dimer (ng/ml) 668(225-3809) 294(220-1428) 341(223-2237) 0.083
Prothrombin fragments1.2 
(pg/ml)
0.21(0.08-0.51) 0.08(0.03-0.37) 0.11(0.04-0.36) 0.051
aPtt (s) 31.2(23.6-39.0) 29.5(24.9-35.3) 30.2(25.1-37.2) 0.559
Pt (s) 15.2(13.7-22.7) 15.2(13.3-16.1) 14.8(13.2-22.9) 0.408
Platelet count (x109/l) 202(159-318) 192(138-316) 202(128-371) 0.782
t-Pa (uI/ml) 0.01(0-0.05) 0.01(0-0.11) 0.01(0-0.09) 0.998
Median (range) or number (percentage) of patients. Chi-square was used and Kruskal-Wallis 
testing. OPCAB, CABG surgery without the use of CPB; CABG, CABG surgery with use of CPB; 
AVR, CABG surgery with use of CPB combined with aortic valve replacement (AVR); PTCA, 
Percutaneous Transluminal Coronary Angioplasty; MI, myocardial infarction; COPD, chronic 
obstructive pulmonary disease. TEG functional fibrinogen test, maximal amplitude (MA).
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operation time (min) 177(138-279) 271(195-486) 318(205-467) 0.000*
cPb time (min) - 105(83-297) 190(104-333) 0.000*
aortic clamping time (min) - 78(0-100) 141(87-258) 0.000*
colloid (ml) 500(0-1500) 1000(0-2150) 1000(500-1500) 0.033*
crystalloid (ml) 1500(500-1500) 1050(300-2300) 1250(480-1830) 0.636
red blood cells (ml) - 0(0-500) 0(0-750) 0.104
fresh frozen Plasma (ml) - - 0(0-300) 0.127
Platelets (ml) - 0(0-300) 0(0-300) 0.372
cell saver (ml) 0(0-1054) 0(0-947) 406(0-1087) 0.108
Patients receiving red 
blood cells
- 3(27) 4(36) 0.095
Patients receiving fresh 
frozen plasma
- - 2(18) 0.119
Patients receiving platelets - 1(9) 2(18) 0.361
Patients receiving cell saver 5(45) 4(36) 9(81) 0.077








Minimum ph 7.41(7.29-7.45) 7.36(7.24-7.43) 7.33(7.16-7.46) 0.014*
Maximum act (sec) 377(295-423) 473(430-789) 473(435-810) 0.000*
Minimum temperature (°c) 34.0(25.5-35.5) 34.3(29.4-35.5) 32.8(29.5-34.3) 0.045*
Intra-aortic balloon pump 
use
- - - -
Postoperative
In hospital mortality - - - -
blood loss (ml)  24h 570(170-2828) 680(350-2780) 610(300-950) 0.402
48h 570(170-3325) 680(420-3300) 610(300-1080) 0.250
colloid (ml) 0(0-1500) 0(0-1250) 250(0-1000) 0.948
crystalloid (ml) - - - -
red blood cells (ml) 0(0-1250) 0(0-1500) - 0.780
fresh frozen Plasma (ml) 0(0-1000) 0(0-1250) 0(0-500) 0.998
Platelets (ml) 0(0-300) 0(0-1300) 0(0-250) 0.324
cell saver (ml) 0(0-300) - - 0.368
Patients receiving red 
blood cells
1(9) 2(18) 0 0.333
Patients receiving fresh 
frozen plasma
2(18) 2(18) 2(18) 1.000
Patients receiving platelets 1(9) 3(27) 1(9) 0.390
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Patients receiving cell saver 1(9) - - 0.357
reoperation for bleeding 0(0-1) - - 0.368
Myocardial infarction - - - -
Intensive care unit length 
of stay (h)
24(20-88) 23(17-306) 23(18-113) 0.689
total length of stay (days) 4(3-8) 7(3-25) 7(4-10) 0.016*
Data presented as median (range) or number (percentage) of patients. Chi-square (categori-
cal) and Kruskal-Wallis (continuous) test. OPCAB, CABG surgery without the use of CPB; CABG, 
CABG surgery with use of CPB; AVR, CABG surgery with use of CPB combined with aortic valve 
replacement (AVR).
The total median amount of blood loss was not different between groups at both 
24 and 48 h after surgery. Two patients (1 OPCAB and 1 CABG) endured excessive 
blood loss of more than 2000 ml in the first 24 h after surgery. One of them (OP-
CAB) was re-operated for surgical bleeding. Furthermore, the  number of patients 
receiving blood transfusions and the amount of blood products received was equal 
among groups. Hospital admission was 3 days longer in patients in the CABG and 
AVR groups. One patient in the CABG group was hospitalized for 25 days due to an 
inflammatory reaction without a clear focus.
Hemodilution
A pronounced drop in Ht was observed in the CABG and AVR groups during the 
first 30 min of CPB (T2) and reperfusion (T3) (T0-T3 CABG 28% decrease; AVR 27% 
decrease, P<0.001). The Ht decrease in OPCAB group was minimal (T0-T3 11% 
decrease, P<0.001) and remained above 0.30 l/l (Figure 1). Five days postoperative 
the Ht level was still below preoperative Ht level in all groups (P<0.001).
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figure 1. Differences in coagulation and fibrinolysis laboratory values between groups.
OPCAB, CABG surgery without the use of CPB; CABG, CABG surgery with use of CPB; AVR, 
CABG surgery with use of CPB combined with aortic valve replacement; FGN, fibrinogen; TEG 
MA, TEG functional fibrinogen test; maximal amplitude (MA); F 1+2, prothrombin fragment 
1+2; Plt, platelets; tPA, tissue plasminogen activator; Ht, hematocrit. Preoperative (T0), before 
CPB (T1), 30 min into CPB or 30 min after the start of the first anastomoses in CABG surgery 
without CPB usage (T2), 5 min after reperfusion or 5 min after the completion of the last anas-
tomosis in CABG surgery without CPB usage (T3), 1 h after reperfusion (T4), 1 day after opera-
tion (T5) and 5 days after operation (T6). *P<0.05 between treatment groups.
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Albumin concentrations showed the same trend as Ht with a pronounced drop 
between baseline and reperfusion measurements in patients operated on CPB and 
a less outspoken in the OPCAB group (Figure 1). At 5 days postoperative albumin 
was nearly back to preoperative values.
Platelets
Platelet counts dropped during operation until 1 h after reperfusion in patients on 
CPB, although the decrease was only significant in the AVR group (29% decrease, 
P=0.011; CABG 21% decrease, P=0.213). The platelet counts in the OPCAB group 
remained quite stable during operation (Figure 1). After operation platelets 
increased above preoperative levels between the first (T5) and fifth (T6) day post-
operative P<0.001 in all groups.
P-selectin expression and arachidonic acid, ADP and collagen induced aggre-
gation were similar between groups at T0, although aggregation was decreased 
related to the use of antiplatelet drugs. Collagen induced platelet aggregation was 
impaired during operation and a rebound of platelet aggregation above preopera-
tive levels was seen postoperative in all patients. Few activated platelets appeared 
during and 1 h after reperfusion (T3 1.63%; T4 1.29% all groups), while upon agonist 
P-selectin increased to approximately 70% at both time points.
Coagulation
Plasma prothrombin fragment 1+2 and D-dimer levels remained quite stable 
throughout operation until the day after surgery, with the OPCAB group demon-
strating a higher level of prothrombin fragment 1+2, which was significant at 5 
min after the completion of the last anastomosis (T3). Five days after operation 
fragment 1.2 was further increased in the OPCABG group. D-dimer concentrations 
increased to approximately four fold at day 5 after operation relative to preopera-
tive concentrations in all groups (T0 vsT6, P<0.001).
Fibrinogen concentrations within the OPCAB group remained stable, but the 
CABG and AVR groups showed a profound decrease during operation (T3: CABG 
29% decrease, P=0.004; AVR 32% decrease, P= 0.003, Figure 1). Postoperatively, 
fibrinogen  doubled compared to  preoperative levels in all groups (P<0.001).
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The TEG and functional fibrinogen MAs demonstrated a similar curve as com-
pared to fibrinogen (and platelets) during CPB and shortly after reperfusion and 
immediately recovered 1 h after protamine neutralization (T4), whereas fibrinogen 
and platelet levels remained below baseline until 1 day after operation (T5). The 
r and α TEG values did not demonstrate significant differences between groups 
during and after surgery.
None of the changes in the thrombin generation lag time (TGlt),time to throm-
bin peak (TTP), thrombin generation peak height (TPH) and area under the curve 
(AUC)  in the NHA were above standard error. Patients in the AVR group  revealed 
an overall impaired thrombin generation at 5 days postoperative, whereas the 
thrombin generation appeared to be increased in the OPCAB and CABG groups, 
resembling a hypercoagulable state (Figure 2).
APTT levels were increased on CPB relative to off-pump surgery due to higher 
heparin dosage during CPB (T3, P<0.001 (OPCAB vs CABG/AVR). PT was stable at 
any time point.
Fibrinolysis
t-PA concentrations transiently rose after reperfusion relative to preoperative levels 
(CABG P= 0.001; AVR P<0.001) and remained low in  the OPCAB group (Figure 1).
The fibrin lysis time (FLT) in the NHA decreased between baseline (T0) and 
1 h after reperfusion (T4) in both the CABG and AVR group (only significant for 
AVR P=0.016, Figure 2). Noticeable is the postoperative FLT elevation (impaired 
fibrinolysis) in all groups.
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figure 2. Diff erences in nha between groups.
OPCAB, CABG surgery without the use of CPB; CABG, CABG surgery with use of CPB; AVR, 
CABG surgery with use of CPB combined with aorti c valve replacement. Nijmegen Hemostasis 
Assay (NHA) measures thrombin generati on lag ti me (ti me between initi ati on and the start of 
thrombin generati on; TGlt); ti me to peak thrombin generati on (ti me at which the thrombin 
generati on reached its maximal rate; TTP); thrombin peak height (maximal velocity of throm-
bin producti on; TPH) and area under the curve (thrombin generati on capacity; AUC) for co-
agulati on and the fi brin lysis ti me (FLT) and plasmin peak height (height of plasmin generati on; 
PPH) for fi brinolysis. Preoperati ve (T0); before CPB (T1); 30 min into CPB or 30 min aft er the 
start of the fi rst anastomoses in CABG surgery without CPB usage (T2); 5 min aft er reperfusion 
or 5 min aft er the completi on of the last anastomosis in CABG surgery without CPB usage (T3); 
1 h aft er reperfusion (T4); 1 day aft er operati on (T5) and 5 days aft er operati on (T6). * P<0.05 
between treatment groups.
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DIscussIon
Although previous studies were performed to gain more insight in the develop-
ment of coagulopathies during cardiac surgery they mainly focused on a restricted 
number of measurements evaluating coagulation or fibrinolysis in a short period of 
observation. In our study a quite large number of laboratory values was measured 
including the novel Nijmegen Hemostasis Assay (NHA) for the evaluation of both 
coagulation and fibrinolysis simultaneously and the interplay of both. Our study 
revealed that the most prominent changes after initiation of CPB were: decreased 
levels of hematocrit, albumin, platelets and fibrinogen, combined with impaired 
clot strength. No perioperative platelet activation was observed and functional 
(collagen induced) platelet aggregation was transiently impaired, but recovered 
after surgery in all groups. Furthermore, plasma prothrombin fragment 1+2 and 
D-dimer levels remained quite stable throughout operation and the changes 
demonstrated in thrombin generation were not above standard errors. Finally, an 
increased t-PA release was demonstrated in patients on CBP.
The absence of perioperative platelet activation combined with the normally 
expressed P-selectin after activation upon agonists, makes in vitro platelet dysfunc-
tion by activation in the CPB circuit unlikely. The decreased platelet aggregation 
observed during operation might be explained by colloid usage and a decreased 
platelet count, although a decrease of 29% should not affect aggregation test-
ing. The stable prothrombin fragment 1+2 plasma levels and lack of significant 
differences at any time point in the D-dimer/fibrinogen ratio virtually exclude 
disseminated intravascular coagulation. Furthermore, stabilization of aPTT after 
reperfusion indicated that coagulation factor consumption is negligible.
Previous papers have reported a massive thrombin generation during CPB (9-
11), however we could not confirm this, despite the use of comparable amounts 
of heparin.
The t-PA burst after reperfusion seen in patients on CPB probably partly results 
from surgical tissue damage, as t-PA is rapidly released by endothelial cells in re-
sponse to venous occlusion, manipulation and arterial ischemia (12). Furthermore, 
a major t-PA burst during reperfusion is created by accumulation in the heart during 
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aortic cross clamping (4), return of pericardial blood during cardiotomy suction (13) 
and the use of cell saver (14), without necessarily resulting in a clinically relevant 
fibrinolysis. Probably, without the use of tranexamic acid (standard procedure in 
most hospitals in the Netherlands), the role of fibrinolysis in bleeding might be 
more pronounced (15).
Coagulation tests, including platelet aggregation, showed a postoperative 
rebound above baseline levels in all patients. This rebound is probably attributed 
to an acute phase response to surgical trauma and CPB usage (9,16). The high fi-
brinogen, D-dimer and prothrombin fragments 1+2 concentrations, combined with 
an increased thrombin generation, suggest a hypercoagulable state, primarily seen 
in patients undergoing isolated CABG (OPCAB and CABG). This hypercoagulable 
state in combination with the postoperative impaired fibrinolysis in all groups, may 
promote the risk of thromboembolic complications (9,17,18). The NHA measure-
ments of patients in the AVR group are largely influenced by medication usage 
(vitamin K antagonists), which are prescribed accoring to protocol, causing slower 
and less thrombin generation.
Preoperative differences in laboratory values (e.g. elevated D-dimer level) may 
be a consequence of the operation indication for OPCAB surgery, more frequently 
performed in older or sicker patients with higher inflammatory markers that may 
be associated with activation of coagulation (19).
Our study was neither intended, nor powered to detect causes of blood loss, 
but rather to obtain insight in the sequence of events that may lead to the de-
velopment of coagulopathy and blood loss after cardiac surgery. Although only 
two patients endured excessive blood loss of more than 2000 ml in the first 24 h 
after surgery, and so, no conclusive adjudication can be made concerning exces-
sive blood loss, the bleeding tendency in ‘normal bleeding patients’ appears to 
be mainly influenced by hemodilution. The parallel decrease in Ht and fibrinogen 
during cardiac surgery with CPB is congruent with several previous studies (1,4,8). 
Scrascia , who compared coagulation, fibrinolysis and intraoperative red blood cell 
transfusions between 36 off-pump CABG patients and 36 CABG patients in whom 
a closed, phosphorylcoline-coated CPB system with a closed-collapsible venous 
reservoir (Sorin Group, Mirandola, Italy) was used, concluded that priming volume 
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reduction is required in order to decrease intraoperative red blood cell transfusion 
(20). However, as hemodilution is not the only difference in this patient model 
we cannot exclude interference of other processes in the development of coagu-
lopathy. The differences measured by the laboratory assays are affected by the 
concentration of the tested analyte (e.g. platelets or fibrinogen), and therefore, 
do not confirm a qualitative defect. This effect might aggravate the decreases seen 
in these analytes in patients on CPB relative to those operated without CPB and 
fortify the outcome towards hemodilution.
The use of tranexamic acid might have affected the results, especially, the mini-
mal differences demonstrated in NHA. However, as all patients used tranexamic 
acid, the differences between groups are not assumed to be affected by this factor. 
Another limitation of this study is that due to the use of heparin, which is known 
to be of great influence on the different laboratory measurements, we were not 
able to perform all laboratory tests at every time point. Especially T2 and T3 are 
strongly influenced by heparin. The decreased MA as measured by TEG is probably 
pronounced by heparin administration. Furthermore, the drop in thrombin genera-
tion peak height (TPH) and area under the curve (AUC) seen between preoperative 
and 1 h after reperfusion (T4) in the AVR group is probably caused by the higher 
amount of heparin administered in those patients.
Conclusion
No evident platelet activation, dysfunction or consumption was demonstrated. In 
patients undergoing CABG surgery with use of tranexamic acid, only minor and 
transient fibrinolysis was observed after reperfusion in patients operated on CBP. 
The most prominent factor impairing hemostasis was hemodilution associated with 
CPB. Restricting hemodilution, by reducing the CPB circuit and priming volume, 
may reduce postoperative blood loss.
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Stopping antiplatelet medication before coronary 
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timing to minimize bleeding?
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As the indication for antiplatelet medication expands, patients may be exposed 
to an increased risk of excessive blood loss when cardiac surgery is required. The 
optimal timing to stop acetylsalicylic acid (ASA) or ASA combined with clopidogrel 
(ASA+Clo) before surgery is subject of controversy.
Methods
A total of 1,065 patients were selected from a prospective randomized study on the 
effect of a fibrin sealant application in coronary artery bypass graft surgery (Fibrin 
sealant Induced Blood Exposure Reduction study; Registration number: NTR1386 
(http://www.trialregister.nl)), and divided into three groups according to the use of 
antiplatelet medication within 10 days prior to surgery: (1) ASA only (n=662), (2) 
ASA+Clo (n=290) or (3) no antiplatelet medication (n=113). To investigate if an op-
timal stop day could be established we fitted a series of multiple linear regression 
models, one for each preoperative day (running from day -10 up to -1). The specific 
day corresponding to the best fitting model (highest adjusted R2, with blood loss in 
the first 48 h postoperatively as the dependent variable) was considered as the best 
estimate for the optimal stop day. Bootstrap analysis (1000 times) was performed 
to calculate the corresponding confidence interval. Furthermore, major adverse 
cardiovascular and cerebral events (MACCE) were evaluated.
Results
We could not estimate an optimal stop day for patients using ASA or ASA+Clo prior 
to their operation. Last use of ASA on day -2 or earlier significantly decreased the 
percentage of patients receiving platelet transfusions compared with continuation 
until surgery (7% vs 13 % for day -1, P=0. 007). In patients using ASA+Clo, this 
percentage was reduced from 41% to 10% (P<0.001). There was no association 
between stop day and the occurrence of MACCE.
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Conclusions
There is no clinically relevant effect on blood loss indicating an optimal stop day 
for ASA alone or in combination with clopidogrel. Last use on day -2 resulted in a 




Bleeding necessitating blood transfusions or even requiring re-exploration is a 
common and serious complication after cardiac surgery (1,2). Especially patients 
undergoing coronary artery bypass graft (CABG) surgery are at increased risk for 
postoperative blood loss as these patients often use antiplatelet medication prior 
to their operation (3). Acetylsalicylic acid (ASA) and clopidogrel (Clo) are plate-
let aggregation inhibitors prescribed to improve outcomes after acute coronary 
syndromes and to reduce early stent failure after percutaneous intervention (PCI) 
(4,5). ASA is an irreversible platelet inhibitor via acetylation of the cyclo-oxygenase 
enzyme and thereby blocking the synthesis of prostaglandin thromboxane A2 in 
the platelet. Clo inhibits platelet activation and thereby aggregation via irrevers-
ible blockade of the adenosine diphosphate chemoreceptor P2Y on the platelet 
membrane. As platelets lack the ability for protein synthesis, the only way aggrega-
tion can be restored is by de novo synthesis of platelets. The platelet lifespan is 
approximately 8-10 days, thus after 4-5 days half of the platelet pool is replenished, 
which is considered sufficient to normalize bleeding time (6).
To reduce the amount of blood loss after CABG surgery, it is important to con-
sider if and when the use of preoperative ASA and Clo should be terminated (6-8). 
However, solid data on the optimal timing is lacking.
The present study investigates the effect of different stop days on blood loss 
within 48 h after isolated CABG surgery in patients who preoperatively used ASA 
only or ASA combined with Clo (ASA+Clo). Furthermore, we included patients using 
no preoperative antiplatelet medication to evaluate differences in 48 h blood loss, 
platelet transfusions received and incidence of major adverse cardiovascular and 
cerebral events (MACCE) between groups.
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MEthoDs
Patient population
The 1,065 patients involved in this study were retrieved from the Fibrin sealant 
Induced Blood Exposure Reduction (FIBER) study, a multicentre randomized con-
trolled study to investigate the cost-effectiveness of the use of a new fibrin sealant 
in preventing blood loss in patients undergoing isolated CABG. The study involved 
seven cardiac surgery centres in The Netherlands. Exclusion criteria were: exclusive 
use of venous grafts, any concomitant procedure (including atrial fibrillation abla-
tion), emergency surgery, participation in any study involving an investigational 
drug or device, Jehovah’s witness and a history of bleeding diathesis or coagu-
lopathy. The trial was performed in accordance with the Declaration of Helsinki 
and relevant Dutch laws, and was approved by the hospitals’ ethics committees. 
The trial was registered with http://www.trialregister.nl (NTR1386). All patients 
provided written informed consent before entering in the study. The FIBER study 
did not define a predetermined mandatory stop day for preoperative antiplatelet 
medication use.
For the current study, patients were divided into three groups according to 
the use of antiplatelet medication within 10 days prior to surgery: (1) ASA only 
(ASA, n=662), (2) ASA+Clo, n=290), or (3) no antiplatelet medication because it was 
stopped for more than 10 days or was never used (None, n=113). Excluded were 
patients using preoperative vitamin K antagonists or dipyridamol, and patients for 
whom the stop date for preoperative antiplatelet medication was not available. 
Twenty-seven patients who used Clo as monotherapy within 10 days before sur-
gery were excluded from analysis because of consequent small patient numbers 
per stop day. For analytical purposes, the ASA+Clo group consisted only of patients 
with the same stop date for ASA+Clo (Figure 1).
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figure 1. study flow chart.
FIBER, Fibrin sealant Induced Blood Exposure Reduction; ITT, intention to treat analysis; CABG, 
coronary artery bypass grafting; None, no antiplatelet medication within 10 days before sur-
gery or never used; ASA, use of acetylsalicylic acid within 10 days prior to surgery; ASA+Clo, 
use of ASA and Clo within 10 days prior to surgery.
Clinical and surgical management
Surgical techniques were used according to the local standards. Tranexamic acid 
was administered during surgery in 916 patients, according to local standards. 
In general, a bolus of approximately 15 mg/kg prior to surgery was followed by 
continuous infusion of approximately 5 mg/kg/hour during operation with some 
variation among study sites. After surgery, heparin was neutralized with protamine 
sulphate (1000 IE heparin:10 mg protamine sulphate). The fibrin sealant CryoSeal, 
produced from an allogeneic single non-remunerated volunteer donor without 
the addition of antifibrinolytics, was randomly applied in 50% of the patients dur-
ing surgery, according the FIBER study protocol, i.e. 5 ml mandatory per internal 
thoracic artery bed, and on anastomosis, cannulation sites, and other parts in 
the surgical field at the discretion of the surgeon. Furthermore, blood from the 
operative field was filtered, stored in a separate cell saver system, and retrans-
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fused according to local standards. The number of units transfused red blood 
cells (RBCs), fresh frozen plasma and platelet or fibrinogen concentrates were the 
primary endpoints of the FIBER study. Blood transfusion practice was based on 
the transfusion guidelines of the American Society of Anesthesiologists (9) and the 
Dutch Institute for Healthcare Improvement (10). It recommends RBC transfusion 
when the hemoglobin (Hb) level is <7 g/dl and advices against the use when the 
Hb is >9 g/dl. In case of the Hb is >7 g/dl and <9 g/dl, the transfusion trigger is 
determined by blood loss, cardiopulmonary reserve, age, comorbidity and at the 
discretion of the anesthesiologist or intensivist. Chest tubes were removed when 
drainage was less than 20 ml per hour or 200 ml per 24 h. Antiplatelet medication 
and low-molecular-weight heparin were both (re)started on the first postoperative 
day. If indicated, vitamin K antagonists were started five days after operation.
End-points
The primary end-point of this study was the amount of blood loss within 48 h 
after operation. Blood loss was measured from the chest tube output starting im-
mediately at arrival at the intensive care unit and continued until the chest drains 
were removed.
The secondary endpoint was MACCE during hospital admission, consisting of 
the parameters: in-hospital mortality, myocardial infarction (defined as presence of 
at least two of the following criteria: (1) ischemic chest pain lasting for more than 
20 min, (2) changes in serial electrocardiogram (ECG) tracings, and (3) Troponine T 
>1 µg/l), reintervention for ischemia (defined in case the need for re-intervention 
was based on changes in serial ECG tracings and Troponine T >1 µg/l), and stroke 
(defined as a new persistent cerebrovascular event leading to neurological defaults 
being diagnosed by a neurologist).
Furthermore, the percentage of patients undergoing platelet transfusions given 
during and directly after surgery was evaluated.
Statistical analysis
Data are expressed as mean (standard deviation) or number (percentages), where 
appropriate. Because the variable 48 h blood loss failed to satisfy the assumption 
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of normality, data for this variable are presented as median (interquartile range 
(IQR)). The logarithm of 48 h blood loss was calculated and used in all analyses. 
Patient characteristics and study outcomes were compared between the three 
treatment groups using analysis of variance for continuous variables and Pearson 
chi-square test or Fisher’s exact test, where appropriate, for categorical variables. 
In case P<0.05, post hoc analysis was used for comparisons between two groups.
Stop day was defined as the last day before surgery on which antiplatelet 
medication was used (operation day is day 0). Last use on day -1 was considered as 
continuation. We defined the optimal stop day as the day shortest before operation 
such that stopping on an earlier day did not decrease blood loss any more. To inves-
tigate if an optimal stop day could be established from the data, we fitted a series 
of multiple linear regression models, one for each day ‘i’ (running from day -10 up 
to day -1) before the operation. In these models, the logarithm of 48-h blood loss 
was the dependent variable and the effect of the variable stop day was modelled. 
For the stop day before day ‘i’, the level of blood loss was assumed to be constant 
and for the stop day after day ‘i’, a linear increase in blood loss was assumed (this 
model is referred to as a ‘broken stick’). All these 10 regression analyses were 
adjusted for the hereunder mentioned covariates. The day ‘i’ corresponding to the 
best fitting model (highest adjusted R2) was considered as the best estimate for the 
optimal stop day. Bootstrap analysis (1000 times) was performed to calculate the 
corresponding confidence interval (CI).
Binary logistic regression analysis using the above covariates was used to calcu-
late adjusted odds ratios (ORs) and 95% CIs for the association of stop day with the 
occurrence of MACCE. Statistical significance was defined as a P <0.05.
rEsults
Patient baseline and surgical characteristics
The treatment groups significantly differed on two baseline characteristics: myo-
cardial infarction within three months prior to surgery and previous PCI (Table 
1). Post hoc analysis revealed that in the ASA+Clo group, the number of patients 
5
Stopping antiplatelet medication before coronary artery bypass graft surgery 109









age, years; mean(sD) 65(10) 66(9) 65(10) 0.43
Male/female, n/n 95/18 531/131 242/48 0.38
Diabetes mellitus; n(%) 38(33.6) 160(24.2) 71(24.5) 0.095
hypertension; n(%) 62(54.9) 378(57.1) 160(55.2) 0.81
ccs Iv; n(%) 10(8.8) 82(12.4) 43(14.8) 0.36
MI <3 months before cabg; n(%) 17(15.0) 84(12.7) 91(31.4) <0.001
Previous cardiac surgery; n(%) 1(0.9) 13(2.0) 6(2.1) 0.89‡
Previous PcI; n(%) 14(12.4) 109(16.5) 78(26.9) <0.001
lvEf; n(%) 0.087‡
30-50% 12(10.6) 81(12.2) 51(17.6)
<30% 5(4.4) 15(2.3) 5(1.7)
Extracardiac arteriopathy; n(%) 13(11.5) 75(11.3) 31(10.7) 0.95
renal insufficiency; n(%) 7(6.2) 40(6.0) 11(3.8) 0.35
coPD; n(%) 15(13.3) 63(9.5) 24(8.3) 0.31
neurological dysfunction disease; n(%) 1(0.9) 21(3.2) 9(3.1) 0.46‡
logistic Euroscore, %; mean(sD) 3.3(3.3) 3.1(3.0) 3.5(3.6) 0.34
laboratory values
hemoglobin, mmol/l; mean(sD) 8.7(0.9) 8.8(0.9) 8.7(0.9) 0.15
hematocrit, l/l; mean(sD) 0.42(0.04) 0.42(0.04) 0.41(0.04) 0.073
Erytrocytes, 1000 billion/l; mean(sD) 4.7(0.7) 4.7(0.6) 4.6(0.5) 0.065
fibrinogen clauss, g/l; mean(sD) 4.6(1.0) 3.7(0.8) 4.4(1.5) 0.085
aPtt, seconds; mean(sD) 31.16(3.48) 30.86(5.84) 31.88(7.77) 0.10
Pt, seconds; mean(sD) 12.91(1.95) 13.00(2.00) 13.74(1.97) <0.001
Platelet count, x109/l; mean(sD) 249(74) 242(71) 252(78) 0.15
surgical characteristics
beating heart cabg; n(%) 13(11.5) 77(11.6) 41(14.1) 0.54
number of arterial grafts, n; mean(sD) 1.7(0.9) 1.7(0.9) 1.6(0.7) 0.63
operation time, min; mean(sD) 223(68) 220(63) 241(71) <0.001
cPb time, min; mean(sD) 88(47) 84(42) 90(51) 0.14
aorta cross clamp time, min; mean(sD) 67(33) 64(29) 69(38) 0.061
cs transfusion, ml; mean(sD) 234(320) 259(315) 245(310) 0.66
fl use; n(%) 65(57.5) 329(49.7) 153(52.8) 0.26
tranexamic acid use, ml/mg; mean(sD) 3089(1693) 2825(1714) 3204(1516) 0.004
IabP; n(%) 1(0.9) 2(0.3) 0 0.31‡
ASA, acetylsalicylic acid; ASA+Clo, acetylsalicylic acid and clopidogrel; SD, standard deviation; 
CCS, Canadian Cardiovascular Society Angina Pectoris classification; MI, myocardial infarction; 
CABG, coronary artery bypass grafting; PC, percutaneous coronary intervention; LVEF, left ven-
tricular ejection fraction; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary 
bypass; CS, cell saver; FL, fibrin sealant; IABP, intra-aortic balloon pump.
‡Fisher’s exact test.
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enduring a myocardial infarction within three months prior to operation was sig-
nificantly higher compared with the None and ASA groups (P=0.001 and P<0.001, 
respectively). PCI procedures were significantly more frequently performed in the 
ASA+Clo group than in the None and ASA groups (P=0.002 and P<0.001, respec-
tively).
Operation time was significantly longer in the ASA+Clo group compared with 
the None and ASA groups (P=0.015 and P<0.001, respectively), although CPB time 
and aorta cross clamp time were not significantly different between the groups. 
Consistent with the longer operation time, the amount of tranexamic acid ad-
ministered in the ASA+Clo group was significantly higher compared with patients 
receiving ASA only (P=0.001).
Blood loss and transfusions
In the ASA+Clo group, the median amount of blood loss 48 h after surgery was 
approximately 30-70 ml higher than in the None and ASA groups (overall test: 
P=0.037; post hoc: ASA vs None, P=0.073 and ASA+Clo vs None, P=0.012). The 
ASA+Clo group also received more blood transfusions after operation, especially 
platelet transfusions (Table 2).
In total, 29 patients (None=3; ASA=13; ASA+Clo=13) underwent reoperation for 
bleeding with a median blood loss of 1885 ml (IQR: 998-2703 ml). Only in two 
patients (None=1; ASA=1) a surgical cause for the excessive bleeding during reop-
eration was found.
5









blood loss <48 h, ml; 
median(IQr)
620(416-905) 660(490-950) 695(500-1013) 0.037
blood transfusions <48 h
Patients receiving Prbc; n(%) 28(24.8) 144(21.8) 85(29.3) 0.044
Patients receiving ffP; n(%) 12(10.6) 59(8.9) 57(19.7) <0.001
Patients receiving Pt; n(%) 10(8.8) 70(10.6) 88(30.3) <0.001
ventilation time >48 h; n(%) 1(0.9) 7(1.1) 1(0.3) 0.59‡
reoperation for bleeding; 
n(%)
3(2.7) 13(2.0) 13(4.5) 0.10‡
length of Icu stay; h; 
mean(sD)
29(26) 32(54) 33(53) 0.79
length of hospital stay, days; 
mean(sD)
9.0(7.8) 8.0(4.4) 9.1(6.1) 0.007
MACCE 5(4.4) 22(3.3) 19(6.6) 0.078
hospital mortality; n(%) 0 5(0.8) 3(1.0) 0.76‡
MI; n(%) 4(3.5) 14(2.1) 13(4.5) 0.12‡
reintervention for ischemia; 
n(%)
0 3(0.5) 1(0.3) 1.00‡
stroke; n(%) 1(0.9) 1(0.2) 2(0.7) 0.18‡
ASA, acetylsalicylic acid; ASA+Clo, acetylsalicylic acid and clopidogrel; IQR, interquartile range; 
PRBC, packed red blood cells; FFP, fresh frozen plasma; PT, platelet transfusions; ICU, intensive 




The median amount of blood loss within 48 h in the ASA group was 660 ml (IQR: 
490-950 ml; Table 2). The median amount of 48-h blood loss relative to the dif-
ferent stop days is shown in Figure 2-1A. The best fitting broken stick model had 
an adjusted R2 of 0.129 (weak correlation) and corresponded to day -10 as the 
estimated optimal stop day. The model yielded an estimated increase in blood loss 
of 2% (P=0.018) for each day stopped later than day -10. Last use of ASA on day -10 
resulted in a blood loss reduction of 25% compared with continuation of ASA until 
surgery. However, the bootstrap CI of the optimal stop day was very wide, running 
from day -1 to -10. Last use of ASA on day -2 or earlier (day -2 to -10) resulted in 
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a significant reduction of median blood loss 48 h after operation (630 ml, IQR: 
480-850 ml) compared with continuation of ASA until surgery (day -1, 690 ml, IQR: 
496-1004 ml, P=0.007; Figure 2-1B).
Platelet transfusions given during and directly after surgery were associated 
with blood loss 48 h after operation (P<0.001). Last use of ASA on day -2 or earlier 
resulted in an almost 50% reduction of the percentage of patients receiving plate-
let transfusions (7%) compared with continuation of ASA until surgery (day -1, 13%, 
P=0.007; Figure 2-2B). Earlier stop days than day -2 did not result in an additional 
decrease in platelet transfusions.
Furthermore, multivariable analysis revealed that a lower preoperative Hb level 
was associated with more blood loss within 48 h after operation in patients using 
ASA before surgery (P=0.012).
ASA and Clopidogrel
The median amount of blood loss within 48 h was 695 ml (IQR: 500-1013 ml; Table 
2). In all fitted (broken stick) regression models, the effect of stop day was not sig-
nificant. Last use of ASA+Clo on day -2 or earlier resulted in a significant reduction 
of median blood loss 48 h after operation (623 ml, IQR: 485-913 ml) compared with 
continuation of ASA+Clo until surgery (day -1, 715 ml, IQR: 513-1078 ml, P=0.005; 
Figure 2-1B).
Also for patients in the ASA+Clo group, platelet transfusions given during 
and directly after surgery were associated with blood loss 48 h after operation 
(P<0.001). Last use of the combination of ASA+Clo on day -2 or earlier resulted in 
a 30% reduction of patients receiving platelet transfusions (10%) compared with 
continuation of both antiplatelet medications until surgery (day -1, 41%, P<0.001; 
Figure 2-2B). Last use on day -3 or earlier even reduced the number of patients 
undergoing platelet transfusions to 5%.
Other factors associated with more blood loss within 48 h after operation in the 
ASA+Clo group were a lower preoperative Hb level (P=0.024) and a higher amount 
of intra-operative colloid usage (P=0.007).
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Major adverse cardiovascular and cerebral events
There was no significant association between the moment of last use of ASA before 
surgery and MACCE (OR=0.990, 95%CI=0.817-1.200, P=0.92) or the moment of last 
use of ASA+Clo and MACCE (OR=0.849, 95%CI=0.635-1.135, P=0.27).
figure 2. Median blood loss and platelet transfusions within 48 h after surgery.
1.  Median blood loss (ml) within 48 h after surgery;
1A  for each stop day until day -10
1B  divided in stop day -1 and days -2 until -10 (>2)
The numbers above the bar charts represent the amount of patients that stopped their anti-
platelet medication on that particular stop day.
2.  Platelet transfusions (percentage of patients transfused) within 48 h after surgery;
2A for each stop day until day -10
2B divided in stop day -1 and days -2 until -10 (>2)
The numbers above the bar charts represent the amount of patients transfused relative to the 
total amount of patients that stopped their antiplatelet medication on that particular stop day.
None, no antiplatelet medication within 10 days before surgery or never used; ASA, use of 




The FIBER study in which no fixed stop day for preoperative antiplatelet medica-
tion was demanded provided an outstanding opportunity to study the effects of 
stop day on bleeding and transfusion requirements in isolated CABG patients. In 
the present study, no clinically relevant difference in blood loss per stop day was 
demonstrated for preoperative use of only ASA or dual antiplatelet therapy with 
ASA+Clo using multiple linear regression models. Last use on day -2, however, re-
sulted in lower amounts of blood loss and percentage of patients receiving platelet 
transfusions, especially in patients using the combination of ASA+Clo. There was no 
association between stop day and the occurrence of MACCE.
ASA and Clo are widespread used drugs among patients undergoing CABG 
surgery. Several large, randomized, double-blind, multicenter studies, such as the 
CAPRIE (11), CURE (12), and CREDO (13) trials, have stressed the beneficial effects 
of prophylactic ASA and Clo therapy in patients at risk of ischemic events. The 2011 
update of the American College of Cardiology Foundation/American Heart Asso-
ciation (ACCF/AHA) guidelines for CABG surgery states that preoperative ASA use 
reduces operative morbidity and mortality rates (14). Yet, at the same time, several 
studies have shown that administration of Clo prior to cardiac surgery, especially 
in combination with ASA, increases the risk of postoperative bleeding (4,15,16). 
Optimal timing for discontinuation of antiplatelet medication prior to surgery is 
thus important.
Both the ACCF/AHA guidelines for CABG surgery and the European Society of 
Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guide-
lines on myocardial revascularization published in 2014 (17) recommend  preop-
erative ASA to be administered without discontinuation (Class I recommendation, 
Level of Evidence: B) and preoperative Clo to be discontinued at day -5 (Class I 
recommendation, Level of Evidence: B) in order to reduce bleeding and the need 
for transfusion. Furthermore, the ESC/EACTS guidelines append that bedside 
platelet function testing is to be preferred as it is a more precise option for guiding 
interruption of treatment, rather than use of an arbitrary, specified stop period.
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In this study, regression analysis demonstrated that last use of ASA on day -10 
was optimal and resulted in an approximately 25% (corresponding with 250 ml) 
blood loss reduction within the first 48 h after isolated CABG surgery compared 
with continuation of ASA until surgery. However, results at this extreme stop day 
apparently were influenced by small patient numbers. Bootstrap analysis revealed 
a CI from stop day -1 till -10 and the correlation with blood loss 48 h after opera-
tion was weak. Correspondingly, Kwak  (18) demonstrated no association between 
stop day of ASA before off-pump CABG and the amount of postoperative blood 
loss. Furthermore, Hijazi (5) found that continuation of low-dose (80 or 100mg per 
day) ASA until CABG surgery did not appear to increase postoperative bleeding or 
the need for allogeneic blood transfusion. For patients who used dual antiplatelet 
therapy with ASA+Clo, regression analysis also revealed no optimal stop day. Prob-
ably, other factors, like a low preoperative Hb level, as revealed by multivariable 
analysis, have a greater influence on 48-h blood loss than interruption time of 
preoperative antiplatelet medication usage.
In patients who last used their antiplatelet medication on day -1, especially in 
patients who used ASA+Clo, the received platelet transfusions appeared to reduce 
48-h blood loss to an amount that it is comparable with the amount of blood loss 
associated with earlier stop days (-2 till -10). Last use of especially the combination 
of ASA+Clo on day -2 or earlier was associated with a lower percentage of patients 
receiving platelet transfusions. This is congruent with the ACCF/AHA guidelines 
which conclude that the amount of blood loss prevented by discontinuation of Clo 
on day -5 relative to later stop days (-4 till -1) is not life threatening, but only de-
creases the amount of blood transfusions required. Several studies reported that 
treatment with Clo within 3 to 4 days preoperatively increased blood transfusion 
requirements, but if discontinued 3 days before surgery, patients did not suffer 
from significantly more blood loss (7,16,19,20).
Because nearly all platelet transfusions were given during and directly after 
surgery, this variable was included in the list of covariates that was controlled for 
in the performed regression analysis to establish an optimal stop day for blood 
loss reduction after surgery. When performing the analysis without correction for 
platelet transfusions, almost similar results were found for patients using only ASA. 
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For patients using the combination of ASA+Clo, without his correction stop day -4 
appeared most optimal for the reduction of 48-h blood loss. However, since the 
amount of blood loss in this patient group seemed to rise from stop day -5 till -10, 
stop day -4 was considered clinically not plausible.
The main, clinically relevant blood loss reduction appeared to occur between 
stop day -1 and -2 in both treatment groups, but especially in the patients on dual 
antiplatelet therapy with ASA+Clo, indicating that the combination of ASA+Clo 
should not be taken on the day before surgery. This is in accordance with an 
earlier study by Mahla  (21) who found that bedside platelet function testing, as 
suggested by the ESC/EACTS guidelines, resulted in an overall 46% shortening of 
the recommended preoperative stop period for Clo-treated patients (mean 2.7 
days versus 5 days). For this reason, the 2012 update of the Society of Thoracic 
Surgeons guideline on use of antiplatelet drugs in patients having cardiac or non-
cardiac operations (22) recommends for patients with acute coronary syndrome 
who require urgent surgery an interruption of dual antiplatelet therapy of 2 days in 
order to decrease bleeding and thrombotic risk (Class IIa recommendation; Level 
of Evidence: B).
The fact that we found no association between stop day and the occurrence 
of MACCE might be due to the fact that the decision to preoperatively continue 
antiplatelet medication was possibly influenced by the perceived thrombotic risk. 
Recently, large series have suggested that patients are at highest risk of stent 
thrombosis when both antiplatelet agents are discontinued (23,24). We therefore 
cannot exclude that last use of a combination of ASA+Clo on day -2 might result in 
an increased risk of MACCE.
A weakness of this study is that despite standard surgical and anesthetic 
principles regarding transfusion strategy were used, most surgeons and anesthe-
siologists knew when a patient last used antiplatelet drugs prior to operation. It is 
conceivable, therefore, that the threshold for blood transfusion in patients who 
continued antiplatelet therapy, especially dual antiplatelet therapy with ASA+Clo, 
was lowered. Furthermore, this study is limited in that we cannot report on the 
effect of last intake of Clo alone due to low patient numbers on this therapy in 
the FIBER cohort. Isolated Clo use until CABG surgery has been associated with a 
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higher incidence of hard-to-manage intra-operative bleeding and blood transfu-
sions (25). Finally, newer and more potent antiplatelet inhibitors (e.g., dipyridamol 
(adenosine reuptake inhibitor), prasugrel, ticagrelor (both adenosine diphosphate 
receptor inhibitors), and thromboxane inhibitors) are not analyzed in this study. 
These medications will probably demonstrate a greater effect of stop day on 48-h 
blood loss but were rarely prescribed within the FIBER study that was conducted 
between March 2009 and January 2012.
In conclusion, an optimal stop day for preoperative use of ASA alone or dual 
antiplatelet therapy with ASA+Clo minimizing 48-h blood loss after isolated CABG 
surgery could not be established using multiple linear regression models. Yet, last 
use on day -2 resulted in a reduction of blood loss and percentage of patients re-
ceiving platelet transfusions, especially with combined preoperative ASA+Clo use, 
and should be considered as the best compromise in the vast majority of these 
patients.
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CHAPTER 6
Multicentre randomized controlled clinical trial to 
investigate the cost-effectiveness of an allogeneic 
single-donor fibrin sealant in coronary artery bypass 
grafting (FIBER) Study
G. Tavilla, E.F. Bruggemans, C.L.I. Gielen, A. Brand, W.B. van den Hout, 
R.J.M. Klautz and J.A. van Hilten




Reduction of blood transfusion in cardiac surgery is an important target. The aim 
of this study was to investigate the cost-effectiveness of the use of CryoSeal, an al-
logeneic single-donor fibrin sealant, in patients undergoing coronary artery bypass 
grafting (CABG).
Methods
This randomized controlled study involved seven cardiac surgery centres in the 
Netherlands. Patients undergoing elective isolated CABG with the use of at least one 
internal thoracic artery (ITA) graft were randomly assigned to receive either CryoSeal 
(5 ml per ITA bed) or no CryoSeal. Primary efficacy endpoints were units transfused 
red blood cells, fresh frozen plasma and platelet concentrates, and length of Inten-
sive Care Unit stay. Secondary efficacy endpoints were 48-h blood loss, reoperation 
for bleeding, mediastinitis, 30-day mortality and length of hospital stay.
Results
Between March 2009 and January 2012, 1,445 patients were randomized. The 
intention-to-treat (ITT) population comprised 1,436 patients; the per-protocol (PP) 
population 1,292. In both the ITT and the PP analysis, no significant difference 
between the treatment groups was observed for any of the primary and secondary 
efficacy endpoints. In addition, no significant difference between the groups was 
seen in the proportion of transfused patients. Estimated CryoSeal costs were €822 
per patient (95%CI €808 to €836), which translated to €72,000 per avoided transfu-
sion (with unbounded 95%CI).
Conclusion
The use of the fibrin sealant CryoSeal did not result in health benefits. Combined 
with the high cost per avoided transfusion, this study does not support the imple-
mentation of routine CryoSeal use in elective isolated CABG. Registration number: 
NTR1386 (http://ww.trialregister.nl).
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IntroDuctIon
Transfusion of blood products is a common intervention in cardiac surgery but is 
not without risk. It is associated with increased in-hospital morbidity, including in-
creased rates of renal failure, serious infection, prolonged ventilator support, atrial 
fibrillation and stroke, as well as increased in-hospital mortality (1). In addition, it 
has been associated with increased long-term mortality (2). The relationship with 
early risk for adverse outcome appears to be dose-dependent, with transfusion 
of no more than 1-2 units of red blood cells (RBCs) already increasing risks after 
isolated coronary artery bypass grafting (CABG). Any reduction in blood transfusion 
during cardiac surgery is thus an important target to improve outcome and reduce 
health care costs (3).
During the past two decades, fibrin sealants have gained popularity as an 
adjunct to achieve hemostasis and reduce RBC transfusion in many surgical fields, 
including cardiac surgery (4). Fibrin sealants are indicated for control of surgical 
bleeding when conventional interventions such as compression, ligation, clipping, 
suturing or electrocoagulation are insufficient. The application of fibrin sealants is 
generally considered clinically safe (5). However, there are still concerns regard-
ing the antigenicity of bovine thrombin or aprotinin used in the majority of the 
commercially available fibrin sealants (6). Furthermore, most fibrin sealants are 
produced of pooled plasma, which is associated with an increased viral or prion 
risk. The use of an autologous fibrin sealant in cardiac surgery, on the other hand, 
may be associated with variable quality arising from co-morbidities.
The fibrin sealant CryoSeal (Sanquin Blood Supply Foundation, Amsterdam, The 
Netherlands) is produced from an allogeneic, single, non-remunerated volunteer 
donor without the addition of antifibrinolytics, and may therefore have potential 
advantages (7). CryoSeal fibrin sealant has not been studied in cardiac surgery 
previously.
In CABG, use of the left internal thoracic artery (ITA) is universally accepted. 
Evidence from several studies suggests that bilateral ITA grafting prolongs survival 
(8,9). However, not only has the use of a single ITA graft been associated with 
increased mediastinal drainage compared to the exclusive use of saphenous vein 
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grafts (10), but also bilateral ITA grafting has been associated with increased post-
operative blood loss compared to single ITA grafting (11). The aim of this study was 
to investigate the cost-effectiveness of the use of CryoSeal in patients undergoing 
elective isolated CABG with the use of single or bilateral ITA.
MEthoDs
The FIBER (Fibrin sealant Induced Blood Exposure Reduction) Study was a mul-
ticentre randomized clinical study involving seven cardiac surgery centres in 
the Netherlands. The trial was performed in accordance with the Declaration of 
Helsinki, the ethical principles of the International Conference on Harmonization 
Good Clinical Practice and relevant Dutch laws, and was approved by the ethics 
committee of the Leiden University Medical Centre, followed by the local ethics 
committees. All patients provided written informed consent before entering in the 
study. A steering committee was responsible for organizing the study, executing 
data analysis and writing the paper.
Inclusion and randomisation
Patients undergoing elective isolated CABG (either on-pump or off-pump) with 
the use of at least one ITA graft were eligible. Exclusion criteria were: CABG with 
exclusive use of saphenous vein grafts; any concomitant procedure including 
ablation for atrial fibrillation; emergency surgery; history of bleeding diathesis 
or coagulopathy; Jehovah’s Witness; participation in any other study involving an 
investigational drug or device; and inability of the patient to understand the study 
information. Once a patient had signed a consent form, they were randomized by 
calling the trail manager. In this telephone call, information about the intended 
procedure (the use of single or bilateral ITA) was requested in order to receive a 
sufficient amount of CryoSeal fibrin sealant (5 ml for each ITA bed) if randomized 
to CryoSeal treatment. Patients were assigned randomly at a ratio of 1:1 to either 
treatment with CryoSeal fibrin sealant or no CryoSeal treatment (control group), 
stratified according to the study site.
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Investigational product
CryoSeal is an allogeneic single-donor fibrin sealant produced from fresh frozen 
quarantined plasma from donations of non-remunerated volunteers. It is pro-
duced by Sanquin Blood Bank (12) using disposables provided by Recuperate 
Medical (Recuperate Medical BV, Haren, The Netherlands). CryoSeal consists of 
two components: cryoprecipitate and thrombin. Cryoprecipitate is the fraction of 
human plasma that contains concentrated coagulation factors, such as fibrinogen, 
fibronectin, plasminogen, factor VIII, factor XIII an von Willebrand factor. Owing to 
the low levels of plasminogen, CryoSeal does not require an artificial fibrinolysis 
inhibitor (such as aprotinin, sourced from bovine lung tissue, or tranexamic acid).
Safety and toxicology
The single-donor plasma was routinely tested on hepatitis C virus, hepatitis B virus, 
human immunodeficiency virus 0-2, human T-limphotropic virus, Treponema palli-
dum hemagglutination assay, and parvovirus B19 at donation. It was retested after 
a quarantine period of at least 6 months before processing to CryoSeal, thereby 
virtually excluding the plasma as a source of infectious disease transmission to the 
recipients.
Given the origin of CryoSeal (no pooled plasma and no addition of bovine or 
chemical fibrinolysis inhibitors), no toxicity was expected. However, CryoSeal is a 
blood product and adverse transfusion reactions may occur.
Feasibility in CABG
To study the feasibility of CryoSeal use in CABG, a pilot-study was performed in 
the Department of Cardiothoracic Surgery, Leiden University Medical Centre. The 
study included 40 consecutive patients who had elective isolated CABG, either 
on-pump or off-pump. It was concluded that CryoSeal can be best applied to the 
ITA bed in this population. No side-effects or postoperative complications were 
reported in the feasibility study.
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Surgical procedure and application of cryoSeal
Surgical techniques were used according to the local standards. After sternotomy, 
harvesting of the ITA, pedicled or skeletonised, was carried out simultaneously with 
saphenectomy (if applicable). Cardioplegic arrest, when applicable, was obtained 
either by use of cold crystalloid solution or by warm or cold blood cardioplegia. 
The surgeon was blinded to treatment group allocation until nearly the end of the 
operation. For each randomized patient, a cooling box was delivered to the operat-
ing room containing either CryoSeal or no CryoSeal. The handling of CryoSeal was 
taught by video instruction before the study. The cooling box was not opened until 
30 min before use of CryoSeal, which had to be applied after the administration 
of protamine. In this way, the routine of achieving hemostasis during surgery was 
influenced minimally. CryoSeal had to be thawed at 40 ºC for at least 20 min before 
use. After the administration of protamine, patients assigned to the study group 
were treated with a maximum of 15 ml CryoSeal each. For each ITA bed, 5 ml 
CryoSeal was used. CryoSeal was applied with the use of a spray tip mounted on a 
5-ml syringe. Any remaining fibrin sealant could be used on anastomoses, cannula-
tion sites and other part of the surgical field, at the discretion of the surgeon. The 
chest was then closed routinely. All CryoSeal not used during the operation was 
returned to the local Hospital Blood Transfusion Services to record the amount of 
fibrin sealant applied to each patient. Surgeons had the discretion to use additional 
tranexamic acid, but use of another fibrin sealant was not allowed.
Transfusion policy
Blood transfusion practice was based on the transfusion guidelines of the American 
Society of Anesthesiologists (13) and the Dutch Institute for Healthcare Improve-
ment (14). The Dutch guidelines support a quite restrictive transfusion policy. It 
recommend RBC transfusion when the hemoglobin level is less than 7 g/dl, and 
advices against transfusion when the level is above 9 g/dl. When the hemoglobin 
is above 7 g/dl and less than 9 g/dl, the transfusion trigger is determined by blood 
loss, cardiopulmonary reserve, age, and/or comorbidity. Management was at the 
discretion of the treating physician.
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Efficacy end-points
The primary efficacy endpoints were number of transfused blood products (RBCs, 
fresh frozen plasma(FFP) and platelet concentrates (PCs)) up to 48 h after surgery 
and duration of stay in the Intensive Care Unit (ICU). Secondary efficacy end-points 
included the amount of blood loss within 48 h after surgery, reoperation for bleed-
ing, mediastinitis, 30-day mortality and length of hospital stay.
Safety and safety reporting
Prespecified serious adverse events (SAEs) were myocardial infarction, stroke, 
mediastinitis, re-operation for ischemia and 30-day mortality. Myocardial infarc-
tion was defined as presence of at least two of the following: (1) ischemic chest 
pain lasting for more than 20 min; (2) changes in serial electrocardiogram (ECG) 
tracings; and (3) troponin T level above 1 µg/l. Stroke was defined as a new persis-
tent cerebrovascular event leading to neurological defaults being diagnosed by a 
neurologist. Diagnosis of mediastinitis required positive substernal tissue cultures. 
Reoperation for ischemia was defined in case the need for reoperation was based 
on changes in serial ECG tracings and troponine T level above 1 µg/L. Each SAE had 
to be recorded on a SAE Form and sent to the Coordinating Principal Investigator. 
SAEs were reported to the local Ethics Committee, according to local requirements.
Other collected adverse events (AEs) included low cardiac output syndrome, 
duration of ventilation of more than 48 h, sepsis, pneumonia, renal insufficiency, 
atrial fibrillation, ventricular fibrillation, transient ischemic accident, superficial 
wound infection and reoperation for bleeding.
Data safety monitoring board
An independent Data Safety Monitoring Board (DSMB) was established to protect 
the safety and welfare of the patients. The DSMB was blinded to group allocation 
when assessing the interim report data.
Statistical analysis
To demonstrate CryoSeal to be cost-effective, a treatment effect of a 50% reduction 
in the number of RBC transfusions and a 0.4 day reduction in duration of ICU stay 
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was needed. The power calculation based on this treatment effect, a power of 
90%, and an α level of 0.05 (two-sided test), showed that the minimum size per 
treatment group should be 500 patients. It was planned to enrol approximately 750 
patients per group to allow for violations of the protocol, non-evaluable patients, 
patient withdrawal from the study, and reliable preplanned subgroup analysis.
A planned interim analysis was conducted by the DSMB after 1,000 patients had 
been randomized and complete ICU data were achieved in at least 90% of those 
patients. The interim analysis was intended as both a safety assessment and su-
periority analysis. For statistical stopping boundaries, the Haybittle-Peto approach 
was used, which requires P < 0.001 as evidence required to consider stopping the 
trial (15). A futility analysis was not considered in order to provide for an adequate 
sample size to perform planned subgroup analyses.
Efficacy and safety analyses
Efficacy and safety analyses were conducted in all randomized patients (intention 
to treat (ITT) population) and for randomized patients who completed the study 
according to the protocol (per-protocol (PP) population).
Heterogeneity in treatment effect across the seven study sites was examined 
for all primary efficacy endpoints using analysis of variance or logistic regression 
analysis, as appropriate. These analyses were conducted by including interaction 
terms for treatment and study site. Heterogeneity was assumed to be present in 
case of a statistically significant treatment x study site interaction effect. Once no 
heterogeneity had been demonstrated, differences in efficacy outcomes between 
the two treatment groups were tested for continuous variables using the Student’s t 
test for independent samples. Comparison on categorical variables was performed 
with Pearson chi-square test or the Fisher’s Exact test, as appropriate.
The robustness of results for alternative population specifications (subgroup 
analysis) was tested in a similar way as for study site. There were four predefined 
subgroup variables: sex, preoperative use of antiplatelet medication within 5 days 
of surgery (yes or no), use of cardiopulmonary bypass (CPB; yes or no), and use of 
single versus bilateral ITA. When a significant treatment x subgroup interaction was 
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detected, a subgroup analysis was conducted for the respective primary efficacy 
endpoint.
For safety analysis, the treatment effect on safety measures was tested by uni-
variable binary logistic regression analysis. Odds ratios and 95% CI were computed 
with the no-CryoSeal treatment group as a reference.
All statistical tests were two-sided. P < 0.05 was considered statistically sig-
nificant. The statistical analyses were performed using SPSS software version 20.0 
(IBM, Armonk, New York, USA).
Economic evaluation
The economic evaluation consisted of a cost-minimization analysis, from the hos-
pital perspective and with a time frame from the operation day to discharge. No 
detectable costs differences were expected in non-hospital or other societal costs, 
or byond the duration of hospitalization. Included cost categories were CryoSeal 
use, blood products, hospitalization and reoperations.
Costs of CryoSeal use were estimated at €705 and €1,080 for surgery with one 
and two ITAs respectively (based on the use of 9 and 14 ml of CryoSeal, a market 
price of €75 per ml, and two additional min of operating time, valued at €15 per 
min (16)). The product costs were counted regardless of whether the patient 
received the CryoSeal; additional operating time was included only if the patient 
actually received the CryoSeal.
Costs of blood products were estimated using unit prices in the Netherlands in 
2012: €215 for RBCs, €185 for FFP and €519 for PCs (17-18). To account for compat-
ibility tests and hospital handling costs, the unit price for RBCs was multiplied by a 
factor four, and the unit prices of FFP and PCs by a factor two (19).
Costs of hospitalization were estimated using standard prices, at €2,288 per 
ICU day and €490 per non-ICU day (13). Reoperation for ischemia, reoperation for 
bleeding and treatment of mediastinitis were valued at €4,000, €2,000, and €3,000 
respectively.
Average costs were compared according to ITT, using unequal-variance t-test, 
multiple imputations to account for missing data (rendering slight differences 
compared to the efficacy analysis), and at 2012 price level. A cost-effectiveness 
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analysis was performed using cost-effectiveness acceptability curves, comparing 
the difference in the proportion of transfused patients to the difference in costs 
(20).
rEsults
Between March 2009 and January 2012, a total of 1,445 patients were included in 
the study (Figure 1). Nine patients withdrew consent or had incomplete data. Thus, 
the ITT population comprised 1,436 patients: 722 patients (50.3%) were random-
ized to CryoSeal, 714 patients (49.7%) to no CryoSeal. There were 144 protocol 
violations: 113 in the CryoSeal group and 31 in the no-CryoSeal group; resulting 
in a PP population of 1,292 patients: 609 and 683 repectively. Protocol violations 
included treatment with less than the required amount of fibrin sealant (n = 98), 
treatment with CryoSeal although randomized to no sealant (n = 6), other than iso-
lated CABG surgery (n = 32) and other reasons (n = 8). The two groups were similar 
with respect to baseline demographic, clinical and surgical characteristics, except 
for the use of CPB (P=0.001 and P=0.005 in the ITT and PP population respectively) 
(Table 1).
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figure 1. consort diagram for the trial. 
ITT, intenti on-to-treat; PP, per-protocol
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table 1. baseline demographic, clinical and surgical characteristics.









(n = 683) P-value§
Demographics
age (years) * 65.7 (9.7) 65.1 (10.0) 65.4 (9.8) 65.1 (9.9) 0.554‡
female gender 126 (17.5) 136 (19.0 %) 110 (18.1 %) 128 (18.7 %) 0.754
Comorbidity
Myocardial infarction 277 (38.4) 272 (38.1) 232 (38.1) 255 (37.3) 0.778
lv function <30% 17 (2.4) 17 (2.4) 16 (2.6) 17 (2.5) 0.875
Previous cardiac surgery 18 (2.5) 13 (1.8) 13 (2.1) 12 (1.8) 0.623
Previous PCI 148 (20.5) 133 (18.6) 127 (20.9) 125 (18.3) 0.248
hypertension 409 (56.6) 398 (55.7) 344 (56.5) 378 (55.3) 0.680
Diabetes 192 (26.6) 174 (24.4) 160 (26.3) 169 (24.7) 0.529
coPD 65 (9.0) 67 (9.4) 54 (8.9) 66 (9.7) 0.623
renal insufficiency 45 (6.2) 37 (5.2) 36 (5.9) 37 (5.4) 0.701
logistic EuroscorE* 3.4 (3.5) 3.3 (3.3) 3.4 (3.5) 3.3 (3.3) 0.634‡
Preoperative medication
anticoagulants within 5 
days
20 (2.8) 12 (1.7) 14 (2.3) 11 (1.6) 0.370
antiplatelets within 5 days 463 (64.1) 460 (64.4) 395 (64.9) 439 (64.3) 0.826
Preoperative laboratory 
data
hemoglobin (mmol/l)* 8.7 (0.9) 8.7 (0.9) 8.7 (0.9) 8.7 (0.9) 0.799‡
hematocrit  (%)* 41.5 (4.2) 41.4 (4.1) 41.4 (4.1) 41.5 (4.1) 0.767‡
Thrombocytes (109/l)*  243.5 (73.6) 243.6 (72.5) 245.0 (73.7) 243.5 (72.3) 0.702‡
Prothrombin time (sec)* 13.6 (3.2) 13.4 (2.7) 13.6 (2.8) 13.4 (2.6) 0.179‡
aPtt (sec)* 31.5 (7.4) 31.0 (5.8) 31.7 (7.4) 31.0 (5.8) 0.112‡
Surgery
use of 2 Itas 292 (40.4) 298 (41.7) 242 (39.7) 294 (43.0) 0.228
use of cPb 615 (85.2) 640 (89.6) 514 (84.4) 612 (89.6) 0.005
cPb timea  (min)* 97.6 (33.9) 100.2 (36.4) 97.4 (31.6) 99.2 (34.8) 0.380‡
use of tranexemic acid 610 (86.2) 620 (88.7) 517 (86.3) 593 (88.6) 0.210
Values in parentheses are percentages unless indicated otherwise; 
* values are means (SD). 
§ Pearson chi-square test except 
‡ Student’s t-test. 
a In case of use of CPB. 
aPTT, Activated Partial Thromboplastin Time; COPD, Chronic Obstructive Pulmonary Disease; 
CPB, Cardiopulmonary Bypass; ITA, Internal Thoracic Artery; LV, Left Ventricular.
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Primary and secondary efficacy outcomes
In both the ITT and the PP analysis, no significant difference between the treatment 
groups on any of the primary and secondary efficacy endpoints was observed. In 
addition, no significant difference between the two groups was seen in the propor-
tion of patients transfused with blood products (Table 2).
table 2. Primary and secondary efficacy endpoints.















 rbc (units)* 0.57 (1.38) 0.59 (1.52) 0.977a 0.57 (1.37) 0.54 (1.38) 0.688a
 rbc (pts transfused) 179 (24.9) 179 (25.1) 0.915 153 (25.2) 166 (24.4) 0.730
 ffP (units)* 0.27 (0.82) 0.32 (1.10) 0.947a 0.25 (0.77) 0.28 (0.97) 0.869a
 ffP (pts transfused) 93 (12.9) 92 (12.9) 0.994 75 (12.4) 81 (11.9) 0.800
 Platelets (units)* 0.19 (0.50) 0.20 (0.55) 0.966a 0.20 (0.50) 0.18 (0.48) 0.507a
 Platelets (pts transfused) 117 (16.3) 115 (16.2) 0.951 105 (17.3) 107 (15.7) 0.444
    Any blood product 249 (34.6) 252 (35.4) 0.763 212 (34.9) 237 (34.8) 0.963
length of Icu stay (hours)* 31.4 (46.9) 34.5 (58.9) 0.267 31.2 (44.7) 34.5 (60.0) 0.251
Secondary Endpoints
blood loss within 48 hours 
(ml)*
809 (542) 817 (692) 0.796 802 (508) 810 (684) 0.823
reoperation for bleeding 21 (2.9) 23 (3.2) 0.731 19 (3.1) 19 (2.8) 0.719
Mediastinitis 10 (1.4) 5 (0.7) 0.203 9 (1.5) 5 (0.7) 0.197
30-day Mortality 7 (1.0) 8 (1.1) 0.779 6 (1.0) 8 (1.2) 0.747
Duration of postoperative 
hospital days*
5.99 (3.95) 6.07 (4.21) 0.710 5.81 (3.44) 6.01 (4.23) 0.362
Values in parentheses are percentages unless indicated otherwise; 
* values are means (SD). 
a Mann-Whitney U test. 
FFP, Fresh Frozen Plasma; ICU, Intensive Care Unit; RBC, Red Blood Cells.
Subgroup analysis
Analysis of variance or logistic regression analysis for the primary efficacy out-
comes revealed only significant treatment x subgroup interaction effects for the 
subgroup variable use of CPB. For this subgroup variable, significant interaction 
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effects were found for the proportion of patients transfused with FFP (P= 0.027), 
units of transfused PCs (P= 0.038), the proportion of patients transfused with PCs 
(P = 0.014) and length of ICU stay (P = 0.035). In the subgroup of patients operated 
on off-pump, significant differences between treatment groups were found for the 
proportion of patients transfused with FFP (P = 0.020), units of transfused PCs (P 
= 0.036) and the proportion of patients transfused with PCs (P = 0.014) in the ITT 
analysis. In the PP analysis, however, these significant differences disappeared. No 
significant differences between the treatment groups were found in the on-pump 
CABG subgroup.
Safety
Except for the duration of mechanical ventilation exceeding 48 h in the ITT analysis 
(P = 0.032), there were no significant differences between the groups in the occur-
rence of SAEs and AEs (Table 3).
Economic evaluation
Of 722 patients randomized to CryoSeal, 642 (88%) actually received this interven-
tion. Estimated CryoSeal costs were €822 (95% CI €808 to €836) per patient. Other 
cost categories showed no statistically significant differences, in line with the lack 
of impact that CryoSeal use had on clinical outcome (Table 4). The overall cost 
difference was estimated at €461 (95% CI €-247 to €1170) per patient.
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table 4: Estimated postoperative hospital costs (by randomization and intention-to-treat 
anlaysis).









use of cryoseal 642 (89) 6 (1)      822         0 <0.001
Blood products
   rbc
   ffP
   Platelets











     443
  1,123
  1,208
     459




























        11
        58
        42
        22
        64




total costs (€) 10,163    9,702 0.202
Values in parentheses are percentages unless indicated otherwise; * values are means. RBCs, 
red blood cells; FFP, fresh frozen plasma; ICU, intensive care unit.
Whether use of CryoSeal in CABG is cost-effective depends on the willingness to 
pay to avoid blood transfusion. Use of CryoSeal resulted a 0.6% estimated decrease 
in the proportion of transfused patients (from 35.5% to 34.9%), which translates 
the estimated cost difference to €72,000 per avoided transfusion (with unbounded 
95%CI). Figure 2 shows the probability that use of CryoSeal is cost-effective com-
pared with no CryoSeal, conditional on the willingness-to-pay per avoided transfu-
sion. For willingness-to-pay up to €10,000 per avoided transfusion, CryoSeal is, at 
most, 21% likely to be cost-effective. Restricting the cost analysis to only the costs 
of CryoSeal (the only significantly different cost category), CryoSeal use is even less 
likely to be cost-effective (Figure 2).
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figure 2. cost-effectiveness acceptability curves: probability that cryoseal is cost-effective 
compared to no cryoseal, conditional on the willingness-to-pay per avoided transfusion.
DIscussIon
In this multicentre study performed in the Netherlands, use of the fibrin sealant 
CryoSeal as an adjunct to achieve hemostasis in patients undergoing elective 
isolated CABG with ITA grafting was not associated with a reduction in blood 
transfusion. The numbers of transfused units of RBCs, FFP and PCs were not sig-
nificantly different between the patients randomized for treatment with CryoSeal 
and patients randomized to no fibrin sealant. The duration of ICU stay and the 
secondary efficacy outcomes also showed no significant differences between the 
two treatment groups. In line with this lack of impact of CryoSeal on outcomes, 
there was no significant difference between the groups on any of the predefined 
cost categories (blood product usage, hospitalization, reoperation for ischemia or 
bleeding, and treatment of mediastinitis) other than the costs of the sealant itself.
The sample size calculation was based on a treatment effect of a 50% reduction 
in RBC transfusion. The control group, however, showed a mean number of only 
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0.6 RBC units transfused per patient. The mean numbers of units of transfused FFP 
and PCs were even lower. Studies on blood transfusion usage in CABG continue 
to show a considerable variability. An average of approximately 2 units of RBCs 
transfused per patient has been reported in studies (21-23) from different con-
tinents, whereas the mean blood loss in these studies appeared to be similar to 
that in the present study. This obvious difference in transfusion practice in CABG 
may reflect an enhanced implementation of blood conservation techniques in the 
Netherlands. Here, intraoperative blood salvage and blood-sparing interventions 
as well as restricted blood transfusion algorithms have become common practice 
recently. This raises the question how the complementary use of a fibrin sealant 
could be cost-effective when already effective blood conservation strategies are 
used. It should be noted, though, that the effectiveness of the CryoSeal could also 
not be demonstrated by comparing postoperative blood loss between the treat-
ment groups in this study. 
Risk factors for postoperative blood loss and blood transfusion in CABG include 
female sex, use of antiplatelet drugs within 5 days before surgery, use of CPB 
and use of bilateral ITA (24,25). Planned subgroup analyses were undertaken in 
subgroups based on these four variables. Only in the subgroup of patients who 
had surgery off-pump did the ITT analysis show significant differences in blood 
transfusion between the treatment groups, in favour of CryoSeal. This potential 
effectiveness of the fibrin sealant in off-pump CABG procedures might be explained 
by the fact that during CPB the coagulation profile is more severely affected. CPB is 
known to be associated with hemodilution by the pump prime, resulting in anemia, 
reduced fibrinogen and platelet levels, and platelet dysfunction (26). Furthermore, 
an increase in thrombin formation has been described after the release of the aor-
tic cross-clamp by liberating blood from the myocardium and pulmonary vascular 
bed (27). The coagulation profile in on-pump patients might be so disturbed that 
CryoSeal use cannot compensate. In off-pump patients, on the other hand, the 
coagulation profile is changed minimally changed (28), and the use of fibrin sealant 
may have contributed to preventing postoperative hemorrhagic complications. It 
should be noted, however, that the significant effects in the ITT analysis were not 
confirmed by the PP analysis.
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The use of fibrin sealants in cardiac surgery is in generally considered to be 
safe, and their use has increased substantially since their commercial introduction 
20 years ago. Recently, however, concerns about early graft occlusion after CABG 
have been reported based on clinical studies. In these studies (29,30), an increased 
risk of myocardial infarction and even 30-day mortality after the use of Tissucol® 
fibrin sealant (Baxter, Vienna, Austria) was observed. These deleterious effects 
were thought to be mainly associated with an inadequate application of Tissucol®, 
insufficient mixing of its components and spray application directly on bypass graft 
anastomoses. The retrospective character of these studies, however, precluded a 
definitive conclusion on the safety of Tissucol®. Although safety was not the main 
purpose of the current study, no significant differences were found between the 
treatment groups in the occurrence of SAEs and AEs, except that with CryoSeal 
the duration of mechanical ventilation more frequently exceeded 48 h in the ITT 
analysis.
Related specifically to the use in CABG, the application site of fibrin sealant and 
the amount given are often not clearly documented in the literature. In the present 
study a standard treatment regimen was followed, requiring 5 ml CryoSeal per ITA 
bed. The rationale for this was that the ITA graft is a risk factor for hemorrhage after 
CABG. It has been reported (31) that, in patients having an ITA harvested, the ITA or 
its bed was the main cause of bleeding in 43%. Not only has single ITA grafting been 
linked to an increased bleeding risk compared to the use of only saphenous vein 
grafts (10), but also bilateral ITA grafting increases the risk of bleeding compared to 
single ITA grafting (11). Furthermore, based on our pilot study, it was established 
that the application of 5 ml of CryoSeal was the optimal amount to cover the entire 
ITA bed.
Whether a strategy in patient blood management is cost-effective depends on 
willingness to pay to avoid transfusion. The present costs analysis was performed 
from a hospital perspective, including costs of CryoSeal, blood products, hospital 
stay and complications related to postoperative bleeding. Prices vary by country 
and by centre; the present study prices for blood products and hospitalization that 
are specific tot the Dutch context, which may not be representative for elsewhere. 
Yet, our study showed no differences between the treatment groups on the respec-
140 CHAPTER 6
tive types of care; therefore, the conclusion of our analysis would not change when 
other prices were used. For the CryoSeal fibrin sealant, a price was used that may 
underestimate the true costs: it included a realistic price for the product itself, 
but only a relatively small surcharge of €30 to account for the approximately 2 
min additional surgery time. Implementation and other in-hospital handling costs 
were neglected, so the economic evaluation is biased in favour of CryoSeal. For 
reasonable willingness-to-pay per avoided transfusion, the fibrin sealant CryoSeal 
is unlikely to be cost-effective.
A limitation of this study was the lack of blinding with the possible risk of 
surgeons’ performance bias. This limitation seems unavoidable, as the use of a 
placebo fibrin sealant is hardly feasible. However, to minimize the influence on 
routine hemostasis, a cooling box was used in every patient which was instructed 
to open only until 30 min before the end of surgery. Furthermore, although num-
ber of blood transfusions required is an objective efficacy measure, it is influenced 
by transfusion policy. Using a restrictive transfusion policy, as has become com-
mon practice in the Netherlands, effectiveness of CryoSeal treatment may not be 
detected. However, even if blood loss was used as an endpoint in this study, there 
would be no evidence for the effectiveness of CryoSeal.
There is limited research on fibrin sealants in cardiac surgery. The majority of 
controlled studies suggest that fibrin sealants are efficacious in reducing postop-
erative blood loss and RBC transfusion. However, previous large studies in this area 
were retrospective, and prospective studies had small numbers (32). Evidence of 
efficacy is only a first step in evaluating whether fibrin sealants are appropriate for 
clinical use (33). So far there are no large randomized controlled studies on the 
cost-effectiveness of a fibrin sealant in CABG.
Conclusion
This multicentre randomized controlled clinical trial demonstrated that the use 
of the fibrin sealant CryoSeal in elective isolated CABG procedures was not cost-
effective. There were no health benefits. In combination with the high costs per 
avoided transfusion, this study does not support the implementation of routine 
CryoSeal use in elective isolated CABG.
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Continuous postoperative pericardial flushing: A pilot 
study on safety, feasibility and effect on blood loss
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Prolonged or excessive blood loss is a common complication after cardiac surgery. 
Blood remnants and clots, remaining in the pericardial space in spite of chest tube 
drainage, induce high fibrinolytic activity that may contribute to bleeding compli-
cations. Continuous postoperative pericardial flushing (CPPF) with an irrigation 
solution may reduce blood loss by preventing the accumulation of clots. In this 
pilot study, the safety and feasibility of CPPF was evaluated and the effect on blood 
loss and other related complications were investigated.
Methods
Between November 2011 and April 2012 twenty-one adult patients undergoing 
surgery for congenital heart disease (CHD) received CPPF from sternal closure up 
to 12 h postoperative. With an inflow Redivac drain that was inserted through one 
of the chest tube incision holes, an irrigation solution (NaCl 0.9% at 38 ºC) was 
delivered to the pericardial cavity using a volume controlled flushing system. Safety 
aspects, feasibility issues and complications were registered. The mean actual 
blood loss in the CPPF group was compared to the mean of a retrospective group 
(n = 126).
Results
CPPF was successfully completed in 20 (95.2%) patients, and no method related 
complications were observed. Feasibility was good in this experimental setting. 
Patients receiving CPPF showed a 30% (P=0.038) decrease in mean actual blood 
loss 12 h postoperatively.
Conclusions
CPPF after cardiac surgery was found to be safe and feasible in this experimental 
setting. The clinically relevant effect on blood loss needs to be confirmed in a 
randomized clinical trial.
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IntroDuctIon
Prolonged or excessive bleeding is one of the most common complications after 
cardiac surgery. Postoperative bleeding requiring transfusions and surgical re-
exploration remains an important complication because it is associated with short- 
and long-term postoperative mortality, morbidity, prolonged hospitalization and 
higher societal healthcare costs (1).
The mechanisms involved in perioperative bleeding are complex and involve 
disturbances in various physiologic systems including primary hemostasis, co-
agulation and fibrinolysis. This may be caused by several surgical factors includ-
ing cardiopulmonary bypass (CPB) and operative trauma. Together with primary 
fibrinolysis, platelet dysfunction and hemodilution these mechanisms contribute 
to dysfunction of the coagulation, fibrinolytic, and inflammatory systems with 
postoperative coagulopathy and bleeding as a result (2,3).   Consequently, the 
normal or generally accepted amount of blood loss after cardiac surgery is higher 
than most other surgical specialties and varies between 300-1500 ml during the 
first 12 h.
The standard operating procedure is to insert chest tubes in order to evacuate 
this blood from the pericardial cavity postoperatively. However, if blood loss or clot 
formation is excessive the chest tubes often fail due to partial or complete block-
age. The resulting stasis of blood and clots in the pericardial cavity leads to high 
fibrinolytic activity and consequently, maintenance of blood loss (3-7). This is also 
supported by the finding that during re-exploration for postoperative bleeding, 
removal of accumulated blood and clots by solely irrigating the pericardial space 
with a warm saline solution is enough to stop the bleeding instantly in a significant 
number of cases8. Following on from this, a method of preventing blood and clots 
from accumulating in the pericardial space could hypothetically stop postopera-
tive bleeding at an earlier stage and reduce bleeding complications. Continuous 
postoperative pericardial flushing (CPPF) was developed for this purpose.
CPPF works by continuously flushing the pericardial cavity with a warm saline 
irrigation solution starting towards the end of surgery just before sternal closure. 
Continuous flushing will result in a lower viscosity mixture that will prevent chest 
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tube blockages and promote the evacuation of blood and clots from the pericardial 
cavity. This pilot study evaluates the safety and feasibility of CPPF. In addition, its ef-
fects on blood loss and other related complications are investigated and discussed. 
To our knowledge, the continuous pericardial flushing method post-cardiac surgery 
has not been used or described before.
lIst of abbrEvIatIons
ACT Activated clotting time
AMC Academic Medical Centre, Amsterdam, The Netherlands
CHD Congenital heart disease
CPB Cardiopulmonary bypass
CPPF Continuous postoperative pericardial flushing
CRP C-reactive protein
FFP Fresh frozen plasma
ICU Intensive care unit
IU International unit
MCTD Mediastinal chest tube drainage
METC Medical ethics committee




In this pilot study, a prospective cohort of patients who underwent surgery and 
CPPF between November 2011 and April 2012 (n = 21, over a 6-month inclusion 
period) was compared to a retrospective group of patients who underwent surgery 
and no CPPF (non-CPPF group) between January 2010 and December 2011 (n = 
126). The study protocol was approved by the internal review board of the Aca-
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demic Medical Centre (AMC) Amsterdam, protocol number METC 2011_270. All 
adult patients undergoing surgical correction for congenital heart disease (CHD) 
were eligible to participate in this prospective cohort study. Exclusion criteria were 
emergency surgery, a history of bleeding diathesis or coagulopathy, participation in 
any study involving an investigational drug or device and the inability to understand 
the study information or give informed consent. Informed consent was obtained 
one day preoperatively from all patients in the CPPF group and data were gathered 
prospectively. Data from the non-CPPF group were obtained retrospectively by 
analysing consecutive patient records before the use of CPPF for a period of 24 
months. All patients underwent cardiac surgery at the AMC, which is a quaternary 
care university hospital. A single surgeon performed surgery on all included pa-
tients in the CPPF group and almost all of the patients in the non-CPPF.
Continuous Postoperative Pericardial Flushing
The method of inserting chest tubes in the CPPF group was the same as routinely 
used in the non-CPPF group; one chest tube (Ch30 Redivac drain, Medica Europe, 
Oss, The Netherlands) in the pericardial space, one chest tube (Ch30 Redivac 
drain, Medica Europe, Oss, The Netherlands) in the anterior mediastinum and in 
case of opened pleural spaces they were each drained separately (Ch30 Redivac 
drain, Medica Europe, Oss, The Netherlands). In the CPPF group an extra infusion 
tube (Ch10 Redivac drain, Dispo Medical, Hattemerbroek, The Netherlands) was 
inserted through the incision hole of one of the standard chest tube incisions and 
positioned in the pericardial space. This extra infusion tube was directly connected 
to the CPPF system that comprises a bag of irrigation solution (NaCl 0,9%) con-
nected to infusion line that runs through a volumetric pump (Infusomat® Space 
by B. Braun, Melsungen, Germany) and through a fluid heating device (Enflow® 
fluid warmer by GE Healthcare, Hoevelaken, The Netherlands). CPPF was started at 
sternal closure and continued for 12 h postoperatively. The irrigation solution NaCl 
0.9%, was delivered to the pericardial cavity at a flow rate of 500 ml/h for the first 
two postoperative hours. It was then set to volume controlled for the next ten hours 
so that the volume corresponded with the patients’ actual blood loss at a 1:1 ratio, 
with a minimum flow rate of 100 ml/hour. The irrigation solution was delivered to 
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the patient at a constant temperature of 38 ºC to avoid changes in patient core 
temperature. Irrigation solution volume and total mediastinal chest tube drainage 
(MCTD) volume were monitored every 15 min for the first two postoperative hours 
and thereafter hourly until chest tube removal. Actual blood loss was calculated 
at the same time intervals by subtracting irrigation solution volume from the total 
MCTD volume. In this way, a secondary manually written record was kept to moni-
tor actual blood loss and trace fluid accumulation. If MCTD volume was >200 ml 
less than the infused irrigation solution volume, the CPPF system was stopped to 
prevent accumulation of fluid in the pericardial and/or pleural spaces. One and the 
same research assistant facilitated both preparation of the CPPF system and the 
safeguarding and control of the system during the CPPF window.
Operative procedures and cardiopulmonary bypass management
Routine anesthetic procedures were employed making circumstances standardized 
and equal for both groups. All patients underwent full median sternotomy; CPB 
(Stöckert S5, Sorin Group, Italy) was instituted in all patients using mild hypother-
mia (30-32 ºC). Before initiation of CPB, all patients received a standard heparin 
dosage of 150 IU/kg bodyweight with an additional optional bolus of 50 IU/kg 
before cannulation. Anticoagulation was monitored by serial measurements of the 
activated clotting time (ACT), which was kept above 450 s at all time during CPB. 
The heparin was reversed by administration of 1ml protamine for each 1000 IU 
heparin and ACT return to baseline served as confirmation.
Transfusion policies
A standardized transfusion protocol was followed in all patients. Intraoperative 
blood management included reinfusion of residual blood from the cardiotomy 
reservoir and packed red blood cell (PRBC) transfusion during CPB were given 
at hemoglobin levels <4.0 mmol/l. Postoperative blood management on the ICU 
included PRBC transfusions for hemoglobin level <5.0 mmol/l; platelet concentrate 
for platelet count <50×109/l or <100×109/l if blood loss exceeded 150 ml/h and 
fresh frozen plasma (FFP) was transfused if the activated partial thromboplastin 
time and prothrombin time were prolonged >150% during active bleeding.
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Primary end-points
The primary end-points of this pilot study were to evaluate the safety and fea-
sibility of CPPF procedure and its effect on actual blood loss. Safety end-points 
during hospitalization were defined as chest tube competence, pericardial and/or 
pleural fluid accumulation, infection and adverse events. Adverse events between 
discharge from hospital until most recent follow-up were also recorded. Feasibility 
end-points were defined as system functionality and labour-intensiveness. Trans-
thoracic echocardiograms and chest radiographs were the imaging modalities of 
choice that were used to evaluate pericardial and pleural effusions on arrival in 
ICU, at 5-7 days postoperatively and on discharge. Pericardial or pleural effusions 
that were clinically significant and required drainage were registered.
Secondary end-points
Secondary end-points included transfusion requirements, time to chest tube 
removal, time to extubation and length of ICU and hospital stay. Transfusion re-
quirements were defined as total PRBC, total FFP and total platelet concentrate 
transfusions as well as the proportion of patients requiring blood product transfu-
sion. The time frames between operation and chest tube removal and between 
operation and extubation were recorded in postoperative hours.
Statistical analysis
Variables are presented as mean (± standard deviation) or as number (percentage), 
unless otherwise noted. An independent-samples t-test was conducted to compare 
mean actual blood loss between the CPPF and non-CPPF group; a P<0.05 was con-
sidered statistically significant. All data analyses were performed using SPSS 20.0 
for Macintosh (IBM® SPSS® Software). Mean actual blood loss curves were plotted 
using GraphPad Prism® 6.0 software for Macintosh. 
Funding
This study was funded intramural with resources from the department of cardio-
thoracic surgery of the Academic Medical Centre, Amsterdam, The Netherlands.
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rEsults
Demographic and preoperative clinical data
Preoperatively we registered there were two significant differences between the 
CPPF and the non-CPPF group of patients with respect to demographic and clinical 
characteristics as shown in Table 1.
table 1. clinical characteristics of the cPPf and non-cPPf group.
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
Mean age (y ± sD) 43.8 ± 13.6 40.5 ± 15.0 0.353
Male / female 11 / 10 73 / 53 0.637
body mass index (mean ± sD, (kg/m2)) 27.5 ± 7.0 24.3 ± 4.6 0.057
Diagnoses:
   tetralogy of fallot 6 (28.6) 14 (11.1) 0.109
   transposition of the great arteries 1 (4.8) 8 (6.3) 0.781
   univentricular heart 0 (0.0) 3 (2.4) 0.478
   connective tissue disease 0 (0.0) 16 (12.7) < 0.001 *
   fabry syndrome 1 (4.8) 1 (0.8) 0.420
   factor v leiden 1 (4.8) 1 (0.8) 0.420
Associated diseases:
   bMI >30 kg/m2 5 (23.8) 11 (8.7) 0.142
   Diabetes 1 (4.8) 4 (3.2) 0.518
   renal insufficiency (at least moderate) 6 (28.6) 18 (14.3) 0.189
   chronic obstructive lung disease 2 (9.5) 7 (5.6) 0.486
   urgent/emergency surgery 0 (0.0) 1 (0.8) 0.685
left ventricular ejection fraction:
   >50% 14 (66.6) 106 (84.1) 0.127
   30-50% 7 (33.3) 18 (14.3) 0.096
   <30% 0 (0.0) 2 (1.6) 0.564
Euroscore I (logistic) (mean ± sD) 6.14 ± 7.27 7.51 ± 6.67 0.389
Euroscore II (mean ± sD) 2.90 ± 2.97 2.84 ± 2.63 0.916
Preoperative anticoagulant use: a
   Acetylsalicylic acid 6 (28.6) 23 (18.3) 0.274
   vitamin K antagonists 4 (19.0) 10 (7.9) 0.235
   other 0 (0.0) 1 (0.8) 0.685
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Surgical procedures and operative data
On comparison with the CPPF group patients in the non-CPPF group had undergone 
significantly more procedures for left-sided lesions (P=0.030), aortic root surgery 
(P<0.001), aortic valve replacement (P=0.008) and Bentall procedure (P=0.008). 
Patients in the CPPF group underwent significantly more procedures for right-sided 
lesions (P<0.001). The complexity of surgical procedures is shown in Table 2 . In-
traoperative variables such as the duration of CPB and aortic cross-clamping were 
similar in both groups and are presented in Table 3.
CPPF safety and feasibility
Postoperative safety aspects of the CPPF group and historic group of patients are 
summarized in Table 4. CPPF was successfully completed in 20 (95.2%) patients. In 
1 (4.8%) patient, CPPF was stopped as a precaution 3.5 h postoperatively as there 
was a >200 ml lag in MCTD volume as fluid had accumulated in the right pleural 
cavity. On extubation the patient spontaneously evacuated all accumulated fluid, 
which was confirmed by chest radiography. All irrigation solution was successfully 
evacuated from the pericardial and/or pleural cavities in all patients before the 
chest tubes were removed. There were no significant differences between groups 
in pleural effusions (P=0.272) or pericardial effusions (P=0.486) at discharge. Post-
operative inflammatory markers were not significantly different between groups.
table 1. clinical characteristics of the cPPf and non-cPPf group. (continued)
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
Preoperative laboratory values:
   hemoglobin (mmol/l) 8.8 ± 0.7 8.9 ± 0.9 0.831
   crP (mg/l) 4.0 ± 4.4 3.6 ± 6.4 0.903
   leukocytes (×109/l) 7.5 ± 2.1 6.4 ± 1.7    0.009 *
   Platelet count (×109/l) 221 ± 70 219 ± 55 0.869
   Inr (median;Q1;Q3;IQr) 1.08 
(0.98;1.62;0.64)
    0.99 
(0.96;1.08;0.12)
0.160
a Use of all antiplatelet agents was discontinued 5 days prior to surgery. CRP, C-reactive 
protein; INR, International normalized ratio.
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table 2. surgical procedures of the cPPf and non-cPPf group.
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
aortic surgery:
   avP 0 (0.0) 1 (0.8) 0.685
   avr +asc. repl. (0|2); +Pvr (0|1); +MvP,PvI (0|1); +vsD repair (0|1) 0 (0.0) 7 (5.6)    0.008 *
   Bentall 
+Pvr (1|4); +hemiarch repl. (0|1); +MvP,tvP (0|3); +vsD repair (0|2)
1 (4.8) 27 (21.4)    0.008 *
   vsrr +avP (0|3); +MvP (0|2) 1 (4.8) 20 (15.9) 0.061
   Ascending aorta replacement +MvP (0|1) 0 (0.0) 4 (3.2) 0.411
   hemiarch replacement + Ductus closure 0 (0.0) 1 (0.8) 0.685
Atrioventricular valve surgery:
   MvP +PvI (1|3); +tvP (0|6); +vsD repair (0|2) 1 (4.8) 12 (9.5) 0.480
   Mvr 0 (0.0) 5 (4.0) 0.356
   tvP 0 (0.0) 4 (3.2) 0.411
septal defects:
   asD I,MvP,tvP 2 (9.5) 1 (0.8) 0.201
   asD II +MvP,tvP (2|1); +tvP (1|3); +PvP (0|1) 2 (9.5) 6 (4.8) 0.377
   vsD +tvP (1|1); +Dcrv (1|0) 2 (9.5) 3 (2.4) 0.298
Pulmonary venous anomalies:
   PaPvc repair +asD (1|4); +tvP (1|1) 2 (9.5) 5 (4.0) 0.422
Coronary artery anomalies:
   alcaPa / arcaPa repair +Pa plasty (0|2); +cabg (0|1) 2 (9.5) 3 (2.4) 0.298
other:
   Pvr +Pa plasty (5|16); +tvP (1|4); +MvP (1|0) 7 (33.3) 20 (15.9) 0.127
   aP plasty + hybrid stent placement 0 (0.0) 1 (0.8) 0.685
   Dsas repair / Morrow 0 (0.0) 1 (0.8) 0.685
   atrial baffle + tvP 1 (4.8) 2 (1.6) 0.344
   TCPC 0 (0.0) 3 (2.4) 0.478
ALCAPA, anomalous left coronary artery from the pulmonary artery; ARCAPA, anomalous right coronary 
artery from the pulmonary artery; Asc, ascending aorta; ASD, atrial septal defect; AVP, aortic valve 
plasty; DCRV, double-chambered right ventricle; DSAS, discrete subaortic stenosis; MVP, mitral valve 
plasty; MVR, mitral valve replacement; PA, pulmonary artery; PAPVC, partial anomalous pulmonary 
venous connection; PVI, pulmonary vein isolation; PVP, pulmonary valve plasty; PVR, pulmonary valve 
replacement; Repl, replacement; TCPC, total cavopulmonary connection; TVP, tricuspid valve plasty; VSD, 
ventricular septal defect. 
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No system-related or other serious problems were encountered. Monitoring 
of inflow and outflow volumes was considered time-consuming but feasible in this 
experimental setting where the monitoring was safeguarded and controlled by a 
research assistant. However, it was considered to be a major drawback for normal 
clinical setting as it would be a significant increase in workload for the ICU nurse and 
repeated calculation will be error prone. Especially in case of bleeding problems 
when a more frequent monitoring and calculation of actual blood loss is required. 
Also, the normal clinical assessment of blood content of MCTD is disturbed as the 
blood is constantly diluted in varying degrees.
table 3. operative data of the cPPf and non-cPPf group.
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
reoperation 10 (47.6) 57 (45.2) 0.841
left sided lesions 9 (42.9) 85 (67.5)    0.030 *
right sided lesions 17 (81.0) 56 (44.4) < 0.001 *
aortic root surgery 2 (9.5) 65 (51.6) < 0.001 *
septal defects 6 (28.6) 21 (16.7) 0.274
Pulmonary venous anomalies 2 (9.5) 5 (4.0) 0.422
Coronary artery anomalies 2 (9.5) 3 (2.4) 0.298
Single procedure 8 (38.1) 63 (50.0) 0.320
Double procedure 11 (52.4) 43 (34.1) 0.110
Triple procedure 1 (4.8) 18 (14.3) 0.103
Quadruple procedure 1 (4.8) 2 (1.6) 0.344
Mean surgical procedures per patient 1.76 1.67 0.230
Mean cPb time (min) ± sD 140 ± 72 151 ± 63 0.443
Mean cross-clamp time (min) ± sD 86 ± 41 101 ± 46 0.186
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table 4. Postoperative safety aspects of the cPPf and non-cPPf group.
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
In-hospital adverse events:
   Cardiac tamponade 0 (0.0) 4 (3.2) 0.411
   reexploration for bleeding 0 (0.0) 9 (7.1)    0.002 *
   Subxyphoidal drainage 0 (0.0) 3 (2.4) 0.478
   Mortality 0 (0.0) 2 (1.6) 0.564
In-hospital infection:
   sternal wound infection 0 (0.0) 3 (2.4) 0.478
   Mediastinitis 0 (0.0) 2 (1.6) 0.564
   Pneumonia 1 (4.8) 3 (2.4) 0.538
   urine tract infection 1 (4.8) 1 (0.8) 0.420
   fever > 38,5°c 2 (9.5) 9 (7.1) 0.703
   max. crP (mg/l, median;Q1;Q3;IQr) 138 (95;200;105) 182 (136;231;95) 0.057








   time until extubation (h ± sD) 7.6 ± 6.1 6.8 ± 5.2 0.535
   time until chest tube removal (h ± sD)             21 ± 8 22 ± 14 0.762
   Icu stay (d  ± sD) 1.4 ± 0.9 1.7 ± 3.8 0.746
   total hospitalization (d ± sD) 7.7 ± 2.4 9.0 ± 8.6 0.472
fluid accumulation at discharge:
   Pleural effusion (trace to mild) 10 (47.6) 77 (61.1) 0.272
      In a surgically opened pleural cavity 5 (23.8) 23 (18.3) 0.563
   Pericardial effusion (trace to mild) 7 (33.3) 38 (30.2) 0.486
      circular (≥50% / ≥6mm) 1 (4.8) 10 (7.9) 0.606
adverse events after discharge:
   late cardiac tamponade 1 (4.8) 3 (2.4) 0.477
      for which subxyphoidal drainage 1 (4.8) 2 (1.6) 0.344
      for which re-sternotomy 0 (0.0) 1 (0.8) 0.685
   reoperation 1 (4.8) 4 (3.2) 0.718
   3-year mortality 0 (0.0) 6 (4.8)    0.014 *
Mean follow-up (y ± sD) 2.9 ± 0.1 4.1 ± 1.0 < 0.001 *
a Time until extubation and chest tube removal were defined as the mean number of hours between sur-
gery and the time of removal. Length of ICU and hospital stay were defined as the mean number of days 
between the date of surgery and the date of ICU and hospital discharge, respectively.
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Effect on mean actual blood loss
Differences in mean actual blood loss on arrival at ICU, at 6 and 12-h postopera-
tively, and the total postoperative blood loss between the CPPF group and non-
CPPF group are presented in Table 5 . The magnitudes of the significant decrease 
in means were 41% (mean difference = 57 ml, 95% CI: 12 to 102) on arrival at ICU 
and 30% (mean difference = 162 ml, 95% CI: 9 to 315) at 12 h postoperatively; 
both had a moderate effect (eta squared = 0.04 and 0.03 respectively). Within the 
non-CPPF group, those who underwent aortic root surgery had 65 ml (P=0.286) 
less blood loss at 12 h postoperatively compared to the non-aortic root surgery 
group. Postoperative mean actual blood loss over hourly intervals and the cumula-
tive total over the first 12 postoperative hours is shown in Figure 1.
Secondary end-points
Differences in allogeneic transfusion requirements between the two groups 
was not statistically significant as shown in Table 5 . No significant differences in 
means between the two groups were found with respect to the time to extubation 
(P=0.535), time to chest tube removal (P=0.762), length of ICU stay (P=0.746), and 
total hospitalization (P=0.472).
table 5. blood loss and Prbc transfusion requirements of the cPPf and non-cPPf group.
CPPf non-cPPf P-value
n=21 (%) n=126 (%)
Postoperative blood loss: (mean ± sD)
   t0: Icu arrival 83 ± 74 140 ± 100    0.014 *
   t6: six hours postoperative 310 ± 195 415 ± 297 0.131
   t12: twelve hours postoperative 376 ± 249 538 ± 330    0.038 *
   total postoperative 608 ± 422 768 ± 630 0.263
Prbc transfusion requirements:
   Patients transfused Prbc intraoperatively 7 (33.3) 38 (30.2) 0.772
   Patients transfused Prbc postoperatively 1 (4.8) 19 (15.0) 0.080
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figure 1. Postoperative actual blood loos over hourly intervals (a) and total cumulatively (b) 
during the first 12 postoperative hours.
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DIscussIon
There are several techniques available that aim to reduce blood loss and associ-
ated exposure to allogeneic blood after surgery. These include minimally invasive 
surgical techniques, blood conservation strategies (9) extracorporeal circulation 
systems (10) and, the systemic (11,12) and topical (13) pharmacological correction 
of hemostasis. Despite the improvements achieved by these techniques we still 
tend to accept a considerable amount of blood loss as being inherent to cardiac 
surgery. Moreover, all techniques available have different targets and/or time of 
action than the CPPF. Therefore, regardless of their effects, the result of CPPF is 
always an additional improvement to the current state of the art. 
Review of literature revealed only a few studies that were focused on chest 
tube functionality and improvement of the postoperative drainage system (14-16). 
None of the studies reported a technique similar to CPPF as described in our paper. 
In addition, none of the postoperative drainage systems initially aimed for the 
complete cleaning of the pericardial space of blood and clots and, also, did not 
have reduction of blood loss as a primary study end point. Thus, to our knowledge, 
a flushing system that has specifically been designed to promote the evacuation 
of contaminated blood and clots out of the pericardial cavity in order to reduce 
postoperative blood loss has not been used or described before.
CPPF showed a 30% reduction in 12-h postoperative blood loss and there were 
no re-explorations for bleeding complications in the CPPF group. The non-CPPF 
group included significantly more aortic root surgery but within the non-CPPF 
group, procedures on the aortic root showed even less blood loss when compared 
to those that had non-aortic root surgery. With respect to important bleeding 
parameters (percentage of redo surgery, cross-clamp and CPB time, single and mul-
tiple procedures, use of anticoagulants, EUROSCORES) no significant differences 
were found between the groups. None of the other significant differences between 
the two groups, as depicted in tables 1 – 3, are known to have implications with 
respect to more or less bleeding tendency. Overall, the mean postoperative blood 
loss in both the CPPF and non-CPPF group can be considered to be low given the 
surgical complexity and high percentage of reoperations; this makes the difference 
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that we found stronger. However, the evidence from this pilot study (prospective 
cohort in comparison with a historic group of patients) is not strong enough to 
draw definitive conclusions with respect to blood loss and bleeding complications. 
Currently, two randomized clinical trials are ongoing at our institution that need to 
provide proof of concept by confirmation of these pilot findings.
On the contrary, one can also put forward that flushing a fresh wound carries 
the risk of disturbing the normal coagulation process, which therefore may lead to 
increased blood loss. Considering the little amount of blood loss that we observed 
in the CPPF group (mean 376 ml) and the fact that no continued bleeding was 
observed, we may abstract that CPPF patients did not tend to have more blood 
loss when compared to the “normal” non-CPPF patients. It is likely that this phe-
nomenon did not occur is because our flushing method includes a slow continuous 
irrigation of flushing fluid rather than hosing the wound using strong mechanical 
forces. CPPF works mainly by dilution and lowering the viscosity of the blood and 
clot mixture in the wound, which enhances evacuation through the chest tubes.
Surgical re-exploration bleeding or suspected or acute cardiac tamponade is 
associated with increased mortality and morbidity (17) and is still needed in 2-6% 
of patients (18,19). As well as its effect on blood loss, CPPF may have an important 
impact on the prevention of acute cardiac tamponade, which was not seen in 
the CPPF group. As stated above, CPPF lowers the viscosity of drainage fluid and 
prevents abundant formation of clots, thereby preventing the chest tubes from 
blocking and promoting chest tube patency. Even the use of multiple rather than 
single mediastinal chest tubes is known not to solve this problem (20).
In theory, partial or complete chest tube blockage can never be completely 
eliminated, which emphasizes the need for careful monitoring of inflow and out-
flow volumes. Intrapericardial pressure monitoring could serve as an extra safety 
assurance. CPPF requires real-time accurate quantification of MCTD volume within 
the CPPF window in order to monitor actual blood loss and to trace possible fluid 
accumulation in the pericardial and/or pleural cavity. The manual monitoring pro-
cedure at time intervals that was used in this study was considered labor intensive 
and should ideally be automated for future clinical use. For the clinical assessment 
of actual blood loss and the detection of surgical hemorrhage, the blood content of 
7
Continuous postoperative pericardial flushing 161
MCTD must be known at any time. Therefore, real time monitoring of hematocrit 
values of MCTD seems indispensable.
On transthoracic echocardiograms on discharge no significant differences in 
pericardial effusion were found between the CPPF group and non-CPPF group of 
patients, and no clinically significant pericardial effusions were encountered in the 
CPPF group. CPPF was stopped in one patient 3.5 h postoperatively as a precaution-
ary measure due to a lag of >200 ml of fluid drainage from the right pleural cavity. 
As long as the protocol is followed strictly, i.e. the maximum accumulation volume 
does not exceed 200 ml, these pericardial or pleural effusions may be considered 
as clinically insignificant.
CPPF requires insertion of an extra drain and infusion of a saline solution into a 
fresh wound area, thereby theoretically increasing the risk of infection. However, 
since both the infusion solution and drain are sterilized and the same incision is 
used as for the standard chest tubes, this risk is considered to be negligible. No 
manifest clinical infections were seen in the CPPF group. Continuous irrigation 
of the wound area may reduce bacterial load and in theory decrease the risk of 
infection. In addition, by evacuating all blood and clots an important nutrient 
medium for potential bacterial infections is eliminated. Besides this, blood outside 
the vascular system i.e. in the pericardial cavity, may itself induce a serious local 
inflammatory reaction. Aiming for a cleaner pericardial space, CPPF may reduce 
postoperative complications related to this inflammatory process. In this context, 
the effect of CPPF on atrial fibrillation (22), the development of adhesions (23,24) 
and impaired postoperative right ventricular function (25) will be the subject of 
future studies.
In summary, so far CPPF can be regarded as safe since no postoperative ad-
verse events that could be related to the CPPF were encountered in this study. 
In this experimental setting the CPPF method was considered feasible. However, 
in our judgement the CPPF method must be automated and the system should 
be equipped with an intra-pericardial pressure sensor and real-time hematocrit 
analysis of MCTD to provide the required high level of safety and feasibility in the 
clinical setting.
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A limitation of this study is the retrospective group comparison. Results regard-
ing the clinical impact on blood loss reduction are not yet conclusive at this stage 
and therefore randomized clinical trials are mandatory for a final conclusion. For 
instance, the surgical procedures in the CPPF group may have been biased towards 
“dryer surgery”. Also, the difference between inflow and outflow volumes may not 
be an accurate measure for actual blood loss while the composition of MCTD fluid 
is both variable in time and patient-dependent.
Conclusion
From our study findings we conclude that CPPF after cardiac surgery is safe and 
feasible in this experimental setting. A positive effect on blood loss and related 
complications may be anticipated, but standardized randomized clinical trials are 
necessary to draw definitive conclusions.
7
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Postoperative blood loss requiring transfusions either or not combined with 
surgical re-exploration is relatively common after cardiac surgery (1-3). There are 
several factors associated with this blood loss, that can be separated into bleeding 
complications with a surgical origin (bleeding vessel, anastomosis or other suture 
line) and those related to ineffective hemostasis. The main focus in this thesis is 
on the latter. Ineffective hemostasis can be due to pre-existing coagulation factor 
deficiencies, drug-induced inhibition of hemostasis or surgery related, acquired 
hemostatic defects. Suggested causes of acquired hemostatic defects in cardiac 
surgery include hemodilution due to priming fluids of CPB, direct hemostatic dis-
turbance due to the CPB circuit, tissue trauma, consumption that ultimately may 
result into disseminated intravascular coagulation, platelet dysfunction and degra-
dation due to excessive fibrinolysis (4-8). Furthermore, factors like hypothermia, 
hypocalcemia, and acidosis hinder adequate hemostasis.
In order to support the process of decision making concerning medication and 
blood product substitution, the aim of this thesis is to improve our understanding 
of the development of (excessive) blood loss due to ineffective hemostasis after 
coronary artery bypass graft surgery. Furthermore, several preventative measures 
to reduce the risk of bleeding are explored.
Part I EtIology anD DIagnosIs of blooD loss aftEr cabg 
surgEry
In part I of the thesis the etiological mechanisms for blood loss after CABG pro-
cedures are investigated. Fibrinogen is a protein that plays an essential role in 
coagulation. Due to the development of e.g. blood loss, hemodilution, platelet 
activation by cardiopulmonary bypass (CPB), a large wound area for clot forma-
tion, hypothermia and acidosis, cardiac surgery can result in a significant reduction 
of fibrinogen concentration and function (9,10). An inverse association between 
pre- and postoperative fibrinogen levels, and bleeding risk, even for levels within 
the normal reference range (1.5-4.0 g/l), has been suggested in several previous 
studies (10,11). However, most of those studies are underpowered to give an 
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unambiguous conclusion. Therefore, we performed a systematic review and meta-
analysis to further clarify this effect of fibrinogen, as described in Chapter 2. Our 
meta-analysis indicated a significant, but weak to moderate correlation between 
pre- and postoperative fibrinogen concentrations and excessive postoperative 
blood loss in cardiac surgery. This confirms the important role of fibrinogen in 
the coagulation process. However, since the correlation is not very strong, it is 
likely that other factors like hematocrit, thrombin formation, platelet number and 
function and clotting factor activities are at least as important in the development 
of (excessive) blood loss. Nevertheless, administration of fibrinogen concentrate 
before and during operation to prevent this (excessive) blood loss, is increasingly 
applied (10,12-14). Although no thrombosis was reported, it is important to keep 
in mind that fibrinogen is an acute-phase protein which level gradually increases 
after surgical procedures (10,15). This might ultimately lead to an increased risk of 
thromboembolic complications in the postoperative period.
Now that we have established an association, although weak, between fibrino-
gen concentrations and the development of (excessive) blood loss after cardiac 
surgery in chapter 2, we studied several factors that might contribute to a reduction 
in fibrinogen concentrations immediately after surgery in Chapter 3 . Three main 
mechanisms involved in a reduction of fibrinogen concentration or function are; 
hemodilution, consumption and degradation (9,16,17). Our results showed that 
hemodilution is likely to be the most important mechanism to reduce fibrinogen 
concentration and function during CABG procedures with the usage of CPB and 
tranexamic acid. To determine if indeed the reduction in fibrinogen concentra-
tion is causally related to the observed coagulopathy as measured by ROTEMTM 
(with prolonged CT and reduced MCF), and not the dilution of other coagulation 
factors, we performed an ex vivo supplementation study in which we added puri-
fied fibrinogen (Haemocomplettan, CSL) to blood of the studied CABG patients. 
Normalization of the coagulation profile after addition of purified fibrinogen con-
firmed that fibrinogen is the first clotting factor to drop below a critical level during 
hemodilution and a major contributor to the onset of dilutional coagulopathy.
The important role of hemodilution in the development of coagulopathy imme-
diately after CABG surgery is confirmed in Chapter 4 in which the hemostatic profile 
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throughout the perioperati ve period up to 5 days aft er CABG surgery is further 
revealed. In this chapter the eff ects of surgical trauma and CPB on coagulati on and 
fi brinolysis were compared between three groups: 1) isolated CABG without use of 
CPB (OPCAB), 2) isolated CABG with the use of CPB (CABG) and 3) CABG procedures 
combined with aorti c valve replacement (CABG+AVR). By comparing these groups 
we could determine the eff ects of CPB usage on coagulati on and fi brinolysis and 
diff erenti ate between the eff ects of short (CABG) and long (CABG+AVR) CPB ti me. 
Overall, pati ents undergoing CABG surgery without the use of CPB revealed higher 
fi brinogen, D-dimer, and prothrombin fragment 1 and 2 concentrati ons in the 
preoperati ve phase relati ve to pati ents operated on CPB (Figure 1). This elevati on 
cannot be explained by older age or the presence of comorbiditi es among pati ents 
in the OPCAB group, relati ve to pati ents operated on CBP in our study populati on 
(18).
figure 1. hemostati c curve in cabg surgery.
OPCAB, off -pump coronary artery bypass surgery, without CPB; CABG, CABG with use of CPB; 
CABG+AVR, CABG with use of CPB combined with aorti c valve replacement.
During CABG surgery and in the fi rst hours aft er operati on hypocoagulability 
develops, most pronounced seen in the CABG and CABG+AVR groups. This bleed-
ing tendency in ‘normal bleeding pati ents’ (a blood loss of less than 2 liters in 
total) appears to be mainly infl uenced by hemodiluti on. No perioperati ve platelet 
acti vati on was observed and functi onal (collagen induced) platelet aggregati on 
was transiently impaired, but recovered aft er surgery in all groups. Furthermore, 
plasma prothrombin fragment 1+2 and D-dimer levels remained quite stable 
throughout operati on and the changes demonstrated in thrombin generati on were 
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not above standard errors. With hemodilution as the most critical factor impairing 
hemostasis, minimizing the volume of priming fluids used in the CPB circuit and 
amount of colloids administered during cardiac surgery, may reduce postoperative 
blood loss. A critical evaluation should be made of all vital signs indicating tissue 
saturation and the actual need for volume administration before providing so. The 
use of minimized extracorporeal systems might further reduce hemodilution (19), 
although magnitude of this effect is debated (20). Another useful technique is prim-
ing of the CPB circuit with patients’ own blood (retrograde autologous priming), in 
which the priming fluid of the CPB circuit is retrograde, through the aortic cannula. 
There is no evidence for a clinically relevant fibrinolysis during or after operation 
when tranexamic acid is administrated, since the t-PA burst seen after reperfusion 
in patients on CPB, probably partly resulting from surgical tissue damage during 
surgery (21), is without clinical consequences. The Nijmegen Hemostasis Assay 
(NHA) even revealed an impaired fibrinolysis 5 days after operation in all groups. 
Probably, without the use of tranexamic acid (which is administered accordingly to 
standard procedure in most hospitals in the Netherlands), the role of fibrinolysis in 
bleeding might be more pronounced (22). This is confirmed in chapter 3 in which 
the effects of the fibrinogen degradation products, originating after e.g. plasmin 
mediated proteolysis, were analyzed in vitro using ROTEMTM. We observed that 
early fibrinogen degradation products have a pronounced effect on blood clot 
formation in vitro and therefore may induce or enhance in vivo coagulopathy. 
However, when tranexamic acid is used during surgery no fibrinogen degradation 
products were observed in the plasma of patients, indicating that in vivo the rela-
tively low tranexamic acid levels are sufficient to prevent fibrinogenolysis.
Although, during and immediately after cardiac surgery patients have a bleeding 
tendency, coagulation restores in the postoperative period. This process develops 
from day 1 until at least day 5 postoperative, in which a rebound above baseline 
levels of fibrinogen, D-dimer, prothrombin fragments 1 and 2 concentrations and 
platelet aggregation, combined with an increased thrombin generation was seen in 
all patients, suggesting a hypercoagulable state. This rebound is probably attributed 
to an acute phase response to surgical trauma and CPB usage (23,24). It was most 
pronounced among patients undergoing isolated CABG (OPCAB and CABG) who do 
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not receive vitamin K antagonists as prescribed in patients undergoing aortic valve 
replacement. The presence of a hypercoagulable state combined with postopera-
tive impaired fibrinolysis, may promote the risk of thromboembolic complications 
(23,25,26). These results emphasize the need for adequate anticoagulant therapy 
to prevent thromboembolic complications in the postoperative phase, especially 
in patients who do not receive vitamin K antagonists by protocol, even in those 
who were bleeding before. A delicate balance between a bleeding tendency and a 
hypercoagulable state has to be maintained. Probably, point-of-care (POC) testing 
might provide a more precise and individual patient orientated diagnostic tool to 
do so in the future (27).
Part II ManagEMEnt anD PrEvEntIon of blooD loss 
aftEr cabg surgEry
In part II of the thesis the management options to prevent and treat bleeding in 
cardiac surgery are described. In order to reduce the amount of blood loss and 
blood transfusions required during and after cardiac surgery it is important that 
antiplatelet medications like, e.g. acetylsalicylic acid and clopidogrel, prescribed 
routinely in patients prior to cardiac surgery, especially CABG, are discontinued 
timely before operation. Solid data on the optimal timing of discontinuation of 
both medications is lacking (28-31). In Chapter 5 we tried to determine the day be-
fore surgery at which acetylsalicylic acid, either or not combined with clopidogrel, 
should be used the latest to establish the lowest amount of blood loss 48 h after 
surgery. Our results showed that there is no clinically relevant optimal stop day 
(defined as the last day before surgery on which antiplatelet medication was used) 
for acetylsalicylic acid alone or in combination with clopidogrel in relation to 48 h 
blood loss. This is in agreement with findings of Mannacio  (32) on the large vari-
ability in platelet function restoration among individuals. However, last use on day 
-2 resulted in a reduction of the percentage of patients receiving platelet transfu-
sions, especially with combined preoperative ASA and clopidogrel use, and should 
be considered as the best compromise in the vast majority of these patients. So, in 
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order to reduce the amount of platelet transfusions a combination of acetylsalicylic 
acid and clopidogrel should not be used the day before surgery. There was no asso-
ciation between any stop day and major adverse cardiovascular and cerebral events 
(MACCE), however, the termination date of the antiplatelet medication was left to 
the discretion of the physician and influenced by expected risk for thromboembolic 
complications. Due to this large variation in patient responsiveness to clopidogrel 
administration, use of antiplatelet medication might possibly be better monitored 
by POC platelet function measurement, in order to reduce peri- and postopera-
tive blood loss and transfusion replacement to a minimum. However, before the 
incorporation of POC platelet function tests as standard care or diagnostic tool can 
be realized, it needs further validation in clinical practice. Our recommendation 
should, therefore, be considered as a practical alternative.
Other preventative measures to reduce blood loss and consecutive blood 
transfusion requirements in cardiac surgery include minimally invasive surgical 
techniques, miniaturized extracorporeal cardiopulmonary circuit, ultrafiltration, 
the use of blood conservation strategies, and the systemic and topical (33) pharma-
cological correction of hemostasis (34-36). An example of a topical pharmacological 
correction is the use of fibrin sealants during operation. Fibrin sealants have gained 
increasing popularity, but have been shown to be less effective than antifibrinolyt-
ics (37). However, since one of the most effective antifibrinolytics, aprotinin, had 
been removed from the market for safety reasons, using fibrin sealants became 
more significant. A recently developed fibrin sealant produced from allogeneic 
single donor plasma, without the addition of fibrinolysis inhibitors or bovine pro-
teins, called CryoSeal™ was studied to evaluate its safety and cost-effectiveness 
in patients undergoing elective isolated CABG surgery, using at least one internal 
thoracic artery, as outlined in Chapter 6 . Results show that the use of the fibrin 
sealant CryoSeal™ did not result in health benefits. Therefore, implementation in 
elective isolated CABG is not recommended.
Despite the improvements achieved by the existing techniques we still tend to 
accept a considerable amount of blood loss as being inherent to cardiac surgery. 
In the final chapter of this thesis, Chapter 7 , the safety, feasibility, and effect on 
blood loss of continuous postoperative pericardial flushing (CPPF) after cardiac 
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surgery was evaluated. We developed a device to remove contaminated pericar-
dial blood (with high fibrinolytic activity and tissue factor concentration (6,21)) 
and clots via dilution and a continuous circulation of infusion liquid through the 
pericardial cavity. Removing this blood and clots probably not only reduces the 
chance of excessive blood loss by preventing a systemic coagulopathy, but also 
might have beneficial effects on several other factors associated with surgery like, 
e.g. inflammation, atrial fibrillation, pericardial effusions (tamponade), and the 
development of adhesions. Our findings support technical safety and feasibility 
regarding infections and (pleural or pericardial) fluid accumulation of the device 
in 20 adult patients undergoing surgical correction for congenital heart disease. In 
one patient CPPF was stopped as a precaution 3.5 h postoperatively as there was a 
>200 ml lag in total mediastinal chest tube drainage volume due to fluid accumula-
tion in the right pleural cavity. The accumulated fluid had spontaneously resolved 
on extubation, confirmed by chest radiography. No system-related or other serious 
problems were encountered. Although, this study was primarily aimed to evaluate 
safety and feasibility of the device, we demonstrated a 30% reduction in 12 h post-
operative blood loss and there were no re-explorations for bleeding complications 
in the CPPF group. These observations suggest a possible role for the device in the 
reduction of postoperative blood loss.
conclusIons anD futurE rEcoMMEnDatIons
After careful evaluation, hemodilution seems to be the most pronounced factor 
associated with the development of the coagulopathy after cardiac surgery, and, 
probably plays an important role in the origination of blood loss after cardiac sur-
gery. Although fibrinogen is (one of the first) clotting factors to drop below a critical 
level during hemodilution, care should be taken with administration of fibrinogen 
concentrate. Fibrinogen is an acute phase protein which levels rise gradually during 
and after operation as response to surgical trauma and CPB usage. The increased 
levels of D-dimer and prothrombin fragments 1 + 2, together with the increased 
thrombin generation, indicate that a hypercoagulable state develops up to at least 
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5 days after cardiac surgery. The combination of both this ‘natural’ rebound to-
wards a hypercoagulable state and the administered fibrinogen concentrate, might 
enhance the risk of thromboembolic complications in the postoperative period. 
Therefore, adequate anticoagulant therapy to prevent thromboembolic compli-
cations in the postoperative phase is needed, especially in patients who do not 
receive vitamin K antagonists by protocol, even in the patients previously bleeding. 
A delicate balance between a bleeding tendency and a hypercoagulable state has 
to be maintained. The use of point of care (POC) evaluation (e.g. TEG or ROTEM) 
might provide faster and a more complete insight in this delicate balance, creating 
a more individual patient orientated treatment. The large variation in patient re-
sponsiveness to clopidogrel administration, often administered before operation, 
further advocates the usage of POC platelet function measurement before, during, 
and after cardiac surgery. A more individual patient orientated treatment might 
contribute to reducing peri- and postoperative blood loss and transfusion replace-
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Bloedverlies na een hartoperatie is een veelvoorkomende complicatie. Veelal 
zijn als gevolg van dit bloedverlies bloedtransfusies vereist, al dan niet gepaard 
gaande met nog een tweede operatie om de bloeding te stoppen. Er zijn verschil-
lende uitlokkende factoren voor dit bloedverlies, te verdelen in bloedingen met 
een chirurgische oorzaak (bijvoorbeeld door een naadlekkage) en bloedingen die 
gerelateerd zijn aan een stollingsprobleem. Dit proefschrift richt zich met name 
op de laatste vorm. Stollingsproblemen bij hartoperaties kunnen ontstaan door 
een reeds bestaand tekort aan stollingsfactoren (bijvoorbeeld door een genetische 
afwijking), het gebruik van bepaalde medicamenten voorgaande aan de operatie of 
kunnen veroorzaakt worden door aan de operatie gerelateerde factoren. Bij deze 
laatste groep kan men denken aan stollingsproblemen die optreden als gevolg van 
verdunning door het toedienen van infusievloeistof ten behoeve van het gebruik 
van de hartlongmachine of om de bloeddruk te stabiliseren. Ook contact van bloed 
met het oppervlak van de hartlongmachine, weefselschade, overmatige activatie 
van stolling en een verhoogde afbraak van stolsels, als gevolg van de operatie, kun-
nen een stollingsprobleem veroorzaken. Andere factoren die een adequate stolling 
in de weg staan, zijn onderkoeling, een laag calciumgehalte in het bloed en een 
hoge zuurgraad (lage pH).
Het verkrijgen van een beter inzicht in de processen die leiden tot het ontstaan van 
(overmatig) bloedverlies kan ondersteunend zijn in de besluitvorming rondom het 
toedienen van medicatie en bloedproducten bij deze patiënten. In dit proefschrift 
wordt het ontstaan van bloedverlies na hartoperaties bestudeerd en worden mo-
gelijke therapieën en preventieve strategieën geëxploreerd.
In het eerste gedeelte van het proefschrift worden de ontstaansmechanismen 
van bloedverlies na hartchirurgie, specifiek na bypass coronaire operaties (CABG), 
bestudeerd. In hoofdstuk 1 wordt een overzicht gegeven van de bestaande litera-
tuur over oorzaken van stollingsproblemen bij hartoperaties. Vervolgens wordt in 
hoofdstuk 2 de rol van fibrinogeen, een essentieel eiwit in het stollingsproces, bij 
het ontstaan van overmatig bloedverlies (gedefinieerd als meer dan 2 liter per 24 
uur of meer dan 200 ml per uur) na hartoperaties bestudeerd. In een meta-analyse 
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wordt een zwakke, significante correlatie gevonden tussen fibrinogeen concentra-
tie (voor en na operatie) en overmatig bloedverlies na hartoperaties. Dit betekent 
dat, hoewel de rol van fibrinogeen belangrijk is in de ontwikkeling van overmatig 
bloedverlies, andere factoren zoals een laag hemoglobine gehalte, de dikte van het 
bloed (hematocriet), de hoeveelheid bloedplaatjes en de functie en activiteit van 
stollingsfactoren op zijn minst net zo belangrijk zijn in dit proces. In de dagelijkse 
praktijk wordt echter, ter preventie van overmatige bloedverlies, in toenemende 
mate fibrinogeen concentraat toegediend voor en tijdens hartoperaties. Van be-
lang hierbij is dat de behandelaar zich realiseert dat fibrinogeen een acute fase 
eiwit is waarvan, als reactie op de operatie, de concentratie geleidelijk toeneemt 
na de operatie. Dit heeft niet geleid tot een toegenomen, gerapporteerd, aantal 
stollingscomplicaties, maar zou uiteindelijk wel degelijk kunnen leiden tot een 
verhoogd risico op trombose na hartoperaties.
In hoofdstuk 3 worden factoren bestudeerd die zouden kunnen bijdragen aan een 
afname van de fibrinogeen concentratie direct na operatie. Er zijn 3 hoofdmecha-
nismen betrokken bij deze afname: 1) verdunning (hemodilutie), 2) verbruik van 
stollingsfactoren (consumptie) en 3) verhoogde afbraak van een stolsel (fibrinolyse 
of degradatie). Hemodilutie leek de belangrijkste factor te zijn die betrokken was 
bij de afname van fibrinogeen concentratie en functie na CABG operaties, waarbij 
gebruik wordt gemaakt van de hartlongmachine en tranexaminezuur, een remmer 
van fibrinolyse, wordt toegediend (standaard protocol in Nederland). Om te beves-
tigen dat de geobserveerde stollingsproblemen daadwerkelijk werden veroorzaakt 
door een afname in fibrinogeen concentratie en niet door afname van andere 
stollingsfactoren, werd (puur) fibrinogeen concentraat (Haemocomplettan, CSL) 
ex vivo toegevoegd aan het bloed van CABG patiënten. Normalisatie van het stol-
lingsprofiel na deze toevoeging bevestigde dat fibrinogeen de eerste stollingsfactor 
is die beneden een kritisch niveau zakt bij hemodilutie.
De belangrijke rol van hemodilutie in de ontwikkeling van een stollingsprobleem 
werd bevestigd in hoofdstuk 4. In dit hoofdstuk wordt de hemostase, oftewel 
het stollingsevenwicht, gedurende de operatie tot en met 5 dagen na CABG 
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operatie bestudeerd. De effecten van weefselschade (ontstaan door de operatie 
zelf) en het gebruik van de hartlongmachine, op zowel de stolling als fibrinolyse, 
werden vergeleken tussen 3 groepen: 1) CABG operaties zonder gebruikmaking 
van de hartlongmachine (OPCAB), 2) CABG operaties met gebruikmaking van de 
hartlongmachine (CABG) en 3) CABG operaties gecombineerd met een aorta(hart)
klepvervanging (CABG +AVR). Door deze groepen onderling te vergelijken kon 
gedifferentieerd worden tussen de effecten van kort (CABG), lang (CABG + AVR) 
of helemaal geen gebruik (OPCAB) van de hartlongmachine. Voor hun operatie 
hadden patiënten die zonder hartlongmachine geopereerd zouden worden een 
meer procoagulant stollingsprofiel, dan patiënten die geopereerd zouden worden 
met gebruikmaking van de hartlongmachine. Tijdens en in de eerste uren na CABG 
operatie, neemt de sterkte van de stolling in alle groepen af. Dit is het meest uitge-
sproken in de CABG en CABG + AVR groepen, beiden geopereerd met gebruikma-
king van de hartlongmachine. Deze bloedingstendens bij een normale hoeveelheid 
bloedverlies (gedefinieerd als minder dan 2 liter in totaal na operatie), wordt met 
name veroorzaakt door hemodilutie. Er werd geen bloedplaatjes activatie geob-
serveerd tijdens operatie en functionele plaatjes aggregatie (samenklontering) 
was weliswaar verminderd, maar herstelde (tot normaal) direct na de operatie in 
alle groepen. Dit maakt de rol van een verminderde werking van bloedplaatjes in 
het ontstaan van bloedverlies in het eerste uur na operatie minder waarschijnlijk. 
Ook de plasma concentraties van protrombine fragmenten 1+2 en D-dimeer, welke 
beiden verhoogd zouden zijn bij overmatige consumptie, bleven redelijk stabiel ge-
durende de operatie. De veranderingen in trombine generatie kwamen niet boven 
de standaard fout. Tevens was er geen bewijs voor klinisch relevante fibrinolyse, 
tijdens of na operatie, onder toediening van tranexaminezuur. Mogelijk zou de rol 
van fibrinolyse meer uitgesproken zijn zonder toediening van tranexaminezuur. Dit 
wordt bevestigd in hoofdstuk 3 waarin fibrinogeen afbraakproducten een duidelijk 
remmend effect op de stolselvorming in vitro veroorzaakten en mogelijk dus in 
vivo een stollingsprobleem (kunnen) verergeren. Echter wanneer tranexaminezuur 
werd toegediend tijdens de CABG operatie, werden geen fibrinogeen afbraakpro-
ducten geobjectiveerd in het plasma van patiënten, wat suggereert dat in vivo de 
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relati ef lage tranexaminezuur niveaus voldoende zijn om (overmati ge) afb raak van 
fi brinogeen te voorkomen.
figuur 1. stollingsevenwicht ti jdens cabg operati e.
OPCAB, CABG operati es zonder gebruik making van de hartlongmachine; CABG, operati es met 
gebruik making van de hartlongmachine en CABG +AVR, CABG operati es gecombineerd met 
een aorta(hart)klepvervanging.
Ondanks dat pati ënten ti jdens en direct na een hartoperati e voornamelijk een 
bloedingstendens laten zien, herstelt de stolling zich geleidelijk tussen de 1e en 
de 5e dag na operati e. Gedurende deze periode wordt een ‘rebound’ boven de 
uitgangswaarden gezien van fi brinogeen, D-dimeer, protrombine fragment 1+2 
concentrati es en plaatjes aggregati e, gecombineerd met een verhoogde trombine 
generati e. In deze postoperati eve periode lijkt er sprake van een ‘hypercoagu-
lable state’, oft ewel een staat van overmati ge stolling. Deze overmati ge stolling 
is hoogstwaarschijnlijk het gevolg van een acute fase respons op weefselschade 
en het gebruik van de hartlongmachine. Het proces is het meest uitgesproken bij 
pati ënten die geen vitamine K antagonisten gebruiken (OPCAB en CABG, oft ewel 
CABG operati es zonder klepvervanging). Uiteindelijk kan dit proces leiden tot een 
verhoogd risico op stollingscomplicati es, oft ewel trombose, na operati e. Adequate 
instelling op anti stollingsmedicati e is daarom van belang, ook bij mensen die eer-
der een bloedingsprobleem hadden. Dit betekent dat een delicaat evenwicht tus-
sen een bloedingstendens en overmati ge stolling zal moeten worden gehandhaafd. 
Mogelijk kan ‘point of care testi ng’, een methode om een laboratoriumtest naast 
of in de buurt van de pati ënt uit te voeren, hier in de toekomst, als preciezer en 
individueel georiënteerd diagnosti cum, een belangrijke rol in spelen. 
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In het tweede deel van het proefschrift wordt ingegaan op de behandeling en 
preventie van (overmatig) bloedverlies. Het doel hiervan is om bloedverlies en 
de benodigde bloedtransfusies tijdens en na hartoperaties te verminderen. Om 
dit doel te bereiken is het onder andere van belang dat de gebruikte antistol-
lingsmedicatie tijdig wordt gestopt (hoofdstuk 5). Er blijkt voor acetylsalicylzuur, 
al dan niet gecombineerd met clopidogrel, geen optimale stop dag te zijn voor een 
hartoperatie om het bloedverlies binnen 48 uur na operatie zo laag mogelijk te 
houden. Het niet gebruiken van deze medicatie op de dag voor operatie leidde wel 
tot een lager percentage patiënten dat bloedtransfusies toegediend kreeg, vooral 
bij mensen die een combinatie van beide medicamenten gebruikten voor operatie. 
Door de hoge variantie in ‘responsiveness’, oftewel de effectiviteit, van clopidogrel 
kan de werking ervan mogelijk het beste geëvalueerd worden middels ‘point of 
care testing’ om zo het bloedverlies en de transfusiebehoefte gedurende en na 
operatie te minimaliseren.
Andere preventieve methoden om bloedverlies en transfusies te verminderen zijn 
minimaal invasieve technieken, ultrafiltratie, bloedconservatie strategieën en het 
gebruik van systemische of plaatselijke farmacologische middelen. Een voorbeeld 
van een plaatselijk farmacologisch middel is het gebruik van fibrinelijm tijdens 
operatie. CryoSeal, een fibrinelijm geproduceerd uit het plasma van een enkele 
donor, blijkt bij CABG operaties geen vermindering van het bloedverlies of andere 
gezondheidswinst te geven (hoofdstuk 6) en daarom wordt het gebruik ervan niet 
aangeraden.
In hoofdstuk 7 wordt de toepassing van ‘continuous postoperative pericardial 
flushing (CPPF)’, oftewel het continue spoelen van het hartzakje na operatie met 
een ontwikkeld spoelsysteem, geëvalueerd. Onderzoek onder 20 patiënten die 
een chirurgische correctie ondergingen vanwege aangeboren hartaandoeningen, 
bevestigde de veiligheid en toepasbaarheid van dit systeem. Daarnaast werd een 
reductie van 30% in het bloedverlies 12 uur na operatie vastgesteld. Het ver-
wijderen van ‘vervuild’ bloed (met hoge fibrinolyse activiteit) en stolsels uit het 
hartzakje middels verdunning kan waarschijnlijk de kans op overmatig bloedverlies 
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verkleinen (door het voorkomen van een systemische reactie), maar heeft mogelijk 
ook een positief effect op andere factoren zoals ontsteking, atriumfibrilleren, tam-
ponade en de ontwikkeling van verklevingen na operatie.
In het laatste hoofdstuk (hoofdstuk 8) worden de resultaten in het licht geplaatst 
van de huidige literatuur en de klinische implicaties voor toekomstige therapie 
bediscussieerd.
‘First and foremost is the need for those who order transfusions to do so mind-
fully, rather than automatically, in response to a given pathophysiologic trigger’
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in mijn promotietraject. Het was lastig om de gehele lading van het proefschrift 
alleen op de Thoraxchirurgie onder te brengen. Gelukkig kwamen we met elkaar 
in contact voor het CLOT artikel. Dank voor jouw kritische, maar altijd terechte 
commentaren en de tijd die je iedere keer weer voor me wist te vinden.
Professor Anneke Brand, beste Anneke, jij hebt me zowel inhoudelijk als persoon-
lijk gesteund in een toch niet altijd gemakkelijk traject. Dank voor je luisterend oor 
en belangeloze steun.
Professor Bas de Mol en Professor Pieter Willem Kamphuisen, graag wil ik jullie beiden 
bedanken voor de tijd die jullie genomen hebben om mijn proefschrift te lezen.
co-auteurs
Professor Theo Stijnen, drs. Jan Schoones, Professor Olaf Dekkers, Jos Grimbergen, 
dr. Jaap Koopman, dr. Waander van Heerde, dr. Giuseppe Tavilla, dr. Wilbert van 
den Hout, drs. Johan Manshanden, dr. Corianne de Borgie en dr. Dave Koolbergen, 
bedankt voor jullie bijdrage aan dit proefschrift.
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Begeleiding
Drs. Eline Bruggemans, beste Eline, dank voor de gesprekken die we hebben gevo-
erd. Waar ik altijd snel wilde, trapte jij op de rem en liet me stil staan bij de inhoud 
en essentie. Daar heb ik veel van geleerd. Jouw rust en precisie neem ik nog steeds 
mee in mijn werk.
Dr. Joost van Hilten, beste Joost, wat hebben we samen veel nagedacht over de 
inhoud en uitvoering van het FIBER project. Dank voor de tijd die je hebt genomen 
om me wegwijs te maken in de wereld van het onderzoek.
Dr. Jan Lindeman, beste Jan, dank voor het meedenken, je adviezen en steunende 
woorden. Af en toe wist ik even niet meer waar ik moest beginnen of hoe ik iets 
moest aanpakken. Jij gaf mij met je opgewekte persoon altijd handvaten om weer 
verder te kunnen en de moed om dit ook te doen.
Professor Paul Quax, beste Paul, eigenlijk werkten we niet samen in een groep of 
project. We raakten met elkaar aan de praat en ons contact leidde uiteindelijk tot 
een project en, na vele brainstormsessies met Jos Grimbergen en Jaap Koopman, 
tot een artikel. 
onderzoeksassistente
Tineke van der Heiden, beste Tineke, met name jou wil ik bedanken voor je einde-
loze hulp, ook in de weekenden. Je stond altijd voor me klaar en was bereid om een 
stap harder te lopen. Dank voor al je hulp.
Kamergenoten
D6-35….. Het is een begrip en volgens mij in vele proefschriften genoemd. Alexander 
Later, Dorottya de Vries, Kirsten Kortekaas, Vivianne Kokje, Mark Ewing, Maarten 
Letsch, Joep Ponten en nog vele anderen studenten, dank voor jullie gezelligheid, 
de broodnodige afleiding, het vele lachen en natuurlijk ook jullie steun.
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In het bijzonder wil ik graag het UWV bedanken voor alle mogelijkheden en tijd die 
ik heb gekregen om mijn promotie af te kunnen ronden. Diederike Holtkamp, jou 
speciaal wil ik bedanken voor je vertrouwen en steun.
vrienden
Lieve vrienden en goede kennissen, dank voor de gezelligheid. Jullie hebben me 
gesterkt in de volharding om mijn promotie af te maken.
Caroline van der Wal, lieve Caroline, toen we elkaar leerden kennen bij Vedette 
waren we nog studentes en nu inmiddels beiden verloofd. Wat heerlijk dat we deze 
periode met al zijn ‘ups en downs’ samen hebben mogen beleven.
Leonie van Zeggeren, lieve Leonie, wat hebben we veel gelachen, gereisd en 
beleefd. Dank voor je vriendschap en steun.
Paranimfen
Dr Colette van den Broek, lieve Colette, wat hebben we veel meegemaakt. Ik had 
niet geweten hoe ik het zonder jou had moeten doen. Dank dat je me ook nu weer 
wil bijstaan.
Dr Madelon den Boeft, lieve Lon, waar moet ik beginnen. Je zit naast me, ook je 
dankwoord te schrijven. Dank voor al je steun, die veel verder ging dan alleen maar 
luisteren. We komen er samen wel. 
familie
Tenslotte wil ik jullie bedanken, lieve papa, mama, Julian en ome Rob. Papa en 
mama, dank voor jullie steun tijdens mijn opleiding en alle kansen die jullie mij ge-
geven hebben. Julian, door dik en dun, voor altijd. Ome Rob, dank voor je geduld, 
vriendschap en alle hulp bij de vele grafische vraagstukken die ik je heb voorgelegd.
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Casper, mijn liefste, mijn verloofde, mijn maatje, mijn alles. Samen lachen, samen 
huilen. Dank dat jij er altijd bent.
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en ontwikkelde en nam deel aan verschillende ‘public health’ projecten. Na het 
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dr. J. Eikenboom. Binnen het proefschrift onderzocht zij verschillende ontstaans-
mechanismen voor bloedverlies na CABG procedures. Verder bestudeerde ze diag-
nostische methoden om dit vast te stellen en onderzocht preventieve maatregelen 
om de hoeveelheid bloedverlies na CABG procedures te reduceren. De resultaten 
van dit onderzoek staan beschreven in dit proefschrift. Tijdens haar promotie is 
zij gestart als assistent op de afdeling Thoraxchirurgie, maar besloot begin 2014 
een overstap te maken naar de Verzekeringsgeneeskunde. Per 3 november 2015 
is zij gestart met de opleiding tot verzekeringsarts aan de NSPOH te Utrecht en 
werkt bij het UWV te Den Haag. Daarnaast is zij sinds oktober 2015 werkzaam als 
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